WO1998024782A2 - Substituted pyrimidine compounds and their use - Google Patents

Substituted pyrimidine compounds and their use Download PDF

Info

Publication number
WO1998024782A2
WO1998024782A2 PCT/US1997/022390 US9722390W WO9824782A2 WO 1998024782 A2 WO1998024782 A2 WO 1998024782A2 US 9722390 W US9722390 W US 9722390W WO 9824782 A2 WO9824782 A2 WO 9824782A2
Authority
WO
WIPO (PCT)
Prior art keywords
radicals
amino
alkyl
alkoxy
optionally substituted
Prior art date
Application number
PCT/US1997/022390
Other languages
French (fr)
Other versions
WO1998024782A3 (en
Inventor
Ulrike D. Spohr
Michael J. Malone
Nathan B. Mantlo
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to EP97954778A priority Critical patent/EP0948497A2/en
Priority to IL13018097A priority patent/IL130180A0/en
Priority to KR1019997005021A priority patent/KR20000069328A/en
Priority to AU60120/98A priority patent/AU733877C/en
Priority to HU0001698A priority patent/HUP0001698A3/en
Priority to NZ335997A priority patent/NZ335997A/en
Priority to CA002274063A priority patent/CA2274063C/en
Priority to JP52585098A priority patent/JP2002514195A/en
Priority to BR9713850-9A priority patent/BR9713850A/en
Publication of WO1998024782A2 publication Critical patent/WO1998024782A2/en
Publication of WO1998024782A3 publication Critical patent/WO1998024782A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention comprises a new class of compounds useful in treating diseases, such as TNF- ⁇ , IL-l ⁇ , IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes.
  • diseases such as TNF- ⁇ , IL-l ⁇ , IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes.
  • the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation.
  • This invention also relates to intermediates and processes useful in the preparation of such compounds.
  • TNF- ⁇ are pro-inflammatory cytokines secreted by a variety of cells, including monocytes and macrophages , in response to many inflammatory stimuli (e . g. , lipopolysaccharide - LPS) or external cellular stress (e.g., osmotic shock and peroxide) .
  • inflammatory stimuli e.g. , lipopolysaccharide - LPS
  • external cellular stress e.g., osmotic shock and peroxide
  • Elevated levels of TNF- ⁇ and/or IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic ⁇ cell destruction; osteoarthritis ; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS) ; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs.
  • ARDS adult respiratory distress syndrome
  • HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2) , and herpes zoster are also exacerbated by TNF- ⁇ .
  • TNF- ⁇ plays a role in head trauma, stroke, and ischemia.
  • TNF- ⁇ levels increased in the contused hemisphere (Shohami et al . , J " . Cereb . Blood Flow Metab . 14, 615 (1994)).
  • the levels of TNF- ⁇ mRNA of TNF- ⁇ increased (Feurstein et al . , Neurosci . Lett . 164, 125 (1993)).
  • Administration of TNF- ⁇ into the rat cortex has been reported to result in significant neutrophil accumulation in capillaries and adherence in small blood vessels.
  • TNF- ⁇ promotes the infiltration of other cytokines (IL-l ⁇ , IL-6) and also chemokines, which promote neutrophil infiltration into the infarct area (Feurstein, Stroke 25, 1481 (1994)). TNF- ⁇ has also been implicated to play a role in type II diabetes (Endocrinol. 130, 43-52, 1994; and Endocrinol . 136, 1474-1481, 1995) .
  • TNF- ⁇ appears to play a role in promoting certain viral life cycles and disease states associated with them. For instance, TNF- ⁇ secreted by monocytes induced elevated levels of HIV expression in a chronically infected T cell clone (Clouse et al . , J. Immunol . 142, 431 (1989)). Lahdevirta et al . , (Am . J. Med. 85, 289
  • TNF- ⁇ is upstream in the cytokine cascade of inflammation.
  • elevated levels of TNF- ⁇ may lead to elevated levels of other inflammatory and proinflammatory cytokines, such as IL-1, IL-6, and IL-8.
  • Elevated levels of IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS) ; psoriasis; Crohn's disease; ulcerative colitis; anaphylaxis; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; sepsis; septic shock; and toxic shock syndrome.
  • Viruses sensitive to TNF- ⁇ inhibition e . g. , HIV-1, HIV-2, HIV- 3, are also affected by IL-1.
  • TNF- ⁇ and IL-1 appear to play a role in pancreatic ⁇ cell destruction and diabetes.
  • Pancreatic ⁇ cells produce insulin which helps mediate blood glucose homeostasis. Deterioration of pancreatic ⁇ cells often accompanies type I diabetes. Pancreatic ⁇ cell functional abnormalities may occur in patients with type II diabetes. Type II diabetes is characterized by a functional resistance to insulin. Further, type II diabetes is also often accompanied by elevated levels of plasma glucagon and increased rates of hepatic glucose production.
  • Glucagon is a regulatory hormone that attenuates liver gluconeogenesis inhibition by insulin. Glucagon receptors have been found in the liver, kidney and adipose tissue.
  • glucagon antagonists are useful for attenuating plasma glucose levels (WO 97/16442, incorporated herein by reference in its entirety). By antagonizing the glucagon receptors, it is thought that insulin responsiveness in the liver will improve, thereby decreasing gluconeogenesis and lowering the rate of hepatic glucose production.
  • IL-1 is a more potent inducer of stromelysin than is TNF- ⁇ (Firestein, Am. J. Pathol . 140, 1309 (1992)). At sites of local injection, neutrophil, lymphocyte, and monocyte emigration has been observed.
  • IL-1 chemokines
  • IL-8 chemokines
  • adhesion molecules adhesion molecules
  • IL-1 also appears to play a role in promoting certain viral life cycles.
  • cytokine- induced increase of HIV expression in a chronically infected acrophage line has been associated with a concomitant and selective increase in IL-1 production (Folks et al., J “ . Immunol . 136, 40 (1986)).
  • Beutler et al. J. Immunol . 135, 3969 (1985) discussed the role of IL-1 in cachexia.
  • IL-8 has been implicated in exacerbating and/or causing many disease states in which massive neutrophil infiltration into sites of inflammation or injury (e.g., ischemia) is mediated by the chemotactic nature of IL-8, including, but not limited to, the following: asthma, inflammatory bowel disease, psoriasis, adult respiratory distress syndrome, cardiac and renal reperfusion injury, thrombosis and glomerulonephritis .
  • IL-8 also has the ability to activate neutrophils.
  • reduction in IL- 8 levels may lead to diminished neutrophil infiltration.
  • TNF- ⁇ Several approaches have been taken to block the effect of TNF- ⁇ .
  • TNF- ⁇ soluble receptors for TNF- ⁇
  • TNFR-55 or TNFR-75 soluble receptors for TNF- ⁇
  • cA2 monoclonal antibody specific to TNF- ⁇
  • R a x is 2-, 3-, or 4-pyridyl
  • R a 2 is H, methyl, or phenyl
  • R a 3 is H, amino
  • WO 97/33883 describes substituted pyrimidine compounds useful in treating cytokine mediated diseases.
  • the present invention comprises a new class of compounds useful in the prophylaxis and treatment of diseases, such as TNF- ⁇ , IL-l ⁇ , IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes.
  • diseases such as TNF- ⁇ , IL-l ⁇ , IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes.
  • the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation.
  • the invention also comprises pharmaceutical compositions comprising the compounds, methods for the prophylaxis and treatment of TNF- ⁇ , IL-l ⁇ , IL-6 and/or IL-8 mediated diseases, such as inflammatory, pain and diabetes diseases, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention.
  • the compounds of the invention are represented by the following general structure:
  • R 1 , R 2 , R 11 and R 12 are defined below.
  • R l and R 2 are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; preferably, 0-2; more preferably, 0-1; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Ri and R 2 is 0-4; preferably, 0-3; more preferably, 0-2; most preferably, 0-1;
  • R 2 is a radical of hydrogen, C 1 -C 4 alkyl , halo, hydroxy, C 1 -C 4 alkoxy, C 1 -C 2 haloalkoxy of 1-3 halo radicals, thiol, C 1 -C 4 alkylthio, aminosulfonyl, C 1 -C 4 alkylaminosulfonyl, di- (C 1 -C 4 alkyl) aminosulfonyl, amino, C 1 -C 4 alkylamino, di- (C 1 -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino or C 1 -C 2 haloalkyl of 1-3 halo radicals;
  • R 2 is a radical of hydrogen, C 1 -C 4 alkyl, halo, hydroxy, C 1 -C 4 alkoxy, trifluoromethoxy, thiol, C 1 -C 4 alkylthio, amino, C 1 -C 4 alkylamino, di- (Cj_- C 4 alkyl) amino, C1 .
  • R 2 is a radical of hydrogen, methyl, ethyl, fluoro, chloro, hydroxy, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino , acetylamino or trifluoromethyl; and most preferably, R 2 is a radical of hydrogen or hydroxy;
  • alkyl, alkenyl or alkynyl radical optionally substituted by (a) 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylammo, alkylsulfonylamino, hydroxy, alkoxy, alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylammo, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, halo, alkyl or haloalkyl;
  • heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or
  • aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;
  • each Z is independently a (1) bond; (2) Ci-C ⁇ alkyl, C 2 -C 8 alkenyl or C 2 -C 8 alkynyl radical optionally substituted by 1-3 radicals of amino, C 3. -C4 alkylamino, di- (C 1 -C 4 alkyl) amino, C 1 -C 5 alkanoylamino,
  • heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1.-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy,
  • each Z is independently a
  • each Z is independently a (1) bond; (2) C 1 -C 8 alkyl or C 2 -C 8 alkenyl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di- (C 1 -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, halo, C 1
  • heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C ⁇ -C 4 alkyl) amino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio or C 1 -C 4 alkyl radicals; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di- (C 1 -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, halo, C1-C 4 alkyl or C 1 -C 2 haloalkyl of 1-3 halo radicals;
  • each Z is independently a
  • C 1 -C 4 alkyl or C 2 -C 5 alkenyl radical optionally substituted by 1-3 radicals of amino, di- (C1-C 2 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 2 alkoxy, C 1 -C 2 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di- (C 1 -C 2 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, halo, C 1 -C 4 alkyl or trifluoromethyl radicals; (3) heterocyclyl radical optionally substitute
  • each Z is independently a
  • C 1 -C 4 alkyl or C 2 -C 5 alkenyl radical optionally substituted by 1-3 radicals of amino, di- (C1-C 2 alkyl) amino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 2 alkoxy, C 1 -C 2 alkylthio or halo, and (b) 1-2 radicals of aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di- (C 1 -C 2 alkyl) amino, acetamido, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, C 1 -C 4 alkyl or trifluoromethyl radicals; or
  • each Z is independently a radical of amino, di-(C ⁇ -C 2 alkyl) amino, acetamido, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 2 alkoxy, C1-C2 alkylthio, cyano, halo, C 1 -C 4 alkyl or trifluoromethyl radicals; more preferably, each Z is independently a radical of amino, di-(C ⁇ -C 2 alkyl) amino, acetamido, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 2 alkoxy, C1-C2 alkylthio, cyano, halo, C 1 -C 4 alkyl or trifluoromethyl radicals; more preferably, each Z is independently a radicals of amino, di-(C ⁇ -C 2 alkyl) amino, acetamido, (C 1 -C 4 alkoxy) carbonylamino,
  • C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, di- (C1-C2 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals; and
  • each Z is independently a
  • C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
  • each Y is independently a (1) hydrogen radical; (2) halo or nitro radical;
  • each Y is independently a
  • each Y is independently a
  • each Y is independently a
  • each Y is independently a
  • each Y is independently a -OR 21 , -SR 21 or -NR 5 R 21 radical;
  • alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, -S0 3 H or halo; or (3) aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl;
  • each R5 is independently
  • each R5 is independently
  • each R5 is independently (1) hydrogen radicals
  • C1-C4 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, di- (C1-C4- alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, - SO 3 H or halo; or
  • each R5 is independently (1) hydrogen radical; (2) C1-C4 alkyl radical optionally substituted by 1-3 radicals of amino, di- (C]_-C2-alkyl) amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo; or (3) phenyl-C ⁇ -C 2 -alkyl, heteroaryl-C ⁇ -C2-alkyl, heterocyclyl-C ⁇ -C2-alkyl or C3-C6-cycloalkyl-C ⁇ -C2-alkyl radicals optionally substituted by 1-3 radicals of amino, di- (C ⁇ C2-alkyl) amino, hydroxy, C1-C2 alkoxy, C ⁇ C2 alkylthio, methoxy, methylthio, C1-C4 alkyl or trifluoromethyl radicals;
  • each R5 is independently
  • each R5 is independently hydrogen or C1-C4 alkyl radical; and most preferably, each R5 is a hydrogen radical; wherein each R 20 is independently
  • alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, N- (alkoxycarbonyl ) -N- (alkyl ) amino , aminocarbonylamino , alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo or aralkoxy, aralkylthio, aralkylsulfonyl, cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkanoyl, hydroxy, alkoxy, alkyl
  • each R 20 s independently
  • heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
  • aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C ⁇ -C4 alkyl) amino, C3.-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
  • each R20 is independently
  • heterocyclyl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di- (C 1 -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl of 1-3 halo radicals; or
  • aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di- (C 1 -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, (C 1 -C4 alkoxy) carbonyl, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, halo, azido, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl of 1- 3 halo radicals;
  • each R 20 is independently (1) C 1 -C 8 alkyl or C 2 -C 5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C3.-C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((C ⁇ -C 4 alkoxy) carbonyl) -N- (C1-C4 alkyl) amino, aminocarbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C1-C 4 alkylsulfonyl, halo or aryl-C ⁇ -C 4 -alkoxy, aryl-C ⁇ -C4- alkylthio, aryl-C ⁇ -C 4 -alkylsulfonyl, C 3 -
  • aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, (C 1 -C 4 alkoxy) carbonyl, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, halo, azido, C 1 -C 4 alkyl or C 1 -C 2 haloalkyl of 1-3 halo radicals;
  • each R 20 is independently (1) C 1 -C 8 alkyl or C 2 -C 5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, N-((C ⁇ -C 4 alkoxy) carbonyl) -N- (C 1 -C4 alkyl) amino, aminocarbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, halo or aryl-C ⁇ -C 4 -alkoxy, aryl-C ⁇ -C 4 - alkylthio, aryl-C ⁇ -C 4 -alkylsulfonyl
  • each R20 is independently substituted by 1-2 radicals of amino, di- (C 1 -C 4 alkyl) amino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C1 . -C 4 alkoxy, C 1 -C 4 alkylthio or C 1 -C 4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, C 1 -C 4 alkylamino, di- (C1-C4 alkyl) amino, acetamido, (C 1 -C 4 alkoxy) carbonylamino, C ⁇ C 4 alkylsulfonylamino, (C 1 -C 4 alkoxy) carbonyl , hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, halo, azido, C 1 -C4 alkyl or trifluoromethyl radicals; more preferably, each R20 is
  • C1-C8 alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C ⁇ -C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((C ⁇ C4 alkoxy) carbonyl) -N- (C1-C4 alkyl) amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C
  • heterocyclyl radical optionally substituted by 1-2 radicals of hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or Ci- C4 alkyl; or
  • aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (C1-C4 alkoxy) carbonyl, amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;
  • each R20 is independently
  • C1-C6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, t- butoxycarbonylamino , N- ( ( t-butoxy) carbonyl ) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals; (2) heterocyclyl radical optionally substituted by 1-2 radicals- of hydroxy or C1-C4 alkyl; or
  • aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
  • each R20 is independently
  • C1-C6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, t- butoxycarbonylamino , N- ( ( t-butoxy) carbonyl ) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
  • heterocyclyl radical or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
  • each R20 is independently
  • Ci-C ⁇ alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, hydroxy or phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
  • each R21 is independently hydrogen radical or R 20 ;
  • each R 22 is independently (1) hydrogen radical; (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; or
  • heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; provided when Z is a bond and Y is -NR 22 - C(0)-NH2, then R 22 is other then an optionally substituted aryl radical;
  • each R 22 is independently
  • C 1 -C 4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di- (C 1 -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, cyano, halo, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl of 1-3 halo radicals; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino
  • each R 22 is independently (1) hydrogen radical; or
  • C 1 -C 4 alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, di- (C 1 -C 2 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C ⁇ C 4 alkoxy, C1-C4 alkylthio, cyano, halo, C 1 -C 4 alkyl or C 1 -C 2 haloalkyl of 1-3 halo radicals;
  • each R 22 is independently hydrogen or C 1 -C 4 alkyl radical; and most preferably, each R 22 is independently hydrogen or methyl radical;
  • R ll and R ⁇ 2 are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of (1) R30; (2) halo or cyano radicals;
  • Rn is other than a 4-pyridyl, 4- pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rn and R 12 is 0-1; preferably, Rn and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of (1) R30;
  • Rn is other than a 4-pyridyl, 4- pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rn and R12 is 0-1;
  • Rn and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of
  • Rn is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of ( 1 ) R30 ;
  • Rn is an aryl radical and R 12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of
  • Rn is an aryl radical optionally substituted by 1-2 radicals of (1) R 30 ; (2) halo or cyano radicals; or (3) -C (0) -NR31R32 , -OR29, -SR29, - S(O)-R 30 , -S(O)2-R30, -S(0)2-NR3lR32- - R31 32 or -NR33- C(0)-R 29 radicals; more preferably, Rn is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl , aminocarbonyl , methyl or trifluoromethyl radicals; more preferably, Rn is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino
  • alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of -NR31R31, -CO2R23, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl , cyano, halo or aralkoxy, aralkylthio, aralkylsulfonyl , heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl , cyano, halo, alkyl or haloalkyl;
  • heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
  • aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl ;
  • each R30 is independently (1) C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl radicals optionally substituted by 1-3 radicals of -NR31R31, - CO2R23 hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo or aryl- C ⁇ -C4-alkoxy, aryl-C ⁇ -C4-alkylthio, aryl-C ⁇ -C4- alkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C
  • heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C ⁇ C4 haloalkyl of 1-3 halo radicals; or
  • aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
  • each R30 is independently
  • each R 30 is independently (1) C 1 -C 4 alkyl radical optionally substituted by
  • aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C 3. -C 4 alkylamino, di- (C 1 -C 4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
  • each R30 is independently
  • C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C2 alkyl) amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
  • aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di- (C1-C2 alkyl) amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
  • each R30 is independently
  • R30 is independently
  • C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
  • each R29 is independently hydrogen radical or R30; and most preferably, R 2 9 is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
  • each R31 is independently
  • alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
  • each R 31 is independently
  • C1-C4 alkyl radical optionally substituted by an C3- C ⁇ cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C ⁇ -C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-C8 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamin
  • each R31 is independently
  • each R31 is independently hydrogen or C1-C4 alkyl radicals; and most preferably, each R31 is independently hydrogen, methyl or ethyl radicals;
  • each R3 2 is independently
  • alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
  • aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
  • each R3 2 is independently (1) hydrogen radicals; (2) C 1 -C 4 alkyl radical optionally substituted by an C 3 - C ⁇ cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di- (C 1 -C 4 alkyl)amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl of 1-3 halo radicals; or
  • aryl, heteroaryl, heterocyclyl or C 3 -C 8 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl of 1-3 halo radicals;
  • each R 3 is independently
  • C 1 -C 4 alkyl radical optionally substituted by an C 3 - Ce cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, C 1 -C4 alkyl or C 1 -C 4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C 3 -C 6 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di- (C 1 -C 4 alkyl) amino
  • each R 32 is independently (1) hydrogen radicals; (2) C 1 -C 4 alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di- (C 1 -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkyl or trifluoromethyl radicals; or
  • phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di- (C 1 -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkyl or trifluoromethyl radicals;
  • each R 32 is independently (1) hydrogen radicals; (2) C 1 -C 4 alkyl radical or C 1 -C alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals;
  • R 32 is independently (1) hydrogen or C 1 -C 4 alkyl radical; or
  • alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
  • each R 33 is independently (1) hydrogen radical; or
  • C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di- (C1-C4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, C 1 -C 4 alkyl or Ci- C 4 haloalkyl of 1-3 halo radicals;
  • each R 33 is independently hydrogen or C 1 -C 4 alkyl radical; and most preferably, each R 33 is independently hydrogen or methyl radical.
  • R 1 and R 12 are the same and are a 5- or 6- member ring having from 1-3 heteroatoms independently selected from N, S, and 0, to which ring a benzene ring is optionally fused
  • R 11 is phenyl or naphthyl optionally substituted with halo, C x -C 6 alkyl, C 1 -C 4 alkoxy, C t -C 4 alkylthiol, hydroxy, amino, C 1 -C 4 alkylamino, or dialkylamino
  • R 11 is a 5- or 6-membered ring having from 1-3 heteroatoms independently selected from N, S, and O, to which ring a benzene ring is optionally fused and optionally substituted with C ⁇ -C j alkyl
  • R 2 is other than OH or NH 2 ; 2.
  • R 11 when R 2 is H, R 11 is phenyl and R 12 is phenyl or 4- pyridyl, then R 1 is other than H, methyl, or amino ; 3. when R 2 is H, R 11 is 2-methylphenyl and R 12 is 2- pyridyl, then R 1 is other than n-propyl; and
  • R 11 and R 12 are each an optionally substituted phenyl radical , then R 1 is other than an optionally substituted 2-pyridyl radical.
  • the compounds of this invention may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and diasteromers .
  • Compounds of interest include the following:
  • R 2 is H and R 11 , and R 1 are one of the combinations given in the following table:
  • R 2 is -OH and R 1 and R 1 are one of the combinations given in the following table:
  • Alkyl means a straight-chain or branched-chain alkyl radical containing preferably 1- 15 carbon atoms (C 1 -C 15 ) , more preferably 1-8 carbon atoms (Ci-Cs) even more preferably 1-6 carbon atoms (C 1 -C6) yet more preferably 1-4 carbon atoms (C 1 -C 4 ) , still more preferably 1-3 carbon atoms (C 1 -C 3 ) , and most preferably 1-2 carbon atoms (C 1 -C 2 ) •
  • Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso- amyl, hexyl, octyl and the like.
  • Hydroalkyl means an alkyl radical as defined above wherein at least one hydrogen radical is replaced with a hydroxyl radical, preferably 1-3 hydrogen radicals are replaced by hydroxyl radicals, more preferably 1-2 hydrogen radicals are replaced by hydroxyl radicals, and most preferably one hydrogen radical is replaced by a hydroxyl radical.
  • examples of such radicals include hydroxymethyl, 1-, 2-hydroxyethyl, 1-, 2-, 3 -hydroxypropyl , 1, 3 -dihydroxy-2-propyl, 1,3- dihydroxybutyl , 1,2,3,4,5,6-hexahydroxy-2-hexyl and the like.
  • Alkenyl alone or in combination, means a straight- chain or branched-chain hydrocarbon radical having one or more double bonds, preferably 1-2 double bonds and more preferably one double bond, and containing preferably 2-15 carbon atoms (C 2 -C 15 ) , more preferably 2-8 carbon atoms (C 2 -Cs) even more preferably 2-6 carbon atoms (C 2 -C 6 ) , yet more preferably 2-4 carbon atoms (C 2 -C 4 ) , and still more preferably 2-3 carbon atoms (C 2 -C 3 ) .
  • alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4- butadienyl and the like.
  • Alkoxy alone or in combination, means a radical of the type "R-0-" wherein “R” is an alkyl radical as defined above and "0" is an oxygen atom.
  • alkoxy radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert- butoxy and the like.
  • Alkoxycarbonyl alone or in combination, means a radical of the type "R-O-C(O)-" wherein "R-0-" is an alkoxy radical as defined above and “C(0)” is a carbonyl radical .
  • Alkoxycarbonylamino alone or in combination, means a radical of the type "R-O-C (0) -NH-" wherein “R-O-C(O)” is an alkoxycarbonyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
  • Alkylthio alone or in combination, means a radical of the type "R-S-" wherein "R” is an alkyl radical as defined above and “S” is a sulfur atom.
  • alkylthio radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio and the like.
  • Alkylsulfinyl means a radical of the type “R-S(O)-" wherein "R” is an alkyl radical as defined above and “S(0)” is a mono-oxygenated sulfur atom.
  • alkylsulfinyl radicals include methylsulfinyl , ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, n-butylsulfinyl, iso-butylsulfinyl, sec-butylsulfinyl , tert-butylsulfinyl and the like.
  • Alkylsulfonyl means a radical of the type “R-S(0) 2 -" wherein "R” is an alkyl radical as defined above and “S(0) 2 " is a di-oxygenated sulfur atom.
  • alkylsulfonyl radicals include methylsulfonyl , ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, iso-butylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl and the like.
  • Aryl alone or in combination, means a phenyl or biphenyl radical, which is optionally benzo fused or heterocyclo fused and which is optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, azido, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, alkanoylamino, amido, amidino, alkoxycarbonylamino, N- alkylamidino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl , dialkylaminoalkyl, N-alkylamido, N,N- dialkylamido, aralkoxycarbonylamino , alkylthio, alkylsulfinyl, alkylsulfonyl , oxo and the like.
  • aryl radicals are phenyl, o-tolyl, 4- methoxyphenyl, 2- (tert-butoxy) phenyl, 3-methyl-4- methoxyphenyl , 2-CF 3 -phenyl, 2-fluorophenyl , 2- chlorophenyl, 3 -nitropheny1, 3-aminophenyl, 3- aceta idophenyl, 2-amino-3- (aminomethyl) phenyl, 6- methyl-3-acetamidophenyl , 6-methyl-2-aminophenyl , 6- methyl-2 , 3-diaminophenyl, 2-amino-3 -methylphenyl, 4,6- dimethyl-2-aminophenyl, 4-hydroxyphenyl, 3-methyl-4- hydroxyphenyl, 4- ( 2-methoxyphenyl) phenyl, 2-amino-l- naphthyl, 2-naphthyl, 3 -amino-2-na
  • Alkyl and arylalkyl alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyl, 1-, 2- phenylethyl, dibenzylmethyl, hydroxyphenylmethyl , methylphenylmethyl , diphenylmethyl , dichlorophenylmethyl , 4-methoxyphenylmethyl and the like.
  • Alkoxy alone or in combination, means an alkoxy radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyloxy, 1-, 2-phenylethoxy, dibenzylmethoxy, hydroxyphenylmethoxy, methylphenylmethoxy, dichlorophenylmethoxy, 4- methoxyphenylmethoxy and the like.
  • Alkoxycarbonyl alone or in combination, means a radical of the type "R-O-C(O)-" wherein “R-0-” is an aralkoxy radical as defined above and “-C(O)-” is a carbonyl radical .
  • Alkanoyl alone or in combination, means a radical of the type "R-C(O)-" wherein "R” is an alkyl radical as defined above and "-C(O)-” is a carbonyl radical.
  • alkanoyl radicals include acetyl, trifluoroacetyl, hydroxyacetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like.
  • Alkanoylamino alone or in combination, means a radical of the type "R-C(0)-NH-" wherein "R-C(O)-" is an alkanoyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
  • aminocarbonyl alone or in combination, means an amino substituted carbonyl (carbamoyl) radical, wherein the amino radical may optionally be mono- or di-substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl, aralkoxycarbonyl and the like.
  • Aminosulfonyl means an amino substituted sulfonyl radical.
  • Benzo fused forms a ring system in which benzene and a cycloalkyl or aryl group have two carbons in common, for example tetrahydronaphthylene and the like.
  • Bicyclic as used herein is intended to include both fused ring systems, such as naphthyl and ⁇ -carbolinyl, and substituted ring systems, such as biphenyl, phenylpyridyl and diphenylpiperazinyl .
  • Cycloalkyl alone or in combination, means a saturated or partially saturated, preferably one double bond, monocyclic, bicyclic or tricyclic carbocyclic alkyl radical, preferably monocyclic, containing preferably 5- 12 carbon atoms (C 5 -C 12 ) , more preferably 5-10 carbon atoms (C 5 -C 10 ) , even more preferably 5-7 carbon atoms (C 5 -C 7 ) , which is optionally benzo fused or heterocyclo fused and which is optionally substituted as defined herein with respect to the definition of aryl.
  • cycloalkyl radicals include cyclopentyl, cyclohexyl, dihydroxycyclohexyl, ethylenedioxycyclohexyl, cycloheptyl, octahydronaphthyl , tetrahydronaphthyl , octahydroquinolinyl, dimethoxytetrahydronaphthyl , 2 , 3-dihydro-lH-indenyl , azabicyclo [3.2.1] octyl and the like.
  • Heteroatoms means nitrogen, oxygen and sulfur heteroatoms.
  • Heterocyclo fused forms a ring system in which a heterocyclyl or heteroaryl group of 5-6 ring members and a cycloalkyl or aryl group have two carbons in common, for example indole, isoquinoline, tetrahydroquinoline, methylenedioxybenzene and the like.
  • Heterocyclyl means a saturated or partially unsaturated, preferably one double bond, monocyclic or bicyclic, preferably monocyclic, heterocycle radical containing at least one, preferably 1 to 4 , more preferably 1 to 3 , even more preferably 1-2, nitrogen, oxygen or sulfur atom ring member and having preferably 3-8 ring members in each ring, more preferably 5-8 ring members in each ring and even more preferably 5-6 ring members in each ring.
  • Heterocyclyl is intended to include sulfone and sulfoxide derivatives of sulfur ring members and N-oxides of tertiary nitrogen ring members, and carbocyclic fused, preferably 3-6 ring carbon atoms and more preferably 5-6 ring carbon atoms, and benzo fused ring systems.
  • Heterocyclyl radicals may optionally be substituted on at least one, preferably 1- 4, more preferably 1-3, even more preferably 1-2, carbon atoms by halogen, alkyl, alkoxy, hydroxy, oxo, thioxo, aryl, aralkyl, heteroaryl, heteroaralkyl , amidino, N- alkylamidino, alkoxycarbonylamino, alkylsulfonylamino and the like, and/or on a secondary nitrogen atom by hydroxy, alkyl, aralkoxycarbonyl, alkanoyl, alkoxycarbonyl, heteroaralkyl, aryl or aralkyl radicals.
  • heterocyclyl is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals.
  • heterocyclyl radicals include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, 4-benzyl-piperazin-l-yl, pyrimidinyl , tetrahydrofuryl, pyrazolidonyl , pyrazolinyl, pyridazinonyl, pyrrolidonyl, tetrahydrothienyl and its sulfoxide and sulfone derivatives, 2 , 3-dihydroindolyl, tetrahydroquinolinyl , 1,2,3, 4-tetrahydroisoquinolinyl, 1,2,3, 4-tetrahydro-l- oxo-isoquinolinyl, 2 , 3-dihydrobenzofuryl , benzopyranyl, methylenedioxyphenyl, ethylenedioxyphenyl and the like.
  • Heteroaryl means a monocyclic or bicyclic, preferably monocyclic, aromatic heterocycle radical, having at least one, preferably 1 to 4, more preferably 1 to 3 , even more preferably 1-2, nitrogen, oxygen or sulfur atom ring members and having preferably 5-6 ring members in each ring, which is optionally saturated carbocyclic fused, preferably 3-4 carbon atoms (C 3 -C 4 ) to form 5-6 ring membered rings and which is optionally substituted as defined above with respect to the definitions of aryl .
  • heteroaryl groups include imidazolyl, l-benzyloxycarbonylimidazol-4-yl, pyrrolyl, pyrazolyl, pyridyl, 3- ( 2-methyl) pyridyl, 3- (4- trifluoromethyl) pyridyl, pyrimidinyl, 5- (4- trifluoromethyl) pyrimidinyl , pyrazinyl, triazolyl, furyl, thienyl, oxazolyl, thiazolyl, indolyl, quinolinyl, 5,6,7, 8-tetrahydroquinolyl , 5, 6, 7 , 8-tetrahydroisoquinolinyl, quinoxalinyl, benzothiazolyl, benzofuryl, benzimidazolyl, benzoxazolyl and the like.
  • Heteroaralkyl and “heteroarylalkyl, " alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by a heteroaryl radical as defined above, such as 3-furylpropyl, 2-pyrrolyl propyl, chloroquinolinylmethyl , 2-thienylethyl, pyridylmethyl, 1-imidazolylethyl and the like.
  • Halogen and "halo”, alone or in combination, means fluoro, chloro, bromo or iodo radicals.
  • Haloalkyl alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-3, is replaced by a halogen radical, more preferably fluoro or chloro radicals .
  • haloalkyl radicals include 1, 1, 1-trifluoroethyl, chloromethyl , 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, bis (trifluoromethyl) methyl and the like.
  • “Pharmacologically acceptable salt” means a salt prepared by conventional means, and are well known by those skilled in the art.
  • the “pharmacologically acceptable salts” include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like.
  • Suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in the art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like.
  • pharmaceutically acceptable salts see infra and Berge et al, J “ . Pharm . Sci . 66, 1 (1977) . 8 " 2
  • Cytokine means a secreted protein that affects the functions of other cells, particularly as it relates to the modulation of interactions between cells of the immune system or cells involved in the inflammatory response.
  • cytokines include but are not limited to interleukin 1 (IL-1) , preferably IL-l ⁇ , interleukin 6 (IL-6) , interleukin 8 (IL-8) and TNF, preferably TNF- ⁇ (tumor necrosis factor- ⁇ ) .
  • TNF, IL-1, IL-6, and/or IL-8 mediated disease or disease state means all disease states wherein TNF, IL- 1, IL-6, and/or IL-8 plays a role, either directly as TNF, IL-1, IL-6, and/or IL-8 itself, or by TNF, IL-1, IL-6, and/or IL-8 inducing another cytokine to be released.
  • TNF a disease state in which IL-1 plays a major role, but in which the production of or action of IL-1 is a result of TNF, would be considered mediated by TNF.
  • leaving group generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate .
  • Protecting group generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like.
  • aralkyl examples include, but are not limited to, benzyl, ortho- methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as p osphonium and ammonium salts .
  • aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9- ( 9-phenylfluorenyl) , phenanthrenyl , durenyl and the like.
  • cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like.
  • Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t- butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, tri-fluoroacetyl, tri-chloro acetyl, phthaloyl and the like.
  • a mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralkyl group and an aralkoxycarbonyl group.
  • Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example, 1, 2-bis (methylene) benzene, phthalimidyl , succinimidyl, maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalkyl rings.
  • the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl .
  • Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like.
  • an addition salt such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like.
  • Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups.
  • aralkyl groups .
  • Alkyl groups are also sutiable groups for protecting hydroxy and mercapto groups, such as tert- butyl .
  • Silyl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl " groups.
  • Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, tri-isopropylsilyl, tert- butyldimethylsilyl , dimethylphenylsilyl, 1,2- bis (dimethylsilyl) benzene, 1, 2-bis (dimethylsilyl) ethane and diphenylmethylsilyl .
  • Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of aminoalcohol compounds can lead to a N,N, O-tri-silyl derivative.
  • silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium flouride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group.
  • Suitable silylating agents are, for example, trimethylsilyl chloride, tert-buty-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF .
  • Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.
  • Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HCl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine .
  • a protecting group such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof.
  • a t-butoxycarbonyl protecting group can be removed utilizing an in
  • Carboxy protecting group such as methyl, ethyl, benzyl, tert-butyl, 4- methoxyphenylmethyl and the like, can be removed under hydroylsis and hydrogenolysis conditions well known to those skilled in the art.
  • Prodrugs of the compounds of this invention are also contemplated by this invention.
  • a prodrug is an active or inactive compound that is modified chemically through in vivo physicological action, such as hydrolysis, metabolism and the like, into a compound of this invention following adminstration of the prodrug to a patient.
  • the suitability and techniques involved in making and using prodrugs are well known by those skilled in the art.
  • For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985) .
  • Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl) , cycloalkyl (for example, cyclohexyl) , aralkyl (for example, benzyl, p- methoxybenzyl) , and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl) .
  • esters such as alkyl (for example, methyl, ethyl) , cycloalkyl (for example, cyclohexyl) , aralkyl (for example, benzyl, p- methoxybenzyl) , and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl) .
  • Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde
  • drugs containing an acidic NH group such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers.
  • EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.
  • Compounds according to the invention can be synthesized according to one or more of the following methods . It should be noted that the general procedures are shown as it relates to preparation of compounds having unspecified stereochemistry. However, such procedures are generally applicable to those compounds of a specific stereochemistry, e.g., where the stereochemistry about a group is (S) or (R) . In addition, the compounds having one stereochemistry (e.g., (R) ) can often be utilized to produce those having opposite stereochemistry (i.e., (S) ) using well- known methods, for example, by inversion.
  • the general procedures are shown as it relates to preparation of compounds having unspecified stereochemistry. However, such procedures are generally applicable to those compounds of a specific stereochemistry, e.g., where the stereochemistry about a group is (S) or (R) .
  • the compounds having one stereochemistry e.g., (R)
  • a general method for the preparation of compounds of formula I involves the condensation of an 1,3- dicarbonyl intermediate IV with an N-C-N containing structure such as an amidine V, a guanidine VI or urea VII (Scheme 1; for a review of synthetic methods see D.J. Brown, Heterocyclic Compounds : the Pyrimidines, Chapter 3, 1994, John Wiley & Sons).
  • Scheme 1
  • a b- dimethylamino-a,b-unsaturated ketone IX can be reacted with amidines V or guanidines VI as described (G.B. Bennett et al . , J. Med. Chem. 21, 623-628, 1978). (Scheme 2).
  • Such b-dimethylamino-a,b-unsaturated ketones IX can be prepared by aminoformylation of an active methylene ketone VIII with Bredereck' s reagent, namely, bis (dimethylamino )methoxymethane (H. Bredereck et al., Chem. Ber . 101, 41-50 (1968); G. B. Bennett et al J . Org . Chem . 43 , 221-225 ( 1977 ) ) Scheme 2
  • Scheme 3 illustrates the conversion of 2- (4-fluorophenyl) -1- (4- pyridyl) ethanone (VIII; Sheldrake, Synthetic
  • ketones VIII may be prepared (e.g., according to Sheldrake, Synthetic communications 23, 1967-1971 (1993)), by employing other heteroaryl carboxaldehydes as the starting material, such as 2- methylpyridine-4-carboxaldehyde, 2, 6-dimethylpyridine-4- carboxaldehyde (Mathes and Sauermilch, Chem . Ber.
  • intermediate IX may also be condensed with urea VII to give the 2(1.7)- pyrimidinone derivative X.
  • X is transformed into chloride XI by reaction with a halogenating agent such as phosphorous oxychloride.
  • a halogenating agent such as phosphorous oxychloride.
  • Treatment of chloride XI with primary and secondary amines, thiolates or alcoholates allows the preparation of further pyrimidines I with R 1 represented by a substituted N, S or 0 groups, as recited above.
  • hydrazines may be reacted with chloride XI to provide 2-hydrazino substituted pyrimidines I.
  • Palladium or nickel catalyzed cross couplings of chloride XI with arylboronic acids or arylzinc halides provide compounds of formula I wherein R 1 is aryl or heteroaryl .
  • Scheme 6 illustrates the reaction of intermediate IX with guanidine VI to give 2-amino substituted I.
  • 2- Amino I is a useful intermediate for further acylations and sulfonylations of the 2-amino group to give acylamido and sulfonamido derivatives.
  • the disubstituted acrylic acid ester XII may be prepared conveniently by condensation of pyridine-4- carboxaldehyde with 4-fluorophenylacetic acid followed by esterification. XII may be reacted with a variety of amidines V at elevated temperature . As a dehydrogenating agent for the conversion of XIII to II, sodium nitrite/acetic acid is suitable.
  • R 12 is any other heteroaryl ring within the definition of R 12 by the appropriate choice of starting material.
  • starting materials include but are not limited to 2-methylpyridine-4-carboxaldehyde, 2 , 6-dimethylpyridine-4-carboxaldehyde (Mathes and Sauermilch, Chem . Ber.
  • methyl 2- nitroisonicotinate (Stanonis, J “ . Org. Chem . 22, 475 (1957)) may be reacted with an aryl acetic acid ester followed by cyclization of the resultant b-keto ester with thiourea analogously to Scheme 9. Subsequent catalytic reduction of the nitro group to an amino group would give a 4-hydroxy-pyrimidine II in which R 12 is represented by a 2-amino-4-pyridyl group (Scheme 10]
  • methyl 2-acetamido isonicotinate may be reacted analogously to Scheme 9 after appropriate protection of the amide nitrogen with e.g. a tert-butyldimethylsilyloxymethyl group (Benneche et al . , Acta Chem . Scand. B 42 384-389 (1988)), a tert- butyldimethylsilyl group, a benzyloxymethyl group, a benzyl group or the like (P x ) .
  • a tert-butyldimethylsilyloxymethyl group (Benneche et al . , Acta Chem . Scand. B 42 384-389 (1988)
  • P x tert-butyldimethylsilyl group
  • compounds of pyrimidines II may be prepared by coupling a suitable derivative of XVIII (L is a leaving group, such as halogen radical and the like, and P 2 is a protecting group, such as benzyl and the like) with an appropriate aryl equivalent.
  • L is a leaving group, such as halogen radical and the like
  • P 2 is a protecting group, such as benzyl and the like
  • aryl/heteroaryl couplings are well known to those skilled in the art and involve an organic-metallic component for reaction with a reactive derivative, e.g., a halogeno derivative, of the second compound in the presence of a catalyst.
  • a reactive derivative e.g., a halogeno derivative
  • the metallo-organic species may be provided either by the pyrimidinone in which case the aryl component provides the reactive halogen equivalent or the pyrimidinone may be in the form of a reactive 5- halogeno derivative for reaction with a metallo organic aryl compound.
  • 5-bromo and 5-iodo derivatives of XVIII may be treated with arylalkyl tin compounds, e.g., trimethylstannylbenzene, in an inert solvent such as tetrahydrofuran in the presence of a palladium catalyst, such as di (triphenylphosphine) palladium (II) dichloride .
  • a palladium catalyst such as di (triphenylphosphine) palladium (II) dichloride .
  • Modification at the 4-position (R 2 of formula I) of pyrimidine II is possible by conversion into the chloro derivative XX by reaction with phosphorous oxychloride (Scheme 14) .
  • a 4-alkoxy derivative XXI may be prepared from chloro derivative XX by nucleophilic substitution with alkoxide.
  • other leaving groups such as tosylates, mesylates and the like, can be used. Also, such leaving groups can also be displaced by amino, thiolates, alcoholates, and the like nucleophiles .
  • the chloro derivative XX may be reduced by catalytic hydrogenation to give a pyrimidine I where R 2 is H, or may be reacted with an alkyl or aryl boronic acid or an alkyl or aryl zinc halide to provide a pyrimidine I where R 2 is alkyl or aryl.
  • compounds of the present invention of formula XXX can be readily prepared by reacting the methylthio intermediate XXXI with the amine NHR 5 R 21 , for example by heating the mixture preferably at a temperature greater than 100°C, more preferably 150- 210°C.
  • compounds of formula XXX can be readily prepared by reacting the methylsulfonyl intermediate XXXII with the amine NHR 5 R 21 , for example by heating the mixture preferably at a temperature greater than 40°C, more preferably 50-210°C.
  • Amines of formula NHR 5 R 21 are commercially available or can be readily prepared by those skilled in the art from commercially available starting materials.
  • an amide, nitro or cyano group can be reduced under reducing conditions, such as in the prescence of a reducing agent like lithium aluminum hydride and the like, to form the corresponding amine.
  • Alkylation and acylation of amino groups are well known in the art.
  • Chiral and achiral substituted amines can be prepared from chiral amino acids and amino acid amides (for example, alkyl, aryl, heteroaryl, cycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and the like substituted glycine, ⁇ -alanine and the like) using methods well known in the art, such as H. Brunner, P. Hankofer, U. Holzinger, B. Treittinger and H. Schoenenberger, Eur. J. Med. Chem. 25, 35-44, 1990; M. Freiberger and R. B. Hasbrouck, J. Am. Chem. Soc.
  • Rl NH - 1-20 2 -Ethylamino- 5- (4-f luorophenyl) -4- (4-pyridyl) - pyrimidine: MS (m/z) : 295.0 (M+H) + ; C 17 H 15 FN 4 requir . 294.3.
  • Rl H0 3 S-CH 2 -CH 2 -NH- 1-22 2- (2-Diethylaminoethylamino) -5- (4-f luorophenyl) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 365.8 (M+H) + ; C 21 H 24 FN 5 requir. 365.5.
  • Rl NH 2 CH 2 CH 2 CH 2 NH- 2-3 2- (4-Aminobutylamino) -5- (4-f luorophenyl) -4- (4- pyridyl) -pyrimidine hydrochloride: MS (m/z) : 338.0 (M+H) * ; C 19 H 20 FN S -HC1 requir. 337.4+36.5.
  • R R 21 , OR 20 or NR 5 R 21
  • the chlorocarbonyl R-C(0)C1 (0.57 mmol) was added dropwise to a solution of 2-amino-5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine (0.38 mmol) in pyridine (3 ml) at ice-bath temperature. It was stirred for 3 h at room temperature, monitored by thin layer chromatography, poured into ice-water, extracted with dichloromethane, dried and evaporated. The crude product can be purified by silica gel column chromatography (hexane-acetone) and recrystallized from a suitable solvent such as ethyl acetate.
  • Step B 5- (4-Fluorophenyl) -2 , 4-bis- (4-pyridyl) - pyrimidine:
  • the resulting material was purified on a column of silica gel (5% methanol/dichloromethane) , then dissolved in methanol (2 ml) and 4N hydrogen chloride/dioxane (2 ml) was added. After 1 h at room temperature, it was evaporated and the remainder taken up in dichloromethane followed by washing with aqueous sodium hydrogencarbonate, drying of the organic solution and evaporation.
  • Step A 4- (4-Pyridyl) -2 (IH) -pyrimidinone: A mixture of 4-acetylpyridine (25 ml, 226.0 mmol) and bis (dimethylamino)methoxymethane (44 ml, 293.8 mmol) was heated at 85°C for 30 min followed by evaporation to dryness to recover a solid of 3- (dimethylamino) -1- (4- pyridyl) -3-propen-l-one. Its ethanolic solution (200 ml) was transferred into ethanolic 1.13 N sodium ethoxide (200 ml) containing urea (16.3 g, 271 mmol).
  • Step B 2-Chloro-4- (4-pyridyl) -pyrimidine: With ice- bath cooling under argon, 4- (4-pyridyl) -2 (IH) - pyrimidinone (13.45 g, 77.7 mmol) and thionyl chloride (92 ml) were combined. N, N-Dimethylformamide (13.2 ml, 170.5 mmol) was added slowly and the mixture was heated to reflux for 1 h. It was evaporated and co-distilled with toluene. At 0°C, water was added to the remainder, then 10% ammonium hydroxide until neutral followed by extraction with dichloromethane.
  • Step C 2- ( ( (S) -2-Amino-3 -phenylpropyl) -amino) -4- (4- pyridyl) -pyrimidine: A mixture of 2-chloro-4- (4- pyridyl) -pyrimidine (4.5 g, 23.7 mmol) and (S)-l,2- benzylethylendiamine (8.0 g, 53.3 mmol) was heated at 100°C for 25 min.
  • Step D 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5-bromo-
  • Step E 2- ( ( (S) -2-Amino-3-phenylpropyl) amino) -5- (3- chloro-4-fluorophenyl) -4- (4-pyridyl) -pyrimidine hydrochloride : A mixture of 2- ( (2 (S) -amino-3-phenyl propyl) amino) -5-bromo-4- (4-pyridyl) -pyrimidine (204 mg, 0.53 mmol), aqueous 2M sodium carbonate (1.66 ml, 3.32 mmol) and 3-chloro-4-fluorobenzene boronic acid (103 mg, 0.637 mmol) in toluene (5 ml) was stirred for 10 min under argon. The mixture was thoroughly degassed (10 times) , before the addition of tetrakis
  • Step A 5- (4-Fluorophenyl) -3-methyl-2-methylsulfonyl-6- (4-pyridyl) -4 (3H) -pyrimidinone: A mixture of 5- (4- fluorophenyl) -3-methyl-2-methylthio-6- (4-pyridyl) -4 (3H) - pyrimidinone (400 mg, 1.22 mmol) and Oxone R (potassium peroxymonosulfate, 2.3 g, 3.74 mmol) in methanol (100 ml) and water (45 ml) was stirred for 13 h. The solvent was concentrated to about 50 ml, followed by extraction with dichloromethane, drying of the organic solution and evaporation.
  • Step B 2- ( ( (S) -2-N, -Dimethylamino-3 -phenylpropyl) - amino) -5- (4-fluorophenyl-3-methyl-6- (4-pyridyl) -4 (3H) - pyrimidinone hydrochloride: A mixture of crude 5- (4- fluorophenyl) -3-methyl-2-methylsulfonyl-6- (4-pyridyl) - 4 ( 3H) -pyrimidinone (430 mg g, 1.19 mmol) and ( S ) -2-N, N- dimethylamino-3-phenylpropylamine (600 mml, -3.4 mmol) was stirred at room temperature for lh and then briefly o warmed at 50 C.
  • a solution of 2-chloroisonicotinic acid (25. Og, 0.16 mol) in 65 mL of concentrated ammonium hydroxide was warmed to 205 Celsius in a steel bomb for 72 h. After cooling to 23 C, the solution was acidified to a pH of 1 using 6N HCl and subsequently filtered to remove unreacted starting material. The solution was concentrated to one fourth the original volume (approx 200 mL) in vacuo, and carefully adjusted to a pH of 6 using 1 N NaOH. After storing the cloudy solution at 0 C for 20 h, the desired 2-aminoisonicotinic acid was filtered off.
  • Step B 5- (4-fluorophenyl) -6- (4- (2-acetamido)pyridyl) ) - 2-thiouracil:
  • 2-Methyl-3-phenylpropylamine A mixture of commercially available 2-methyl-3-phenylpropylamide (4.32 g, 26.5 mmol) and lithium aluminium hydride (1.3 g, 34.3 mmol) in tetrahydrofuran (184 ml) was stirred at room temperature for 5 h. It was poured into aqu. sat. sodium sulfate and extracted with dichloromethane followed by drying of the organic solution and evaporation to provide the amine as an oil . Other syntheses have been reported, e.g. Dornow and Fust, Chem. Ber. 87, 984 (1954).
  • Example 24 A mixture of commercially available 2-methyl-3-phenylpropylamide (4.32 g, 26.5 mmol) and lithium aluminium hydride (1.3 g, 34.3 mmol) in tetrahydrofuran (184 ml) was stirred at room temperature for 5 h. It was poured into aqu
  • Step A Methyl 2-amino-3- (2-fluorophenyl) propionate: 5g (27.3 mmol) of (D,L) - (2-fluoro-phenyl) alanine was suspended in 50 ml methanolic HCl and stirred at room temperature for 3 days . The reaction mixture was concentrated in vacuo and dried to give a yellow oil . MS (m/z): 198 (M+H) * ; C 10 H 12 FNO 2 requir . 197.2.
  • Step B 2-Amino-3- (2-fluorophenyl)propionamide: Methyl 2-amino-3- (2-fluorophenyl) propionate was suspended in 50 ml 30% ammonium hydroxide and stirred at room temperature for 18 hrs. The mixture was filtered, washed with cold water and 2-amino-3- (2-fluorophenyl) propionamide was collected as a white solid. MS (m/z) : 183.1 (M+H) * ; C 9 H u FN 2 0 requir. 182.2.
  • Step A Methyl (2S.3R, ⁇ S) -3- (N-benzyl -N- ⁇ - methylbenzylamino) -2-methyl-3-phenylpropionate was prepared as reported for the 2R, 3S, ⁇ R-enantiomer (S) .G. Davies and I.A.S. Walters, J. Chem. Soc. Perkin Trans. I, 1129-1139 (1994).
  • Step B Methyl (2S , 3R) -3-amino-2-methyl-3- phenylpropionate : A mixture of methyl (2S, 3R, ⁇ S) -3- (N- benzyl -N- ⁇ -methylbenzylamino) -2-methyl-3- phenylpropionate (13.0 g, 33.55 mmol) and 10% palladium- on-carbon (13.0 g) in glacial acetic acid (260 ml) was hydrogenated under a balloon of hydrogen for 24 h. The catalyst. was removed by filtration followed by evaporation and co-distillation with toluene to provide the title compound as a white solid. MS (m/z) : 194.2 (M+H) * ; C ⁇ H ⁇ NO. requir. 193.3.
  • Step D (1R, 2R) -2-methyl-1-phenyl-l, 3-propanediamine: Lithium aluminium hydride (2.3 g, 60.60 mmol) was added in portions to a stirring solution of (2S, 3R) -3-amino-2- methyl-3-phenylpropionamide (2.6 g, 14.59 mmol) in tetrahydrofuran (54 ml) at ice-bath temperature. After 45 min, the mixture was heated at reflux for 16 h. With ice-bath cooling, the reaction was quenched by the portionwise addition of sodium sulfate decahydrate and some methanol until hydrogen evolution ceased. The solids were removed by filtration and washed with dichloromethane. The combined filtrates were evaporated to provide the title compound. MS (m/z) : 165.2 (M+H) * ; C 10 H 16 N 2 requir. 164.3.
  • Biological Assays The following assays were used to characterize the ability of compounds of the invention to inhibit the production of TNF- ⁇ and IL-l- ⁇ .
  • the second assay measured the inhibition of TNF- ⁇ and/or IL-l- ⁇ in mice after oral administration of the test compounds .
  • the third assay a glucagon binding inhibition in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit glucagon binding.
  • the fourth assay a Cyclooxygenase enzyme (COX-1 and COX-2) inhibition activity in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit COX-1 and/or COX-2.
  • COX-1 and COX-2 a Cyclooxygenase enzyme
  • Test compounds were evaluated in vi tro for the ability to inhibit the production of TNF by monocytes activated with bacterial lipopolysaccharide (LPS) .
  • Fresh residual source leukocytes (a byproduct of plateletpheresis) were obtained from a local blood bank, and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation on Ficol- Paque Plus (Pharmacia) .
  • PBMCs peripheral blood mononuclear cells
  • PBMCs peripheral blood mononuclear cells
  • PBMCs peripheral blood mononuclear cells
  • PBMCs were suspended at 2 x 10 s /ml in DMEM supplemented to contain 2% FCS, 10 mM, 0.3 mg/ml glutamate, 100 U/ml penicillin G and 100 mg/ml streptomycin sulfate (complete media) .
  • Cells were plated into Falcon flat bottom, 96 well culture plates (200 ⁇ l/well) and cultured overnight at 37°C and 6% C0 2 . Non-adherent cells were removed by washing with 200 ⁇ l/well of fresh medium. Wells containing adherent cells (-70% monocytes) were replenished with 100 ⁇ l of fresh medium.
  • Test compounds were dissolved in DMZ. Compound stock solutions were prepared to an initial concentration of 10 - 50 uM. Stocks were diluted initially to 20 - 200 ⁇ M in complete media. Nine twofold serial dilutions of each compound were then prepared in complete medium. Treatment of cells wi th test compounds and activation of
  • Standards consisted of eleven 1.5-fold serial dilutions from a stock of 1 ng/ml recombinant human TNF (R&D Systems) . Plates were incubated at room temperature for 1 hr on orbital shaker (300 rpm) , washed and replenished with 100 ⁇ l/well of 0.5 ⁇ g/ml goat anti-human TNF- ⁇ (R&D systems #AB-210-NA) biotinylated at a 4:1 ratio. Plates were incubated for 40 min, washed and replenished with 100 ⁇ l/well of alkaline phosphatase-conjugated streptavidin (Jackson ImmunoResearch #016-050-084) at 0.02 ⁇ g/ml.
  • Plates were incubated 30 min, washed and replenished with 200 ⁇ l/well of 1 mg/ml of p-nitrophenyl phosphate. After 30 min, plates were read at 405 nm on a Vmax p*-late reader.
  • Standard curve data were fit to a second order polynomial and unknown TNF- ⁇ concentrations determined from their OD by solving this equation for concentration. TNF concentrations were then plotted vs. test compound concentration using a second order polynomial. This equation was then used to calculate the concentration of test compounds causing a 50% reduction in TNF production.
  • Compounds of the invention can also be shown to inhibit LPS-induced release of IL-l ⁇ , IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-l ⁇ , IL- 6 and/or IL-8 by methods well known to those skilled in the art.
  • compounds of this invention can also be shown to inhibit LPS induced release of IL-l ⁇ , IL-6 and/or IL- 8 from monocytes by measuring concentrations of IL-l ⁇ , IL-6 and/or IL-8 by methods well known to those skilled in the art.
  • the compounds of the invention may lower elevated levels of TNF- ⁇ , IL-1, IL-6, and IL-8 levels. Reducing elevated levels of these inflammatory cytokines to basal levels or below is favorable in controlling, slowing progression, and alleviating many disease states. All of the compounds are useful in the methods of treating disease states in which TNF- ⁇ , IL- l ⁇ , IL-6, and IL-8 play a role to the full extent of the definition of TNF- ⁇ -mediated diseases described herein.
  • mice Male DBA/1LACJ mice were dosed with vehicle or test compounds in a vehicle (the vehicle consisting of 0.5% tragacanth in 0.03 N HCl) 30 minutes prior to lipopolysaccharide (2 mg/kg, I.V.) injection.
  • vehicle the vehicle consisting of 0.5% tragacanth in 0.03 N HCl
  • lipopolysaccharide 2 mg/kg, I.V.
  • the following compounds exhibit activities in the monocyte assay (LPS induced TNF release) with IC 50 values of 20 ⁇ M or less: 5- (4-Fluorophenyl) -2- (4-pyridyl) -4- (4-pyridyl) - pyrimidine
  • Compounds of the invention may be shown to have anti-inflammatory properties in animal models of inflammation, including carageenan paw edema, collagen induced arthritis and adjuvant arthritis, such as the carageenan paw edema model (C. A. Winter et al Proc. Soc. Exp. Biol. Med. (1962) vol 111, p 544; K. F. Swingle, in R. A. Scherrer and M. W. Whitehouse, Eds., Antiinflammatory Agents, Chemistry and Pharmacology, Vol. 13-11, Academic, New York, 1974, p. 33) and collagen induced arthritis (D. E. Trentham et al J. Exp. Med. (1977) vol. 146, p 857; J. S. Courtenay, Nature (New Biol.) (1980), Vol 283, p 666).
  • the assay is described in WO 97/16442, which is incorporated herein by reference in its entirety.
  • Reagents The reagents can be prepared as follows: (a) prepare fresh IM o-Phenanthroline (Aldrich) (198.2 mg/ml ethanol); (b) prepare fresh 0.5M DTT (Sigma); (c) Protease Inhibitor Mix (1000X) : 5 mg leupeptin, 10 mg benzamidine, 40 mg bacitracin and 5 mg soybean trypsin inhibitor per ml DMSO and store aliquots at -20°C; (d) 250 ⁇ M human glucagon (Peninsula): solubilize 0.5 mg vial in 575 ⁇ l 0.
  • Final protein concentration of a membrane preparation is determined on a per batch basis.
  • the determination of inhibition of glucagon binding can be carried out by measuring the reduction of I 125 - glucagon binding in the presence of compounds of Formula
  • the mixture is incubated for 60 min. at 22°C on a shaker at 275 rpm.
  • the mixture is filtered over pre-soaked (0.5% polyethylimine (PEI)) GF/C filtermat using an Innotech Harvester or Tomtec Harvester with four washes of ice-cold 20mM Tris buffer (pH 7.8).
  • the radioactivity in the filters is determined by a gamma- scintillation counter.
  • compounds of the invention may also be shown to inhibit the binding of glucagon to glucagon receptors .
  • THP-1 The human monocytic leukemia cell line, THP-1, differentiated by exposure to phorbol esters expresses only COX-1; the human osteosarcoma cell line 143B expresses predominantly COX-2.
  • THP-1 cells are routinely cultured in RPMI complete media supplemented with 10% FBS and human osteosarcoma cells (HOSC) are cultured in minimal essential media supplemented with 10% fetal bovine serum (MEM-10%FBS) ; all cell incubations are at 37°C in a humidified environment containing 5% C0 2 .
  • THP-1 cells are grown to confluency, split 1:3 into RPMI containing 2% FBS and 10 mM phorbol 12-myristate 13-acetate (TPA) , and incubated for 48 hours on a shaker to prevent attachment.
  • Cells are pelleted and resuspended in Hank's Buffered Saline (HBS) at a concentration of 2.5 x 10 6 cells/mL and plated in 96-well culture plates at a density of 5 x 10 5 cells/mL.
  • Test compounds are diluted in HBS and added to the desired final concentration and the cells are incubated for an additional 4 hours.
  • Arachidonic acid is added to a final concentration of 30 mM, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.
  • COX-2 Assay For the COX-2 assay, subconfluent HOSC are trypsinized and resuspended at 3 x 10 6 cells/mL in MEM- FBS containing 1 ng human IL-lb/mL, plated in 96-well tissue culture plates at a density of 3 x 10 4 cells per well, incubated on a shaker for 1 hour to evenly distribute cells, followed by an additional 2 hour static incubation to allow attachment. The media is then replaced with MEM containing 2% FBS (MEM-2%FBS) and 1 ng human IL-lb/mL, and the cells incubated for 18-22 hours.
  • MEM-2%FBS MEM-2% FBS
  • test compound diluted in HBS is added to achieve the desired concentration and the cells incubated for 4 hours .
  • the supernatants are removed and replaced with MEM containing 30 mM arachidonic acid, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.
  • the compounds of the invention or a pharmaceutical composition thereof are useful for prophylaxis and treatment of rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic ⁇ cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS) ; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis ; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs.
  • ARDS adult respiratory distress syndrome
  • HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2) , and herpes zoster, all of which are sensitive to TNF- ⁇ and/or IL-1 inhibition or glucagon antagonism, will also be positively effected by the compounds and methods of the invention.
  • CMV cytomegalovirus
  • the compounds of the present invention also may possess analgesic properties and may be useful for the treatment of pain disorders, such as hyperalgesia due to excessive IL-1.
  • the compounds of the present invention may also prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway, including cyclooxygenase (WO 96/03387, incorporated herein by reference in its entirety) .
  • the compounds of the invention are also useful research tools for studying the physiology associated with blocking these effects.
  • the methods of the invention comprise administering an effective dose of a compound of the invention, a pharmaceutical salt thereof, or a pharmaceutical composition of either, to a subject (i.e., an animal, preferably a mammal, most preferably a human) in need of a reduction in the level of TNF- ⁇ , IL-1, IL-6, and/or IL-8 levels and/or reduction in plasma glucose levels and/or which subject may be suffering from rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic ⁇ cell destruction; osteoarthritis ; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS) ; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Re
  • CMV cytomegalovirus
  • this invention comprises the use of a compound of the invention, or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment either acutely or chronically of a TNF- ⁇ , IL-l ⁇ , IL-6, and/or IL-8 mediated disease state, including those described previously.
  • the compounds of this invention are useful in the manufacture of a analgesic medicament and a medicament for treating pain disorders, such as hyperalgesia.
  • the compounds of the present invention also are useful in the manufacture of a medicament to prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway.
  • this invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an effective TNF- ⁇ , IL-l ⁇ , IL-6, and/or IL-8 lowering amount and/or effective plasma glucose level lowering amount of a compound of the invention and a pharmaceutically acceptable carrier or diluent, and if desired other active ingredients.
  • the compounds of the invention are administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • Therapeutically effective doses of the compounds of the present invention required to arrest the progress or prevent tissue damage associated with the disease are readily ascertained by one of ordinary skill in the art using standard methods.
  • the compounds of the present invention may be administered orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles.
  • parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.
  • the dosage regimen for treating a TNF- ⁇ , IL-1, IL- 6, and IL-8 mediated diseases and/or hyperglycemia with the compounds of this invention and/or compositions of this invention is based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. Dosage levels of the order from about 0.01 mg to 30 mg per kilogram of body weight per day, preferably from about 0.1 mg to 10 mg/kg, more preferably from about 0.25 mg to 1 mg/kg are useful for all methods of use disclosed herein.
  • the pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.
  • the pharmaceutical composition may be in the form of, for example, a capsule, a tablet, a suspension, or liquid.
  • the pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient.
  • these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg, more preferably from about 5 to 150 mg .
  • a suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.
  • the active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water.
  • suitable carriers including saline, dextrose, or water.
  • the daily parenteral dosage regimen will be from about 0.1 to about 30 mg/kg of total body weight, preferably from about 0.1 to about 10 mg/kg, and more preferably from about 0.25 mg to 1 mg/kg.
  • Injectable preparations such as sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known are using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1, 3-butanediol .
  • a non-toxic parenterally acceptable diluent or solvent for example as a solution in 1, 3-butanediol .
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed, including synthetic mono- or diglycerides .
  • fatty acids such as oleic acid find use in the preparation of injectables .
  • Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable non- irritating excipient such as cocoa butter and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
  • a suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily.
  • the active ingredient may comprise from 0.001% to 10% w/w, e . g. , from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e.g., liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose.
  • liquid or semi-liquid preparations suitable for penetration through the skin e.g., liniments, lotions, ointments, creams, or pastes
  • drops suitable for administration to the eye, ear, or nose e.g., liniments, lotions, ointments, creams, or pastes
  • the compounds of this invention are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration.
  • the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinyl- pyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration.
  • the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers.
  • Other adjuvants and modes of administration are well known in the pharmaceutical art.
  • the carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art .
  • the pharmaceutical compositions may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions) .
  • the pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.
  • Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch.
  • Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.
  • optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base.
  • appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts.
  • a different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers.
  • Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate.
  • the synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound.
  • the optically active compounds of the invention can likewise be obtained by using active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.
  • the compounds of the present invention can be used in the form of salts derived from inorganic or organic acids.
  • the salts include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hyroxy-ethanesulfonate, lactate, maleate, methansulfonate, nicotinate, 2- naphthalenesulfonate, oxalate, palmoate, pectinate, pers

Abstract

Selected novel substituted pyrimidine compounds are effective for prophylaxis and treatment of diseases, such as TNF-α, IL-1β, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Description

SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE
BACKGROUND OF THE INVENTION This is a nonprovisional application derived from U.S. provisional application serial no. 60/032,128 filed December 5, 1996, U.S. provisional application serial no. 60/050,950 filed June 13, 1997 and U.S. nonprovisional patent application serial no. not yet assigned filed November 21, 1997 each of which are incorporated herein by reference in their entirety. The present invention comprises a new class of compounds useful in treating diseases, such as TNF-α, IL-lβ, IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. This invention also relates to intermediates and processes useful in the preparation of such compounds.
Interleu in-1 (IL-1) and Tumor Necrosis Factor
(TNF-α) are pro-inflammatory cytokines secreted by a variety of cells, including monocytes and macrophages , in response to many inflammatory stimuli ( e . g. , lipopolysaccharide - LPS) or external cellular stress (e.g., osmotic shock and peroxide) .
Elevated levels of TNF-α and/or IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; osteoarthritis ; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS) ; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2) , and herpes zoster are also exacerbated by TNF-α.
It has been reported that TNF-α plays a role in head trauma, stroke, and ischemia. For instance, in animal models of head trauma (rat) , TNF-α levels increased in the contused hemisphere (Shohami et al . , J". Cereb . Blood Flow Metab . 14, 615 (1994)). In a rat model of ischemia wherein the middle cerebral artery was occluded, the levels of TNF-α mRNA of TNF-α increased (Feurstein et al . , Neurosci . Lett . 164, 125 (1993)). Administration of TNF-α into the rat cortex has been reported to result in significant neutrophil accumulation in capillaries and adherence in small blood vessels. TNF-α promotes the infiltration of other cytokines (IL-lβ, IL-6) and also chemokines, which promote neutrophil infiltration into the infarct area (Feurstein, Stroke 25, 1481 (1994)). TNF-α has also been implicated to play a role in type II diabetes (Endocrinol. 130, 43-52, 1994; and Endocrinol . 136, 1474-1481, 1995) .
TNF-α appears to play a role in promoting certain viral life cycles and disease states associated with them. For instance, TNF-α secreted by monocytes induced elevated levels of HIV expression in a chronically infected T cell clone (Clouse et al . , J. Immunol . 142, 431 (1989)). Lahdevirta et al . , (Am . J. Med. 85, 289
(1988)) discussed the role of TNF-α in the HIV associated states of cachexia and muscle degradation. TNF-α is upstream in the cytokine cascade of inflammation. As a result, elevated levels of TNF-α may lead to elevated levels of other inflammatory and proinflammatory cytokines, such as IL-1, IL-6, and IL-8. Elevated levels of IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS) ; psoriasis; Crohn's disease; ulcerative colitis; anaphylaxis; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; sepsis; septic shock; and toxic shock syndrome. Viruses sensitive to TNF-α inhibition, e . g. , HIV-1, HIV-2, HIV- 3, are also affected by IL-1.
TNF-α and IL-1 appear to play a role in pancreatic β cell destruction and diabetes. Pancreatic β cells produce insulin which helps mediate blood glucose homeostasis. Deterioration of pancreatic β cells often accompanies type I diabetes. Pancreatic β cell functional abnormalities may occur in patients with type II diabetes. Type II diabetes is characterized by a functional resistance to insulin. Further, type II diabetes is also often accompanied by elevated levels of plasma glucagon and increased rates of hepatic glucose production. Glucagon is a regulatory hormone that attenuates liver gluconeogenesis inhibition by insulin. Glucagon receptors have been found in the liver, kidney and adipose tissue. Thus glucagon antagonists are useful for attenuating plasma glucose levels (WO 97/16442, incorporated herein by reference in its entirety). By antagonizing the glucagon receptors, it is thought that insulin responsiveness in the liver will improve, thereby decreasing gluconeogenesis and lowering the rate of hepatic glucose production.
In rheumatoid arthritis models in animals, multiple intra-articular injections of IL-1 have led to an acute and destructive form of arthritis (Chandrasekhar et al . , Clinical Immunol Immunopathol . 55, 382 (1990)). In studies using cultured rheumatoid synovial cells, IL-1 is a more potent inducer of stromelysin than is TNF-α (Firestein, Am. J. Pathol . 140, 1309 (1992)). At sites of local injection, neutrophil, lymphocyte, and monocyte emigration has been observed. The emigration is attributed to the induction of chemokines (e.g., IL-8), and the up-regulation of adhesion molecules (Dinarello, Eur. Cytokine Netw. 5, 517-531 (1994)). IL-1 also appears to play a role in promoting certain viral life cycles. For example, cytokine- induced increase of HIV expression in a chronically infected acrophage line has been associated with a concomitant and selective increase in IL-1 production (Folks et al., J". Immunol . 136, 40 (1986)). Beutler et al. ( J. Immunol . 135, 3969 (1985)) discussed the role of IL-1 in cachexia. Baracos et al . {New Eng. J. Med. 308, 553 (1983)) discussed the role of IL-1 in muscle degeneration. In rheumatoid arthritis, both IL-1 and TNF-α induce synoviocytes and chondrocytes to produce collagenase and neutral proteases, which leads to tissue destruction within the arthritic joints. In a model of arthritis (collagen-induced arthritis (CIA) in rats and mice) , intra-articular administration of TNF-α either prior to or after the induction of CIA led to an accelerated onset of arthritis and a more severe course of the disease (Brahn et al . , Lymphokine Cytokine Res . 11, 253 (1992); and Cooper, Clin . Exp . Immunol . 898, 244 (1992)).
IL-8 has been implicated in exacerbating and/or causing many disease states in which massive neutrophil infiltration into sites of inflammation or injury (e.g., ischemia) is mediated by the chemotactic nature of IL-8, including, but not limited to, the following: asthma, inflammatory bowel disease, psoriasis, adult respiratory distress syndrome, cardiac and renal reperfusion injury, thrombosis and glomerulonephritis . In addition to the chemotaxis effect on neutrophils, IL-8 also has the ability to activate neutrophils. Thus, reduction in IL- 8 levels may lead to diminished neutrophil infiltration. Several approaches have been taken to block the effect of TNF-α. One approach involves using soluble receptors for TNF-α (e.g., TNFR-55 or TNFR-75), which have demonstrated efficacy in animal models of TNF-α- mediated disease states. A second approach to neutralizing TNF-α using a monoclonal antibody specific to TNF-α, cA2 , has demonstrated improvement in swollen joint count in a Phase II human trial of rheumatoid arthritis (Feldmann et al . , Immunological Reviews, pp. 195-223 (1995)). These approaches block the effects of TNF-α and IL-1 by either protein sequestration or receptor antagonism.
Bennett et al . (J". Med. Chem . 21, 623 (1978)) synthesized a number of pyrimidines of the form:
Figure imgf000007_0001
i where, inter alia , Ra x is 2-, 3-, or 4-pyridyl, Ra 2 is H, methyl, or phenyl, and Ra 3 is H, amino. They reported that none of these compounds tested against rat adjuvant-induced edema displayed a level of activity sufficient to warrant further investigation and that additional testing confirmed that the compounds represented a series of false positives in the carrageenan-induced edema model. Ife et al. (Bioorg. Med. Chem. Lett. 5, 543 (1995)) reported that another pyrimidine (R = 2-methylphenyl , Ra 2 = 2-pyridyl, and Ra 3 = n-propyl , wherein Ra Ra 2, and Ra 3 are as in structure i, supra) had several times lower H+/K+-ATPase inhibitory activity than related 4- (2- pyridyl) -5-phenylthiazole compounds.
WO 97/33883 describes substituted pyrimidine compounds useful in treating cytokine mediated diseases.
BRIEF DESCRIPTION OF THE INVENTION
The present invention comprises a new class of compounds useful in the prophylaxis and treatment of diseases, such as TNF-α, IL-lβ, IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds, methods for the prophylaxis and treatment of TNF-α, IL-lβ, IL-6 and/or IL-8 mediated diseases, such as inflammatory, pain and diabetes diseases, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention. The compounds of the invention are represented by the following general structure:
Figure imgf000008_0001
wherein R1, R2, R11 and R12 are defined below.
The foregoing merely summarizes certain aspects of the invention and is not intended, nor should it be construed, as limiting the invention in any way. All patents and other publications recited herein are hereby incorporated by reference in their entirety. DETAILED DESCRIPTION OF THE INVENTION In accordance with the present invention, there is provided compounds of the formula:
Figure imgf000009_0001
(I) or a pharmaceutically acceptable salt thereof, wherein
Rl and R2 are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; preferably, 0-2; more preferably, 0-1; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Ri and R2 is 0-4; preferably, 0-3; more preferably, 0-2; most preferably, 0-1;
preferably, R2 is a radical of hydrogen, C1-C4 alkyl , halo, hydroxy, C1-C4 alkoxy, C1-C2 haloalkoxy of 1-3 halo radicals, thiol, C1-C4 alkylthio, aminosulfonyl, C1-C4 alkylaminosulfonyl, di- (C1-C4 alkyl) aminosulfonyl, amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino or C1-C2 haloalkyl of 1-3 halo radicals;
more preferably, R2 is a radical of hydrogen, C1-C4 alkyl, halo, hydroxy, C1-C4 alkoxy, trifluoromethoxy, thiol, C1-C4 alkylthio, amino, C1-C4 alkylamino, di- (Cj_- C4 alkyl) amino, C1.-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino or trifluoromethyl; more preferably, R2 is a radical of hydrogen, methyl, ethyl, fluoro, chloro, hydroxy, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino , acetylamino or trifluoromethyl; and most preferably, R2 is a radical of hydrogen or hydroxy;
wherein each Z is independently a
(1) bond;
(2) alkyl, alkenyl or alkynyl radical optionally substituted by (a) 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylammo, alkylsulfonylamino, hydroxy, alkoxy, alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylammo, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, halo, alkyl or haloalkyl;
(3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or
(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;
preferably, each Z is independently a (1) bond; (2) Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl radical optionally substituted by 1-3 radicals of amino, C3.-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino,
(C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1.-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy,
C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (4) aryl or heteroaryl radical optionally substituted by
1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy,
C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each Z is independently a
(1) bond;
(2) C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1.-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each Z is independently a (1) bond; (2) C1-C8 alkyl or C2-C8 alkenyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
(3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(Cι-C4 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl radicals; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
more preferably, each Z is independently a
(1) bond;
(2) C1-C4 alkyl or C2-C5 alkenyl radical optionally substituted by 1-3 radicals of amino, di- (C1-C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals; (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di- (C1-C2 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or C1-C4 alkyl radicals; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di- (C1-C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, Ci- C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each Z is independently a
(1) bond;
(2) C1-C4 alkyl or C2-C5 alkenyl radical optionally substituted by 1-3 radicals of amino, di- (C1-C2 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo, and (b) 1-2 radicals of aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di- (C1-C2 alkyl) amino, acetamido, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals; or
(3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) amino, acetamido, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals; more preferably, each Z is independently a
(1) bond; or
(2) C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, di- (C1-C2 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals; and
most preferably, each Z is independently a
(1) bond; or
(2) C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
each Y is independently a (1) hydrogen radical; (2) halo or nitro radical;
(3) -C(0)-R2o or -C(NR5)-NR5R2i radical;
(4) -OR21, -0-C(0)-R2l, -0-C(0)-NR5R2ι or -O-C (0) -NR22- S(0)2-R o radical;
(5) -SR21, -S(0)-R2o, ~S(O)2-R20, -S(0)2-NR5R2l, -S(0)2- NR22-C(0)-R2ι, -S(O)2-NR22-C(O)-OR20 or -S (0) 2-NR22-C (0) -
NR5R21 radical; or
(6) -NR5R21, -NR22-C(0)-R2ι, -NR22-C(O)-OR20, -NR22-C(0)- NR5R21, -NR22-C(NR5)-NR5R21, -NR2 -S (0) 2-R20 or -NR22- S(0)2- R5R2i radical;
preferably, each Y is independently a
(1) hydrogen radical;
(2) halo radical;
(3) -C(0)-R2o or -C(NR5)-NR5R2i radical; (4) -OR21, -0-C(0)-R2ι or -0-C (0) -NR5R21 radical; (5) -SR21, -S(0)-R2o, -S(O)2-R20 or -S (0) 2-NR5R2ι radical; or
(6) -NR5R21, -NR22-C(0)-R2l, -NR22-C(O)-OR20, -NR22-C(0)- R5R2I -NR22-C(NR5)-NR5R21, -NR22-S (0) 2-R20 or -NR22~ S(0)2-NR5 2l radical;
more preferably, each Y is independently a
(1) hydrogen radical;
(2) -C(O)-R20 radical; (3) -OR21, -SR21, -S(0)-R2o, -S(O)2-R20 or -S (0) 2-NR5R21 radical; or
(4) -NR5R21, -NR22-C(0)-R2l, -NR22-C(O)-OR20, -NR22-C(0)- NR5R21, -NR22-S(O)2-R20 or -NR22"S (0) 2-NR5R2ι radical;
more preferably, each Y is independently a
(1) hydrogen radical;
(2) -C(0)-R2o radical;
(3) -OR21, -SR21, -S(O)-R20, -S(0)2-R2o or -S (0) 2-NR5R21 radical; or (4) -NR5R21, -NR22-C(0)-R2ι or -NR22-S (0) 2-R2o radical;
more preferably, each Y is independently a
(1) -C(0)-R2o radical;
(2) -OR21, -SR21, -S(0)-R2o, -S(O)2-R20 or -S (0) 2-NR5R2ι radical; or
(3) - R5R21, -NR22-C(0)-R2ι or -NR22-S (0) 2- 20 radical.
most preferably, each Y is independently a -OR21, -SR21 or -NR5R21 radical;
wherein each R5 is independently
(1) hydrogen radicals;
(2) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, -S03H or halo; or (3) aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl;
preferably, each R5 is independently
(1) hydrogen radicals;
(2) C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (Cι-C4-alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, -S03H or halo; or
(3) aryl, heteroaryl, aryl-Cι-C4-alkyl, heteroaryl-Cι~C4- alkyl, heterocyclyl, heterocyclyl-Cι-C4-alkyl, C3-C8 cycloalkyl or C3-C8-cycloalkyl-Cι-C4-alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (Cι-C4~alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R5 is independently
(1) hydrogen radicals;
(2) C1-C4 alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4-alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, -S03H or halo; or
(3) aryl, heteroaryl, aryl-Cι-C4-alkyl, heteroaryl-Cι-C4~ alkyl, heterocyclyl, heterocyclyl-Cι-C4-alkyl, C3-C8 cycloalkyl or C3-C8-cycloalkyl-Cι-C4-alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4-alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R5 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, di- (C1-C4- alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, - SO3H or halo; or
(3) phenyl-Cι-C2-alkyl, heteroaryl-Cι-C2-alkyl, heterocyclyl-Cι-C2-alkyl or C3-C6-cycloalkyl-Cι-C2-alkyl radicals optionally substituted by 1-3 radicals of amino, di- (Cι-C4-alkyl) amino, hydroxy, C1-C4 alkoxy, Ci- C4 alkylthio, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
more preferably, each R5 is independently (1) hydrogen radical; (2) C1-C4 alkyl radical optionally substituted by 1-3 radicals of amino, di- (C]_-C2-alkyl) amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo; or (3) phenyl-Cι-C2-alkyl, heteroaryl-Cι-C2-alkyl, heterocyclyl-Cι-C2-alkyl or C3-C6-cycloalkyl-Cι-C2-alkyl radicals optionally substituted by 1-3 radicals of amino, di- (Cι~C2-alkyl) amino, hydroxy, C1-C2 alkoxy, Cι~ C2 alkylthio, methoxy, methylthio, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R5 is independently
( 1 ) hydrogen radical ;
(2) C1-C4 alkyl radical optionally substituted by 1-3 halo radicals; or
(3) phenyl-Cι-C2-alkyl or heteroaryl-Cι-C2-alkyl, radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals;
more preferably, each R5 is independently hydrogen or C1-C4 alkyl radical; and most preferably, each R5 is a hydrogen radical; wherein each R20 is independently
(1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, N- (alkoxycarbonyl ) -N- (alkyl ) amino , aminocarbonylamino , alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo or aralkoxy, aralkylthio, aralkylsulfonyl, cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkanoyl, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl, halo, alkyl or haloalkyl; (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, halo, azido, alkyl or haloalkyl;
preferably, each R20 s independently
(1) C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N- ( (C1-C4 alkoxy) carbonyl) - N- (C1-C4 alkyl)amino, aminocarbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , halo or aryl-Cι-C4-alkoxy, aryl-Cι-C4-alkylthio, aryl-Cι~C4- alkylsulfonyl, C3-C8 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C3.-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl , halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C3.-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R20 is independently
(1) Ci-Cδ alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((Cι-C4 alkoxy) carbonyl) - N- (C1-C4 alkyl) amino, aminocarbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C3.-C4 alkylsulfonyl, halo or aryl-Cι-C4-alkoxy, aryl-C1.-C4-alkylth.io, aryl-Cι-C4- alkylsulfonyl , C3-C8 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C4 haloalkyl of 1- 3 halo radicals;
more preferably, each R20 is independently (1) C1-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C3.-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((Cι-C4 alkoxy) carbonyl) -N- (C1-C4 alkyl) amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-Cι-C4-alkoxy, aryl-Cι-C4- alkylthio, aryl-Cι-C4-alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals; (2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(Cj_-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
more preferably, each R20 is independently (1) C1-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((Cι-C4 alkoxy) carbonyl) -N- (C1-C4 alkyl) amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-Cι-C4-alkoxy, aryl-Cι-C4- alkylthio, aryl-Cι-C4-alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di- (C1-C4 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1.-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, acetamido, (C1-C4 alkoxy) carbonylamino, Cι~ C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals; more preferably, each R20 is independently
(1) C1-C8 alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((Cι~C4 alkoxy) carbonyl) -N- (C1-C4 alkyl) amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or Ci- C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (C1-C4 alkoxy) carbonyl, amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R20 is independently
(1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, t- butoxycarbonylamino , N- ( ( t-butoxy) carbonyl ) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals; (2) heterocyclyl radical optionally substituted by 1-2 radicals- of hydroxy or C1-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
more preferably, each R20 is independently
(1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, t- butoxycarbonylamino , N- ( ( t-butoxy) carbonyl ) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
most preferably, each R20 is independently
(1) Ci-Cδ alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, hydroxy or phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals; each R21 is independently hydrogen radical or R20;
each R22 is independently (1) hydrogen radical; (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; or
(3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; provided when Z is a bond and Y is -NR22- C(0)-NH2, then R22 is other then an optionally substituted aryl radical;
preferably, each R22 is independently
(1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; provided when Z is a bond and Y is -NR22-C (0) -NH2 , then R22 is other then an optionally substituted aryl radical;
more preferably, each R22 is independently (1) hydrogen radical; or
(2) C1-C4 alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, di- (C1-C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, Cι~ C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
more preferably, each R22 is independently hydrogen or C1-C4 alkyl radical; and most preferably, each R22 is independently hydrogen or methyl radical;
Rll and Rι2 are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of (1) R30; (2) halo or cyano radicals;
(3) -C(O)-R30, -C(0)-OR29, -C (0) -NR3ιR32 or -C(NR3ι)- NR31R32 radicals;
(4) -OR29, -0-C(0)-R29, -0-C(0)-NR3ιR32 or -0-C (0) -NR33- S(O)2~R30 radicals; (5) -SR29, -S(O)-R30, -S(O)2-R30, -S (0) 2-NR31R32 , -S(0)2- NR33-C(O)-R30/ ~S (0) 2-NR33-C (0) -OR30 or -S (0) 2-NR33-C (0) - NR31R32 radicals; or
(6) -NR31R32, -NR33-C(0)-R29, -NR33-C(O)-OR30, -NR33-C (0) - R31 32, -NR33-C(NR3ι)-NR3iR32, -NR33-S (0) 2-R3O or -NR33- S(0)2-NR3iR32 radicals; provided that (1) Rn is other than a 4-pyridyl, 4- pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rn and R12 is 0-1; preferably, Rn and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals;
(3) -C(0)-R3o, -C(0)-OR29, -C (0) -NR31R32 or -C(NR31)- NR31R32 radicals;
(4) -OR29, -0-C(0)-R29, -0-C(0)-NR3ιR32 or -0-C (0) -NR33- S(O)2-R30 radicals;
(5) -SR29, -S(O)-R30, -S(O)2-R30- -S(0)2-NR3lR32. -S(0)2- NR33-C(O)-R30 -S(O)2-NR33-C(O)-OR30 or -S (0) 2-NR33-C (0) - NR31R32 radicals; or
(6) -NR31R32, -NR33-C(0)-R29 -NR33-C (0) -OR30 , -NR33-C(0)- NR31R32, -NR33-C(NR3ι)-NR3iR32, -NR33-S (0) 2-R30 or -NR33-
S (0) 2-NR31R32 radicals; provided that (1) Rn is other than a 4-pyridyl, 4- pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rn and R12 is 0-1;
more preferably, Rn and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of
(1) R30;
(2) halo or cyano radicals;
(3) -C(O)-R30, -C(0)-OR29, -C(0)-NR3ιR32 or -C(NR3ι)- NR31R32 radicals; or
(4) -OR29, -SR29, -S(O)-R30» -S(O)2-R30, -S (0) 2-NR3lR32 , -NR31R32, -NR33-C(0) -R29 or -NR33-C(0) -OR30 radicals;
more preferably, Rn is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of ( 1 ) R30 ;
(2) hal.o or cyano radicals;
(3) -C(O)-R30, -C(0)-OR29, -C(0)-NR3ιR32 or -C(NR3ι)- NR31R32 radicals; or (4) -OR29, -SR29, -S(O)-R30 ~S(O)2-R30» ~S (0) 2-NR31R32 , -NR31R32 or -NR33-C (0) -R29 radicals;
more preferably, Rn is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of
(1) R30;
(2) halo or cyano radicals; or
(3) -C(0)-NR3ιR32, -OR29, -SR29, -S(O)-R30, -S(O)2-R30, " S(0)2-NR3iR32, -NR31R32 or -NR33-C (0) -R2g radicals;
more preferably, Rn is an aryl radical optionally substituted by 1-2 radicals of (1) R30; (2) halo or cyano radicals; or (3) -C (0) -NR31R32 , -OR29, -SR29, - S(O)-R30, -S(O)2-R30, -S(0)2-NR3lR32- - R31 32 or -NR33- C(0)-R29 radicals; more preferably, Rn is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl , aminocarbonyl , methyl or trifluoromethyl radicals; more preferably, Rn is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and most preferably, Rn is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl , methyl or trifluoromethyl radicals; more preferably, R12 is a heteroaryl radical optionally substituted by 1-2 radicals of (1) R30; (2) halo or cyano radicals; or (3) -C (0) -NR31R32 , -OR29, -SR29, -NR31R32 or -NR33-C (0) -R29 radicals; more preferably, R12 is a heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; more preferably, R12 is a 4-pyridyl, 4- quinolinyl, 4-imidazolyl or 4-pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and most preferably, Rl2 is a 4-pyridyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals ;
wherein each R30 is independently
(1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of -NR31R31, -CO2R23, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl , cyano, halo or aralkoxy, aralkylthio, aralkylsulfonyl , heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl , cyano, halo, alkyl or haloalkyl;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl ;
preferably, each R30 is independently (1) C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl radicals optionally substituted by 1-3 radicals of -NR31R31, - CO2R23 hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo or aryl- Cι-C4-alkoxy, aryl-Cι-C4-alkylthio, aryl-Cι-C4- alkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or Cι~ C4 haloalkyl of 1-3 halo radicals; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R30 is independently
(1) C1-C4 alkyl radical optionally substituted by 1-3 radicals of
(a) -NR31R31;
(b) C1-C4 alkoxy-carbonyl or phenoxycarbonyl or phenylmethoxycarbonyl optionally substituted by 1-3 radicals of amino, alkylamino, di- (Cι-C4-alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl; or
(c) hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, or phenyl-Ci- C4~alkoxy, phenyl-Cι-C4-alkylthio, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; (2) C1-C4 haloalkyl of 1-3 halo radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R30 is independently (1) C1-C4 alkyl radical optionally substituted by
(a) amino, C1-C4 alkylamino or di- (Cι-C4-alkyl) amino radicals; or
(b) hydroxy, C1-C4 alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) C1-C2 haloalkyl of 1-3 halo radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C3.-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R30 is independently
(1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di- (C1-C2 alkyl) amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R30 is independently
(1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by
1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals ;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
most preferably, R30 is independently
(1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R30; and most preferably, R29 is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
each R31 is independently
(1) hydrogen radicals;
(2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
preferably, each R31 is independently
(1) hydrogen radicals;
(2) C1-C4 alkyl radical optionally substituted by an C3- Cζ cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-C8 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R31 is independently
(1) hydrogen radicals; or
(2) C1-C4 alkyl radical optionally substituted by an phenyl or heteroaryl radical optionally substituted by
1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R31 is independently hydrogen or C1-C4 alkyl radicals; and most preferably, each R31 is independently hydrogen, methyl or ethyl radicals;
each R32 is independently
(1) hydrogen radicals;
(2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
(3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
preferably, each R32 is independently (1) hydrogen radicals; (2) C1-C4 alkyl radical optionally substituted by an C3- Cδ cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(3) aryl, heteroaryl, heterocyclyl or C3-C8 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R3 is independently
(1) hydrogen radicals;
(2) C1-C4 alkyl radical optionally substituted by an C3- Ce cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-C6 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R32 is independently (1) hydrogen radicals; (2) C1-C4 alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or
(3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R32 is independently (1) hydrogen radicals; (2) C1-C4 alkyl radical or C1-C alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals;
most preferably, R32 is independently (1) hydrogen or C1-C4 alkyl radical; or
(2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; and
wherein each R33 is independently
( 1 ) hydrogen radical ; or
(2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
preferably, each R33 is independently (1) hydrogen radical; or
(2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or Ci- C4 haloalkyl of 1-3 halo radicals;
more preferably, each R33 is independently hydrogen or C1-C4 alkyl radical; and most preferably, each R33 is independently hydrogen or methyl radical.
The following provisos relate to compounds of the invention, only, and not to the pharmaceutical compositions or methods of use, which encompass the full breadth of compounds recited above (unless expressly stated otherwise) :
1. when R1 and R12 are the same and are a 5- or 6- member ring having from 1-3 heteroatoms independently selected from N, S, and 0, to which ring a benzene ring is optionally fused, R11 is phenyl or naphthyl optionally substituted with halo, Cx-C6 alkyl, C1-C4 alkoxy, Ct-C4 alkylthiol, hydroxy, amino, C1-C4 alkylamino, or dialkylamino, or R11 is a 5- or 6-membered ring having from 1-3 heteroatoms independently selected from N, S, and O, to which ring a benzene ring is optionally fused and optionally substituted with C^-Cj alkyl, then R2 is other than OH or NH2; 2. when R2 is H, R11 is phenyl and R12 is phenyl or 4- pyridyl, then R1 is other than H, methyl, or amino ; 3. when R2 is H, R11 is 2-methylphenyl and R12 is 2- pyridyl, then R1 is other than n-propyl; and
4. when R11 and R12 are each an optionally substituted phenyl radical , then R1 is other than an optionally substituted 2-pyridyl radical.
The compounds of this invention may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and diasteromers .
Compounds of interest include the following:
Figure imgf000037_0001
wherein R2 is H and R11, and R1 are one of the combinations given in the following table:
Figure imgf000037_0002
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0002
and
Figure imgf000055_0001
wherein R2 is -OH and R1 and R1 are one of the combinations given in the following table:
Figure imgf000055_0003
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Additional preferred compounds are listed in the Examples , infra .
As utilized herein, the following terms shall have the following meanings: "Alkyl", alone or in combination, means a straight-chain or branched-chain alkyl radical containing preferably 1- 15 carbon atoms (C1-C15) , more preferably 1-8 carbon atoms (Ci-Cs) even more preferably 1-6 carbon atoms (C1-C6) yet more preferably 1-4 carbon atoms (C1-C4) , still more preferably 1-3 carbon atoms (C1-C3) , and most preferably 1-2 carbon atoms (C1-C2) • Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso- amyl, hexyl, octyl and the like.
"Hydroxyalkyl" , alone or in combination, means an alkyl radical as defined above wherein at least one hydrogen radical is replaced with a hydroxyl radical, preferably 1-3 hydrogen radicals are replaced by hydroxyl radicals, more preferably 1-2 hydrogen radicals are replaced by hydroxyl radicals, and most preferably one hydrogen radical is replaced by a hydroxyl radical. Examples of such radicals include hydroxymethyl, 1-, 2-hydroxyethyl, 1-, 2-, 3 -hydroxypropyl , 1, 3 -dihydroxy-2-propyl, 1,3- dihydroxybutyl , 1,2,3,4,5,6-hexahydroxy-2-hexyl and the like.
"Alkenyl", alone or in combination, means a straight- chain or branched-chain hydrocarbon radical having one or more double bonds, preferably 1-2 double bonds and more preferably one double bond, and containing preferably 2-15 carbon atoms (C2-C15) , more preferably 2-8 carbon atoms (C2-Cs) even more preferably 2-6 carbon atoms (C2-C6) , yet more preferably 2-4 carbon atoms (C2-C4) , and still more preferably 2-3 carbon atoms (C2-C3) . Examples of such alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4- butadienyl and the like. "Alkoxy", alone or in combination, means a radical of the type "R-0-" wherein "R" is an alkyl radical as defined above and "0" is an oxygen atom. Examples of such alkoxy radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert- butoxy and the like.
"Alkoxycarbonyl", alone or in combination, means a radical of the type "R-O-C(O)-" wherein "R-0-" is an alkoxy radical as defined above and "C(0)" is a carbonyl radical .
"Alkoxycarbonylamino", alone or in combination, means a radical of the type "R-O-C (0) -NH-" wherein "R-O-C(O)" is an alkoxycarbonyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
"Alkylthio", alone or in combination, means a radical of the type "R-S-" wherein "R" is an alkyl radical as defined above and "S" is a sulfur atom. Examples of such alkylthio radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio and the like.
"Alkylsulfinyl" , alone or in combination, means a radical of the type "R-S(O)-" wherein "R" is an alkyl radical as defined above and "S(0)" is a mono-oxygenated sulfur atom. Examples of such alkylsulfinyl radicals include methylsulfinyl , ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, n-butylsulfinyl, iso-butylsulfinyl, sec-butylsulfinyl , tert-butylsulfinyl and the like.
"Alkylsulfonyl" , alone or in combination, means a radical of the type "R-S(0)2-" wherein "R" is an alkyl radical as defined above and "S(0)2" is a di-oxygenated sulfur atom. Examples of such alkylsulfonyl radicals include methylsulfonyl , ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, iso-butylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl and the like.
"Aryl", alone or in combination, means a phenyl or biphenyl radical, which is optionally benzo fused or heterocyclo fused and which is optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, azido, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, alkanoylamino, amido, amidino, alkoxycarbonylamino, N- alkylamidino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl , dialkylaminoalkyl, N-alkylamido, N,N- dialkylamido, aralkoxycarbonylamino , alkylthio, alkylsulfinyl, alkylsulfonyl , oxo and the like. Examples of aryl radicals are phenyl, o-tolyl, 4- methoxyphenyl, 2- (tert-butoxy) phenyl, 3-methyl-4- methoxyphenyl , 2-CF3-phenyl, 2-fluorophenyl , 2- chlorophenyl, 3 -nitropheny1, 3-aminophenyl, 3- aceta idophenyl, 2-amino-3- (aminomethyl) phenyl, 6- methyl-3-acetamidophenyl , 6-methyl-2-aminophenyl , 6- methyl-2 , 3-diaminophenyl, 2-amino-3 -methylphenyl, 4,6- dimethyl-2-aminophenyl, 4-hydroxyphenyl, 3-methyl-4- hydroxyphenyl, 4- ( 2-methoxyphenyl) phenyl, 2-amino-l- naphthyl, 2-naphthyl, 3 -amino-2-naphthyl, 1-methyl-3- amino-2-naphthyl, 2 , 3-diamino-l-naphthyl, 4, 8-dimethoxy- 2-naphthyl and the like.
"Aralkyl" and "arylalkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyl, 1-, 2- phenylethyl, dibenzylmethyl, hydroxyphenylmethyl , methylphenylmethyl , diphenylmethyl , dichlorophenylmethyl , 4-methoxyphenylmethyl and the like. "Aralkoxy" , alone or in combination, means an alkoxy radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyloxy, 1-, 2-phenylethoxy, dibenzylmethoxy, hydroxyphenylmethoxy, methylphenylmethoxy, dichlorophenylmethoxy, 4- methoxyphenylmethoxy and the like.
"Aralkoxycarbonyl" , alone or in combination, means a radical of the type "R-O-C(O)-" wherein "R-0-" is an aralkoxy radical as defined above and "-C(O)-" is a carbonyl radical .
"Alkanoyl", alone or in combination, means a radical of the type "R-C(O)-" wherein "R" is an alkyl radical as defined above and "-C(O)-" is a carbonyl radical. Examples of such alkanoyl radicals include acetyl, trifluoroacetyl, hydroxyacetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like.
"Alkanoylamino", alone or in combination, means a radical of the type "R-C(0)-NH-" wherein "R-C(O)-" is an alkanoyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
"Aminocarbonyl", alone or in combination, means an amino substituted carbonyl (carbamoyl) radical, wherein the amino radical may optionally be mono- or di-substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl, aralkoxycarbonyl and the like.
"Aminosulfonyl " , alone or in combination, means an amino substituted sulfonyl radical. "Benzo", alone or in combination, means the divalent radical C6H4= derived from benzene. "Benzo fused" forms a ring system in which benzene and a cycloalkyl or aryl group have two carbons in common, for example tetrahydronaphthylene and the like.
"Bicyclic" as used herein is intended to include both fused ring systems, such as naphthyl and β-carbolinyl, and substituted ring systems, such as biphenyl, phenylpyridyl and diphenylpiperazinyl .
"Cycloalkyl", alone or in combination, means a saturated or partially saturated, preferably one double bond, monocyclic, bicyclic or tricyclic carbocyclic alkyl radical, preferably monocyclic, containing preferably 5- 12 carbon atoms (C5-C12) , more preferably 5-10 carbon atoms (C5-C10) , even more preferably 5-7 carbon atoms (C5-C7) , which is optionally benzo fused or heterocyclo fused and which is optionally substituted as defined herein with respect to the definition of aryl. Examples of such cycloalkyl radicals include cyclopentyl, cyclohexyl, dihydroxycyclohexyl, ethylenedioxycyclohexyl, cycloheptyl, octahydronaphthyl , tetrahydronaphthyl , octahydroquinolinyl, dimethoxytetrahydronaphthyl , 2 , 3-dihydro-lH-indenyl , azabicyclo [3.2.1] octyl and the like.
"Heteroatoms" means nitrogen, oxygen and sulfur heteroatoms.
"Heterocyclo fused" forms a ring system in which a heterocyclyl or heteroaryl group of 5-6 ring members and a cycloalkyl or aryl group have two carbons in common, for example indole, isoquinoline, tetrahydroquinoline, methylenedioxybenzene and the like. "Heterocyclyl" means a saturated or partially unsaturated, preferably one double bond, monocyclic or bicyclic, preferably monocyclic, heterocycle radical containing at least one, preferably 1 to 4 , more preferably 1 to 3 , even more preferably 1-2, nitrogen, oxygen or sulfur atom ring member and having preferably 3-8 ring members in each ring, more preferably 5-8 ring members in each ring and even more preferably 5-6 ring members in each ring. "Heterocyclyl" is intended to include sulfone and sulfoxide derivatives of sulfur ring members and N-oxides of tertiary nitrogen ring members, and carbocyclic fused, preferably 3-6 ring carbon atoms and more preferably 5-6 ring carbon atoms, and benzo fused ring systems. "Heterocyclyl" radicals may optionally be substituted on at least one, preferably 1- 4, more preferably 1-3, even more preferably 1-2, carbon atoms by halogen, alkyl, alkoxy, hydroxy, oxo, thioxo, aryl, aralkyl, heteroaryl, heteroaralkyl , amidino, N- alkylamidino, alkoxycarbonylamino, alkylsulfonylamino and the like, and/or on a secondary nitrogen atom by hydroxy, alkyl, aralkoxycarbonyl, alkanoyl, alkoxycarbonyl, heteroaralkyl, aryl or aralkyl radicals. More preferably, "heterocyclyl", alone or in combination, is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals. Examples of such heterocyclyl radicals include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, 4-benzyl-piperazin-l-yl, pyrimidinyl , tetrahydrofuryl, pyrazolidonyl , pyrazolinyl, pyridazinonyl, pyrrolidonyl, tetrahydrothienyl and its sulfoxide and sulfone derivatives, 2 , 3-dihydroindolyl, tetrahydroquinolinyl , 1,2,3, 4-tetrahydroisoquinolinyl, 1,2,3, 4-tetrahydro-l- oxo-isoquinolinyl, 2 , 3-dihydrobenzofuryl , benzopyranyl, methylenedioxyphenyl, ethylenedioxyphenyl and the like.
"Heteroaryl" means a monocyclic or bicyclic, preferably monocyclic, aromatic heterocycle radical, having at least one, preferably 1 to 4, more preferably 1 to 3 , even more preferably 1-2, nitrogen, oxygen or sulfur atom ring members and having preferably 5-6 ring members in each ring, which is optionally saturated carbocyclic fused, preferably 3-4 carbon atoms (C3-C4) to form 5-6 ring membered rings and which is optionally substituted as defined above with respect to the definitions of aryl . Examples of such heteroaryl groups include imidazolyl, l-benzyloxycarbonylimidazol-4-yl, pyrrolyl, pyrazolyl, pyridyl, 3- ( 2-methyl) pyridyl, 3- (4- trifluoromethyl) pyridyl, pyrimidinyl, 5- (4- trifluoromethyl) pyrimidinyl , pyrazinyl, triazolyl, furyl, thienyl, oxazolyl, thiazolyl, indolyl, quinolinyl, 5,6,7, 8-tetrahydroquinolyl , 5, 6, 7 , 8-tetrahydroisoquinolinyl, quinoxalinyl, benzothiazolyl, benzofuryl, benzimidazolyl, benzoxazolyl and the like.
"Heteroaralkyl" and "heteroarylalkyl, " alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by a heteroaryl radical as defined above, such as 3-furylpropyl, 2-pyrrolyl propyl, chloroquinolinylmethyl , 2-thienylethyl, pyridylmethyl, 1-imidazolylethyl and the like.
"Halogen" and "halo", alone or in combination, means fluoro, chloro, bromo or iodo radicals.
"Haloalkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-3, is replaced by a halogen radical, more preferably fluoro or chloro radicals . Examples of such haloalkyl radicals include 1, 1, 1-trifluoroethyl, chloromethyl , 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, bis (trifluoromethyl) methyl and the like.
"4 (3H) -pyrimidinone" (A) and "4-hydroxy-pyrimidine" (B) are names of two tautomers of the same compound which may be used interchangeably. It is intended that the use of one of these terms inherently includes the other.
Figure imgf000083_0001
(A) (B)
"Pharmacologically acceptable salt" means a salt prepared by conventional means, and are well known by those skilled in the art. The "pharmacologically acceptable salts" include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like. When compounds of the invention include an acidic function such as a carboxy group, then suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in the art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like. For additional examples of "pharmacologically acceptable salts," see infra and Berge et al, J". Pharm . Sci . 66, 1 (1977) . 8"2
"Cytokine" means a secreted protein that affects the functions of other cells, particularly as it relates to the modulation of interactions between cells of the immune system or cells involved in the inflammatory response. Examples of cytokines include but are not limited to interleukin 1 (IL-1) , preferably IL-lβ, interleukin 6 (IL-6) , interleukin 8 (IL-8) and TNF, preferably TNF-α (tumor necrosis factor-α) .
"TNF, IL-1, IL-6, and/or IL-8 mediated disease or disease state" means all disease states wherein TNF, IL- 1, IL-6, and/or IL-8 plays a role, either directly as TNF, IL-1, IL-6, and/or IL-8 itself, or by TNF, IL-1, IL-6, and/or IL-8 inducing another cytokine to be released. For example, a disease state in which IL-1 plays a major role, but in which the production of or action of IL-1 is a result of TNF, would be considered mediated by TNF.
"Leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate .
"Protecting group" generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples of aralkyl include, but are not limited to, benzyl, ortho- methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as p osphonium and ammonium salts . Examples of aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9- ( 9-phenylfluorenyl) , phenanthrenyl , durenyl and the like. Examples of cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals, preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t- butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, tri-fluoroacetyl, tri-chloro acetyl, phthaloyl and the like. A mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralkyl group and an aralkoxycarbonyl group. Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example, 1, 2-bis (methylene) benzene, phthalimidyl , succinimidyl, maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl . Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, aralkyl groups . Alkyl groups are also sutiable groups for protecting hydroxy and mercapto groups, such as tert- butyl . Silyl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl "groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, tri-isopropylsilyl, tert- butyldimethylsilyl , dimethylphenylsilyl, 1,2- bis (dimethylsilyl) benzene, 1, 2-bis (dimethylsilyl) ethane and diphenylmethylsilyl . Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of aminoalcohol compounds can lead to a N,N, O-tri-silyl derivative. Removal of the silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium flouride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group. Suitable silylating agents are, for example, trimethylsilyl chloride, tert-buty-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF . Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.
Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HCl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine . Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4- methoxyphenylmethyl and the like, can be removed under hydroylsis and hydrogenolysis conditions well known to those skilled in the art.
The symbols used above have the following meanings:
CRxRγ- =
-NRxRy
Figure imgf000087_0001
Figure imgf000087_0002
Prodrugs of the compounds of this invention are also contemplated by this invention. A prodrug is an active or inactive compound that is modified chemically through in vivo physicological action, such as hydrolysis, metabolism and the like, into a compound of this invention following adminstration of the prodrug to a patient. The suitability and techniques involved in making and using prodrugs are well known by those skilled in the art. For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985) . Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl) , cycloalkyl (for example, cyclohexyl) , aralkyl (for example, benzyl, p- methoxybenzyl) , and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl) . Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.
Compounds according to the invention can be synthesized according to one or more of the following methods . It should be noted that the general procedures are shown as it relates to preparation of compounds having unspecified stereochemistry. However, such procedures are generally applicable to those compounds of a specific stereochemistry, e.g., where the stereochemistry about a group is (S) or (R) . In addition, the compounds having one stereochemistry (e.g., (R) ) can often be utilized to produce those having opposite stereochemistry (i.e., (S) ) using well- known methods, for example, by inversion.
Pyrimidines :
A general method for the preparation of compounds of formula I involves the condensation of an 1,3- dicarbonyl intermediate IV with an N-C-N containing structure such as an amidine V, a guanidine VI or urea VII (Scheme 1; for a review of synthetic methods see D.J. Brown, Heterocyclic Compounds : the Pyrimidines, Chapter 3, 1994, John Wiley & Sons). Scheme 1
Figure imgf000089_0001
IV V, VI, VII
Additionally, as a 1, 3-dicarbonyl synthon, a b- dimethylamino-a,b-unsaturated ketone IX can be reacted with amidines V or guanidines VI as described (G.B. Bennett et al . , J. Med. Chem. 21, 623-628, 1978). (Scheme 2). Such b-dimethylamino-a,b-unsaturated ketones IX can be prepared by aminoformylation of an active methylene ketone VIII with Bredereck' s reagent, namely, bis (dimethylamino )methoxymethane (H. Bredereck et al., Chem. Ber . 101, 41-50 (1968); G. B. Bennett et al J . Org . Chem . 43 , 221-225 ( 1977 ) ) Scheme 2
Figure imgf000089_0002
I Scheme 3
Figure imgf000090_0001
According to this approach, Scheme 3 illustrates the conversion of 2- (4-fluorophenyl) -1- (4- pyridyl) ethanone (VIII; Sheldrake, Synthetic
Communications 23, 1967 (1993)) into the enamine IX. Intermediate IX may be condensed with a variety of amidines V and guanidines VI to provide 2-substituted 5- ( 4-fluorophenyl) -4- (4-pyridyl) -pyrimidines I . Further ketones VIII may be prepared (e.g., according to Sheldrake, Synthetic communications 23, 1967-1971 (1993)), by employing other heteroaryl carboxaldehydes as the starting material, such as 2- methylpyridine-4-carboxaldehyde, 2, 6-dimethylpyridine-4- carboxaldehyde (Mathes and Sauermilch, Chem . Ber. 88, 1276-1283 (1955)), quinoline-4-carboxaldehyde, pyrimidine-4-carboxaldehyde, 6-methylpyrimidine-4- carboxaldehyde , 2-methylpyrimidine-4-carboxaldehyde , 2 , 6-dimethylpyrimidine-4-carboxaldehyde (Bredereck et al., Chem . Ber . 97, 3407-3417 (1964)). Furthermore, 2- nitropyridin-4-carboxaldehyde may be prepared from 2- nitro-4-methylpyridine (Stanonis, J". Org. Chem . 22, 475 (1957) )by oxidation of the methyl group (Venemalm et al., Tet. Lett. 34, 5495-5496 (1993)). Its further conversion via a ketone VIII would lead to a 2-nitro-4- pyridyl derivative I (Scheme 4) . Catalytic reduction of the nitro group to an amino group would provide a derivative of I with R12 represented by a 2-amino-4- pyridyl group. Conventional acetylation of the amino group then leads to the 2-acetamido-4-pyridyl derivative.
Scheme 4
Figure imgf000091_0001
As displayed in Scheme 5, intermediate IX may also be condensed with urea VII to give the 2(1.7)- pyrimidinone derivative X. X is transformed into chloride XI by reaction with a halogenating agent such as phosphorous oxychloride. Treatment of chloride XI with primary and secondary amines, thiolates or alcoholates allows the preparation of further pyrimidines I with R1 represented by a substituted N, S or 0 groups, as recited above. Likewise, hydrazines may be reacted with chloride XI to provide 2-hydrazino substituted pyrimidines I.
Scheme 5
Figure imgf000092_0001
Scheme 6
Figure imgf000092_0002
R = NH2
R1 = NR22C (0) R21
R* NR22S02R2°
Palladium or nickel catalyzed cross couplings of chloride XI with arylboronic acids or arylzinc halides provide compounds of formula I wherein R1 is aryl or heteroaryl .
Scheme 6 illustrates the reaction of intermediate IX with guanidine VI to give 2-amino substituted I. 2- Amino I is a useful intermediate for further acylations and sulfonylations of the 2-amino group to give acylamido and sulfonamido derivatives.
For the synthesis of 4-hydroxy-pyrimidines II, the approach displayed in Scheme 7 may be followed (for a review of synthetic methods see: D.J. Brown, Heterocyclic Compounds: the Pyrimidines, supra) . This approach involves the cyclization reaction between an acrylic acid ester XII and an amidine V followed by oxidation of the resulting dihydropyrimidinone XIII to give II.
Figure imgf000093_0001
For the synthesis of 2-substituted 5- (4- fluorophenyl) -6- (4-pyridyl) -4-hydroxy-pyrimidines II (Scheme 8) , the disubstituted acrylic acid ester XII may be prepared conveniently by condensation of pyridine-4- carboxaldehyde with 4-fluorophenylacetic acid followed by esterification. XII may be reacted with a variety of amidines V at elevated temperature . As a dehydrogenating agent for the conversion of XIII to II, sodium nitrite/acetic acid is suitable.
Accordingly, further compounds of formula II may be obtained in which R12 is any other heteroaryl ring within the definition of R12 by the appropriate choice of starting material. Such starting materials include but are not limited to 2-methylpyridine-4-carboxaldehyde, 2 , 6-dimethylpyridine-4-carboxaldehyde (Mathes and Sauermilch, Chem . Ber. 88, 1276-1283 (1955)), quinoline- 4-carboxaldehyde, pyrimidine-4-carboxaldehyde, 6- methylpyrimidine-4-carbox-aldehyde, 2-methylpyrimidine- 4-carboxaldehyde, 2, 6-dimethylpyrimidine-4-carboxaldehyde (Bredereck et al . , Chem . Ber. 97, 3407-3417 (1964)). The use of 2-nitropyridine-4-carboxaldehyde would lead to a derivative of formula II with R12 represented by a 2-nitro-4-pyridyl group. Catalytic reduction of the nitro to an amino group would provide the 2-amino-4-pyridyl derivative of II. The approach displayed in Scheme 8 is applicable to the use of other aryl acetic acids leading to compounds of formula II with different aryl groups as R11.
Figure imgf000094_0001
XIII II
Another approach (Scheme 9) leading to 5,6-diaryl- 4-hydroxy-pyrimidines involves the cyclization of the b- keto ester XIV with thiourea to give the thiouracil derivative XV. XV can be S-monomethylated to XVI. Reaction of XVI with primary and secondary amines leads to 2-amino substituted 4-hydroxy-pyrimidines II. Further 2-thioether derivatives of II with R1 = SR21 can be obtained, for example by alkylation of XV with alkyl halides. Treatment of XV or XVI with Raney nickel and H provides compounds of structure II wherein R1 is H. Scheme 9
Figure imgf000095_0001
XIV
Figure imgf000095_0002
Although Scheme 9 illustrates syntheses in which R12 is 4-pyridyl, this approach may be equally applied to any other heteroaryl ring within the definition of R12 by the appropriate choice of the starting material . Such starting materials include but are not limited to ethyl 2-methyl isonicotinate (Efimovsky and Rumpf, Bull . Soc . Chim . FR . 648-649 (1954)), methyl pyrimidine-4- carboxylate, methyl 2-methylpyrimidine-4-carboxylate, methyl 6-methylpyrimidine-4-carboxylate and methyl 2,6- dimethylpyrimidine-4-carboxylate (Sakasi et al . , Heterocycles 13, 235 (1978)). Likewise, methyl 2- nitroisonicotinate (Stanonis, J". Org. Chem . 22, 475 (1957)) may be reacted with an aryl acetic acid ester followed by cyclization of the resultant b-keto ester with thiourea analogously to Scheme 9. Subsequent catalytic reduction of the nitro group to an amino group would give a 4-hydroxy-pyrimidine II in which R12 is represented by a 2-amino-4-pyridyl group (Scheme 10]
Scheme 10
Figure imgf000096_0001
Furthermore, methyl 2-acetamido isonicotinate (Scheme 11) may be reacted analogously to Scheme 9 after appropriate protection of the amide nitrogen with e.g. a tert-butyldimethylsilyloxymethyl group (Benneche et al . , Acta Chem . Scand. B 42 384-389 (1988)), a tert- butyldimethylsilyl group, a benzyloxymethyl group, a benzyl group or the like (Px) .
Scheme 11
Figure imgf000096_0002
Removal of the protecting group Px of the resulting pyrimidine II with a suitable reagent (e.g., tetrabutylammonium fluoride in the case where T?1 is t- butyldimethyl-silyloxymethyl) would then lead to a pyrimidine II with R12 represented by a 2-acetamido-4- pyridyl group. Needless to say, ethyl p-fluorophenyl acetate may be substituted by any alkyl arylacetate in the procedure illustrated in Scheme 9 thus providing compounds of formula II with different R11 aryl substituents .
In a further process, compounds of pyrimidines II may be prepared by coupling a suitable derivative of XVIII (L is a leaving group, such as halogen radical and the like, and P2 is a protecting group, such as benzyl and the like) with an appropriate aryl equivalent.
Figure imgf000097_0001
XVIII Such aryl/heteroaryl couplings are well known to those skilled in the art and involve an organic-metallic component for reaction with a reactive derivative, e.g., a halogeno derivative, of the second compound in the presence of a catalyst. The metallo-organic species may be provided either by the pyrimidinone in which case the aryl component provides the reactive halogen equivalent or the pyrimidinone may be in the form of a reactive 5- halogeno derivative for reaction with a metallo organic aryl compound. Accordingly, 5-bromo and 5-iodo derivatives of XVIII (L = Br, I) may be treated with arylalkyl tin compounds, e.g., trimethylstannylbenzene, in an inert solvent such as tetrahydrofuran in the presence of a palladium catalyst, such as di (triphenylphosphine) palladium (II) dichloride . (Peters et al., J". Heterocyclic Chem . 27, 2165-2173, (1990). Alternatively, the halogen derivative of XVIII may be converted into a trialkyltin derivative (L = Bu3Sn) by reaction with e.g. tributylstannyl chloride following lithiation with butyllithium and may then be reacted with an aryl halide in the presence of a catalyst.
(Sandosham and Undheim, Acta Chem . Scand. 43, 684-689 (1989) . Both approaches would lead to pyrimidines II in which Ru is represented by aryl and heteroaryl groups. As reported in the literature (Kabbe, Lieb. Ann . Chem . 704, 144 (1967); German Patent 1271116 (1968)) and displayed in Scheme 12, 5-aryl-2 , 6-dipyridyl-4-hydroxy- pyrimidines II may be prepared in a one step synthesis by reaction of the cyanopyridine with an arylacetyl ester, such as ethyl phenylacetate in the presence of sodium methoxide.
Scheme 12
Figure imgf000098_0001
II
Analogously, as reported (Kabbe, supra) and displayed in Scheme 13, 4-amino-5- (aryl) -2 , 6-dipyridyl- pyrimidines XIX are obtained in a one step synthesis by reaction of cyanopyridine with arylacetonitrile, such as 4-fluorophenylacetonitrile .
Scheme 13
Figure imgf000098_0002
XIX
Modification at the 4-position (R2 of formula I) of pyrimidine II is possible by conversion into the chloro derivative XX by reaction with phosphorous oxychloride (Scheme 14) . A 4-alkoxy derivative XXI may be prepared from chloro derivative XX by nucleophilic substitution with alkoxide. Alternatively, in stead of the chloro group, other leaving groups, such as tosylates, mesylates and the like, can be used. Also, such leaving groups can also be displaced by amino, thiolates, alcoholates, and the like nucleophiles . For example, the chloro derivative XX may be reduced by catalytic hydrogenation to give a pyrimidine I where R2 is H, or may be reacted with an alkyl or aryl boronic acid or an alkyl or aryl zinc halide to provide a pyrimidine I where R2 is alkyl or aryl. Scheme 14
Figure imgf000099_0001
In Scheme 15, compounds of the present invention of formula XXX can be readily prepared by reacting the methylthio intermediate XXXI with the amine NHR5R21, for example by heating the mixture preferably at a temperature greater than 100°C, more preferably 150- 210°C. Alternatively, compounds of formula XXX can be readily prepared by reacting the methylsulfonyl intermediate XXXII with the amine NHR5R21, for example by heating the mixture preferably at a temperature greater than 40°C, more preferably 50-210°C.
Scheme 15
Figure imgf000099_0002
Amines of formula NHR5R21 are commercially available or can be readily prepared by those skilled in the art from commercially available starting materials. For example, an amide, nitro or cyano group can be reduced under reducing conditions, such as in the prescence of a reducing agent like lithium aluminum hydride and the like, to form the corresponding amine. Alkylation and acylation of amino groups are well known in the art. Chiral and achiral substituted amines can be prepared from chiral amino acids and amino acid amides (for example, alkyl, aryl, heteroaryl, cycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and the like substituted glycine, β-alanine and the like) using methods well known in the art, such as H. Brunner, P. Hankofer, U. Holzinger, B. Treittinger and H. Schoenenberger, Eur. J. Med. Chem. 25, 35-44, 1990; M. Freiberger and R. B. Hasbrouck, J. Am. Chem. Soc. 82, 696-698, 1960; Dornow and Fust, Chem. Ber. 87, 984, 1954; M. Kojima and J. Fujita, Bull. Chem. Soc. Jpn. 55, 1454-1459, 1982; W. Wheeler and D. O'Bannon, Journal of Labelled Compounds and Radiopharmaceuticals XXXI, 306, 1992; and S. Davies, N. Garrido, 0. Ichihara and I. Walters, J. Chem. Soc, Chem. Commun. 1153, 1993.
The following Examples are presented for illustrative purposes only and are not intended, nor should they be construed, as limiting the invention in any manner. Those skilled in the art will appreciate that modifications and variations of the compounds disclosed herein can be made without violating the spirit or scope of the present invention.
EXAMPLES Example 1 General procedure for the preparation of 2-substi tuted 5- (4 - fluorophenyl ) -4 - (4 -pyridyl ) -pyrimidines a. 3- (Dimethylamino) -2- (4-fluorophenyl) -1- (4-pyridyl) - 3-propene-l-one :
(According to Bennett et al . , J. Org. Chem. 43, 221 (1977) ) .
Figure imgf000101_0001
A mixture of 2- (4-fluorophenyl) -1- (4-pyridinyl) ethanone (300 mg, 1.39 mmol) and bis (dimethylamino) methoxymethane (300 mml, 1.95 mmol) was heated at 110°C for 1.5 h under argon. It was evaporated and the yellow, crystallizing residue dried in an oil pump vacuum before used in the succeeding reaction. MS (m/z) : 270.8 (M+H) + ; C16H15FN20 requir. 270.3. "H-NMR (CDC13) : d 8.57, 7.25 (2m, each 2H, Pyrid.), 7.36 (s, 1H, CH=) , 7.13, 6.99 (2m, each 2H, PhF) , 3.00 (bs, 6H, 2CH3) . b. General procedure:
(According to Bennett et al . , J. Med. Chem. 21, 623 (1978) ) .
Figure imgf000102_0001
A solution of 3- (dimethylamino) -2- (4-fluorophenyl) -1- (4- pyridinyl) -3-propene-l-one (1.39 mmol) in absol. ethanol
(9 ml) was transferred into a solution of the RX-C(NH)NH2 (1.67 mmol) in ethanol (2 ml) prepared from sodium (1.67 mmol) and the amidine or guanidine hydrochloride (1.67 mmol) . After heating under reflux for 1.5 to 24 h, it was evaporated and the resulting material was applied either directly to a column of silica gel (1-5% met anol/dichloromethane) or was taken up in dichloromethane followed by washing with water, drying of the organic solution and evaporation prior to column chromatography.
The following pyrimidines were prepared according to this general procedure by reacting 3- (dimethylamino) - 2- (4-fluorophenyl) -1- (4-pyridinyl) -3-propene-l-one with amidines :
1-1 5- (4-Fluorophenyl) -2-methyl-4- (4-pyridyl) - pyrimidine: MS (m/z) : 266.0 (M+H) +; C16HX2FN3 requir . 265.3. "H-NMR (CDCIJ) : d 8.70 (d, 1H, H-6, Pyrim.),
8.59, 7.32 (2m, each 2H, Pyrid.), 7.20-7.00 (m, 4H, PhF) , 2.88 (s, 3H, CH3) .
1-2 5- (4 -Fluorophenyl) -2-isopropyl-4- (4-pyridyl) - pyrimidine: MS (m/z) : 294.4 (M+H) + ; C18H16FN3 requir . 293.4. 'H-NMR (CDCl,) : d 8.73 (s, 1H, H-6, Pyri .) ,
8.60, 7.35 (2m, each 2H, Pyrid.) , 7.20-7.04 (m, 4H, PhF) , 3.37 (m, 1H, CH(CH3)2) , 1.50, 1.47 (2s, each 3H, 2CH3) . R, = (CH3).CH- 1-3 2-tert-Butyl-5- (4-f luorophenyl) -4- (4-pyridyl) - pyrimidine: MS (m/z) : 307.8 (M+H) + ; C19H18FN3 requir . 307.4. 'H-NMR (CDC13) : d 8.72 (s, IH, H-6, Pyrim.) , 8.59, 7.38 (2m, each 2H, Pyrid.) , 7.21-7.06 (m, 4H, PhF) , 1.52 (s, 9H, 3CH3) . Rx = (CH3)3C-
1-4 2- (l-Chloro-2-methoxyethyl) -5- (4-f luorophenyl) -4- ( 4 -pyridyl ) -pyrimidine : MS (m/z) : 344.2 (M+H) + ; C18H15C1FN30 requir. 343.8. "H-NMR (CDC13) : d 8.81 (s, IH, H-6, Pyrim.) , 8.61, 7.35 (2m, each 2H, Pyrid.) , 7.22-
7.08 (m, 4H, PhF) , 5.29 (dd, IH, CHCl) , 4.31, 4.04 (2dd, each IH, CH20) , 3.47 (s, 3H, CH30) . Rx = CH3OCH2CH(CD-
1-5 2- (Cyclopropyl) -5- (4-f luorophenyl) -4- (4-pyridyl) - pyrimidine: MS (m/z) : 292.0 (M+Hf; C18H14FN3 requir . 291.3. "H-NMR (CDCI3) : d 8.60 (s, IH, H-6, Pyrim.) , 8.57, 7.32 (2d, each 2H, Pyrid.) , 7.16-7.00 (m, 4H, PhF) , 2.32 (m, IH, -CH-) , 1.2, 1.1 (2m, each 2H, 2CH2) .
Rl =
>-
1-6 2- ( Adamant -1-yl) -5- (4-f luorophenyl) -4- (4-pyridyl) - pyrimidine: MS (m/z) : 386.0 (M+H) + ; C25H21FN3 requir . 385.5. "H-NMR (CDClj) : d 8.76 (s, IH, H-6, Pyrim.) , 8.61, 7.51 (2m, each 2H, Pyrid.), 7.22-7.08 (m, 4H, PhF) , -1.9-1.5 (broad, 15H, CH2, CH) .
Figure imgf000103_0001
1-7 2 -Benzyl-5- (4-f luorophenyl) -4- (4-pyridyl) - pyrimidine: MS (m/z) : 342.2 (M+H)\- C22H16FN3 requir . 341.4. 'H-NMR (CDCI3) : d 8.71 (s, IH, H-6, Pyrim.) , 8.60, 7.48 (2m, each 2H, Pyrid.) , 7.42-7.04 ( , 9H, PhF, Ph) , 4.42 (s, 2H, CH2Ph) .
Figure imgf000104_0001
1-8 2- (2 , 6-Dichlorobenzyl) -5- (4-f luorophenyl) -4- (4- pyridyl ) -pyrimidine : MS (m/z) : 410.2 (M) + ; C22H14C12FN3 requir. 410.3. XH-NMR (CDC13) : d 8.68 (s, IH, H-6, Pyrim.) , 8.57 (d, 2H, Pyrid.) , 7.44-7.03 (m, 9H, Pyrid. PhF, PhCl2) , 4.93 (s, 2H, CH2) .
Figure imgf000104_0002
1-9 5- (4 -Fluorophenyl) -2-phenoxymethyl-4- (4-pyridyl) - pyrimidine: MS (m/z) : 358.2 (M+H) + ; C22H16FN30 requir . 357.4. XH-NMR (CDC13) : d 8.83 (s, IH, H-6, Pyrim.) , 8.60 (m, 2H, Pyrid.) , 7.36-6.98 (m, 11H, Pyrid., PhF, Ph) , 5.43 (s, 2H, CH2) .
O^/
Rl =
1-10 5 σ- (4-Fluorophenyl) -2 -phenyl thiomethyl-4- (4- pyr idinyl ) -pyrimidine : MS (m/z) : 374.2 (M+H) + ; C22H16FN3S requir. 373.5. *H-NMR (CDC13) : d 8.72 (s, IH, H-6, Pyrim.) , 8.56, 7.49 (2m each 2H, Pyrid.) , 7.32-7.02 (m, 9H, PhF, Ph) , 4.50 (s, 2H, CH2) .
Rl =
1-11 5 σ- (4 -Fluorophenyl) -2-phenyl-4- (4-pyridyl) - pyrimidine: MS (m/z) : 328.2 (M+H) + ; C21H14FN3 requir . 327.4. 'H-NMR (CDC13) : d 8.85 (s, IH, H-6, Pyrim.) , 8.63, 7.4 (2m, each 2H, Pyrid.) , 8.56, 7.6-7.5, 7.25- 7.05 (m, 9H, PhF, Ph) .
Figure imgf000104_0003
1-12 5- (4-Fluorophenyl) -2- (4-hydroxyphenyl) -4- (4- pyridyl) -pyrimidine : MS (m/z): 344.2 (M+H)*; C21H14FN30 requir. 343.4. 'H-NMR (DMSO-d6) : d 10.2 (bs, IH, OH), 8.90 (s, IH, H-6, Pyrim., Pyrim.), 8.60, 7.42 (2m, each 2H, Pyrid.), 8.35, 7.40-6.92 (m, 8H, PhF, PhOH) .
Rl =
HO
1-13 5- ( x4 -Fxluorophenyl) -2- (4-aminophenyl) -4- (4-pyridyl) - pyrimidine : MS (m/z) : 343.2 (M+H)*; C21H15FN4 requir . 342.4. "H-NMR (CDC13) : d 8.75 (s, IH, H-6, Pyrim.), 8.60, 7.41 (2m, each 2H, Pyrid.) , 8,40, 7.22-6.79 (m, 8H, PhF, Ph) , 4.00 (bs, 2H, NH .
Figure imgf000105_0001
1-14 5- (4 -Fluorophenyl) -2- (3-pyridyl) -4- (4-pyridyl) - pyrimidine: MS (m/z) : 329.0 (M+H) + ; C20H13FN4 requir . 328.4. 'H-NMR (CDC13) : d 9.80 (bs, H-2 , 3 -Pyrid. ) , 8.90 (s, IH, H-6, Pyrim.) , 8.84, 8.80 (2m, each IH, 3- Pyrid.), 8.66, 7.45 (2m, each 2H, 4-Pyrid. ) , 7.50 (m, IH, 3-Pyrid.), 7.28-7.10 (m, 4H, PhF) .
Figure imgf000105_0002
1-15 5- (4-F luorophenyl) -2- (2-pyridyl) -4- (4-pyridyl) - pyrimidine: MS (m/z) : 329.0 (M+H) + ; C20H13FN4 requir . 328.4. "H-NMR (CDC13) : d 9.01 (s, IH, H-6, Pyrim.), 8.92, 8.66, 7.94, 7.48 (4m, each lH, 2-Pyrid. ) , 8.66, 7.47 (2m, each 2H, 4-Pyrid.), 7.26, 7.14 (2m, each 2H, PhF) .
Figure imgf000105_0003
1-16 5- (4 -Fluorophenyl) -2- (2-pyrazinyl) -4- (4-pyridyl) - pyrimidine: MS (m/z) : 330.2 (M+H)*; C19H12FN5 requir . 329.3. *H-NMR (CDC13) : 9.84 ( , IH, H-3 , Pyraz . ) , 9.01 (s, IH, H-6, Pyrim.) , 8.84, 8.76 (2m, each IH, H-5, H-6,
Pyraz.) , 8.65, 7.44 (2m, each 2H, Pyrid.) , 7.26, 7.13 (2m, each 2H, PhF) .
Figure imgf000106_0001
1-17 5- (4 -Fluorophenyl) -2- (2-methylthiazol-4-yl) -4- (4- pyridyl) -pyrimidine: MS (m/z) : 349.0 (M+H) + ; C19H13FN4S requir. 348.4. 'H-NMR (CDCl,) : d 8.90 (s, IH, H-6, Pyrim.) , 8.63, 7.42 (2m, each 2H, Pyrid.) , 8.32 (s, IH, H-5, Thiaz.) , 7.22, 7.10 (2m, each 2H, PhF) , 2.88 (s, 3H, CH,) .
Figure imgf000106_0002
1-18 5- (4 -Fluorophenyl) -4- (4-pyridyl) -2- (2-thienyl) - pyrimidine: MS (m/z) : 334.2 (M+H) + ; C19H12FN3S requir . 333.4. "H-NMR (CDCIJ) : d 8.74 (s, IH, H-6, Pyrim.) ,
8.63, 7.41 (2m, each 2H, Pyrid.) , 8.13, 7.55 (2m, each IH, Thioph.) , 7.20 (m, 3H, PhF, Thioph. ) . 7.10 (m, 2H, PhF) .
Figure imgf000106_0003
The following pyrimidines were prepared according to the general procedure by reacting 3- (dimethylamino) -2- (4- fluorophenyl) -1- (4-pyridinyl) -3-propene-l-one with guanidines :
1-19 2-Amino-5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine: MS (m/z): 267.0 (M+H) +; C15HnFN4 requir . 266.3. XH-NMR (DMS0-d6) : d 8.54, 7.26 (2m, each 2H, Pyrid.), 8.35 (s, IH, H-6, Pyrim.), 7.22-7.12 (m, 4H, PhF) , 6.97 (s, 2H, NH2) . Rl = NH - 1-20 2 -Ethylamino- 5- (4-f luorophenyl) -4- (4-pyridyl) - pyrimidine: MS (m/z) : 295.0 (M+H) + ; C17H15FN4 requir . 294.3. 'H-NMR (CDC13) : d 8.56, 7.32 (m, each 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.12-6.99 ( , 4H, PhF) , 5.33 (unresolv.t, IH, NH) , 3.58 (m, 2H, CH2) , 1.32 (t, 3H, CH3) . Rl = CH3CH2-NH-
1-21 5- (4-Fluorophenyl) -4- (4-pyridyl) -2- (2- sulfoethylamino) -pyrimidine: MS (m/z) : 375.2 (M+H)\- C17H15FN403S requir. 374.4. "H-NMR (DMS0-d6) : d 8.51, 7.25 (2d, each 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.32 (t, IH, NH) , 7.2-7.1 (m, 4H, PhF) , 3.62 (q, 2H, CH2N) , 2.72 (t, 2H, CH2) . Rl = H03S-CH2-CH2-NH- 1-22 2- (2-Diethylaminoethylamino) -5- (4-f luorophenyl) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 365.8 (M+H) + ; C21H24FN5 requir. 365.5. "H-NMR (CDC13) : d 8.55, 7.28 (2m, each 2H, Pyrid.) , 8.34 (s, IH, H-6, Pyrim.) , 7.08, 7.01 (2m, each 2H, PhF) , 5.95 (bs, IH, NH) , 3.60 (q, 2H, CH2N) , 2.76 (t, 2H, CH.) , 2.65 (q, 4H, 2CH2CH3) , 1.08 (t, 6H, 2CH3) . Rl = ( CH3CH2 ) 2NCH2CH2NH-
1-23 (4 -Fluorophenyl) -4- (4-pyridyl) -2- (thioureido) - pyrimidine: MS (m/z) : 326.2 ( +H) + ; C16H12FN5S requir . 325.4. 'H-NMR (DMS0-d6) : d 10.84, 10.11, 9.20 (3s, each IH, NH, SH) , 8.75 (s, IH, H-6, Pyrim.) , 8.59, 7.32 (2m, each 2H, Pyrid.) , 7.28, 7.21 (2m, each 2H, Ph)F. S
Rl - H2N^N^ H
1-24 2- (2 , 6-Dichlorophenylamino) -5- (4-f luorophenyl) -4- ( 4 -pyridyl ) -pyrimidine : MS (m/z) : 410.8 (M)\- C21H13C12FN4 requir. 411.3. 'H-NMR (CDCl,) : d 8.54, 7.30 (2m, each 2H, Pyrid.) , 8.45 (s, IH, H-6, Pyrim.) , 7.45 (d, 2H, PhCl2) , 7.21 (t, IH, PhCl2) , 7.12, 7.04 (2m, each 2H, PhF) .
Figure imgf000108_0001
1-25 2- (2 , 6-Dimethylphenylamino) -5- (4-f luorophenyl) -4- ( 4 -pyridyl ) -pyrimidine : MS (m/z) : 371.0 (M+H)\- C23H19FN 44 requir. 370.4. 'H-NMR (CDC13) : d 8.56, 7.32 (2d, each 2H, Pyrid.) , 8.40 (s, IH, H-6, Pyrim.) , 7.20 (s, 3H, PhCl2) , 7.11, 7.04 (2m, each 2H, PhF) , 6.66 (s, IH, NH) , 2.20 (s, 6H, 2CH3) .
Figure imgf000108_0002
1-26 5- (4 -Fluorophenyl) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 373.0 (M+H) + ; C22H17FN40 requir . 372.4. 'H-NMR
(CDC13) : d 8.62, 7.40 (2m, each 2H, Pyrid.) , 8.60 (m, IH, PhOMe) , 8.52 (s, IH, H-6, Pyrim.) , 7.99 (s, IH, NH) , 7.18-6.94 (m, 7H, PhF, PhOMe) , 3.96 (s, 3H, CH30) .
Figure imgf000108_0003
1-27 5- (4 -Fluorophenyl) -2- (4-f luor opheny lamino) -4- (4- pyridyl) -pyrimidine: MS (m/z) : 361.0 (M+H) + ; C21H14F2N4 requir. 360.4. XH-NMR (CDC13) : d 8.58, 7.32 (m, 2H, Pyrid.) , 8.46 (s, IH, H-6, Pyrim.) , 7.62 (m, 2H, PhF) , 7.24 (bs, IH, NH) , 7.13-7.00 (m, 6H, PhF) .
Figure imgf000108_0004
1-28 2- (4-Ethylphenylamino) -5- (4-f luorophenyl) -4- (4- pyridyl) -pyrimidine: MS (m/z) : 371.2 (M+H) + ; C23H19FN4 requir. 370.4. 'H-NMR (CDC13) : d 8.61, 7.41 (2m, each 2H, Pyrid.) , 8.49 (s, IH, H-6, Pyrim.) , 7.60, 7.23 (2d, each 2H, PhEth) , -7.28 (NH) , 7.13, 7.06 (2m, each 2H, PhF), 2.67 (q, 2H, CH2) , 1.27 (t, 3H, CH,) .
Figure imgf000109_0001
1-29 5- (4-Fluorophenyl) -4- (4-pyridyl) -2- (3- trifluoromethylphenylamino) -pyrimidine : MS (m/z) : 411.0 (M+H ,- C22H14F4N4 requir . 410.4. 'H-NMR (CDC13) : d 8.60, 7.35 (2m, each 2H, Pyrid.), 8.52 (s, IH, H-6, Pyrim.), 8.23, 7.73, 7.46 (s, dd, t, each IH, PhCF3) , 7.44 (s, IH, NH) , 7.31 (dd, IH, PhCF3) , 7.13, 7.05 (2m, each 2H, PhF) .
H
Figure imgf000109_0002
1-30 2- (Benzylamino) -5- (4-f luorophenyl) -4- (4-pyridyl) pyrimidine: MS (m/z) : 357.0 (M+H) + ; C22H17FN4 requir . 356.4. "H-NMR (CDC13) : d 8.55, 7.28 (2m, each 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.44-7.28 (m, 5H, Ph) , 7.09, 7.02 (2m, each 2H, PhF) , 5.71 (t, IH, NH) , 4.75 (d, IH, CH,) .
Rl = CTB H
1-31 5- (4 -Fluorophenyl) -2- (2-phenylethylamino) -4- (4- pyridyl) -pyrimidine: MS (m/z) : 371.0 (M+Hf; C23H19FN4 requir. 370.4. 'H-NMR (CDC13) : d 8.56 (m, 2H, Pyrid.:
8.35 (s, IH, H-6, Pyrim.) , 7.38-7.22 (m, 7H, Ph,
Pyrid.) , 7.08, 7.02 (2m, each 2H, PhF) , 5.32 (t, IH,
NH) , 3.80 (q, 2H, CH2N) , 2.92 (t, 2H, CH2) .
H
Figure imgf000109_0003
1-32 5- (4-Fluorophenyl) -4- (4-pyridyl) -2-pyrrolidino- pyrimidine: MS (m/z) : 321.2 (M+H)*; C19H17FN4 requir . 320.4. 'H-NMR (CDC13) : d 8.54, 7.32 (2d, each 2H, Pyrid.) , 8.37 (s, IH, H-6, Pyrim.) , 7.06, 7.00 (2m, each 2H, PhF) , 3.68, 2.05 (2m, each 4H, 4CH2) .
Figure imgf000110_0001
1-33 5- (4 -Fluorophenyl) -2-morpholino-4- (4-pyridyl) - pyrimidine: MS (m/z) : 337.2 (M+H)*; C19H17FN40 requir . 336.4. "H-NMR (CDCI3) : d 8.56, 7.31 (2m, each 2H, Pyrid.) , 8.40 (s, IH, H-6, Pyrim.) , 7.10, 7.03 (2m, each 2H, PhF) , 3.94, 3.83 (2m, each 4H, 4CH2) .
Figure imgf000110_0002
1-34 2- (3 , 5-Dimethylpyrazolyl) -5- (4-f luorophenyl) -4- (4- pyridyl ) -pyrimidine : MS (m/z) : 346.0 (M+H)+; C20H16FN5 requir. 345.4. 'H-NMR (CDC13) : d 8.80 (s, IH, H-6,
Pyrim.) , 8.60, 7.35 (2m, each 2H, Pyrid.) , 7.18, 7.08
(2m, each 2H, PhF) , 6.08 (s, IH, Pyraz.) , 2.70, 2.30
(2s, each 3H, 2CH3) .
Figure imgf000110_0003
1-35 5- (4 -Fluorophenyl) -4- (4-pyridyl) -2- (3 , 5- bis ( trif luoromethyl ) benzenesulf amoyl ) -pyrimidine : MS (m/z) : 542.8 (M+H) + ; C23H13F7N402S requir . 542.4. "H-NMR (DMSO-d6) : d 8.63 (s, IH, H-6, Pyrim.) , 8.56 (m, 2H, Pyrid.) , 8.49, 8.43 (2s, 2H, IH, Ph(CF3)2) , 7.26-7.15 ( , 6H, PhF, Pyrid. ) .
Figure imgf000110_0004
1-36 2- (4-Aminobenzenesulf amoyl ) -5- (4-f luorophenyl) -4- ( 4 -pyridyl ) -pyrimidine : MS (m/z) : 421.8 (M+H)\- C21H16FN502S requir. 421.5. 'H-NMR (DMSO-d6) : d 8.58 (s, IH, H-6, Pyrim.) , 8.575 (m, 2H, Pyrid.) , 7.64, 6.56 (2d, each 2H, PhNH2) , 7.28-7.15 (m, 6H, PhF, Pyrid.) , 5.99 (s, 2H, NH2) .
° °
Figure imgf000111_0001
1-37 2- (2 -Dimethylaminoethylthio) -5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine was prepared according to the general procedure by reacting 3- (dimethylamino) -2- (4- fluorophenyl) -1- (4-pyridinyl) -3-propene-l-one with S-(2- dimethylaminoethyl) isothiourea. MS (m/z): 355.2 (M+H)+; C19H19FN4S requir . 354.5. "H-NMR (CDCl,) : d 8.59, 7.32 (2m, each 2H, Pyrid.), 8.58 (s, IH, H-6, Pyrim.), 7.16, 7.08 (2m, each 2H, PhF), 3.40, 2.76 (2m, each 2H, 2CH2) , 2.37 (s, 6H, 2CH3) .
Rl (CH3)2NCH2CH2S-
Examplθ 2 General procedure for the preparation of 2-N substituted 2-amino-5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidines a. 5- (4-Fluorophenyl) -4- (4-pyridyl) -2 (IH) -pyrimidinone :
Figure imgf000111_0002
Urea (0.67 g, 11.15 mmol) was added to a stirred ethanolic 0.62 N sodium ethoxide solution (15 ml). An ethanolic solution (60 ml) of 3- (dimethylamino) -2- (4- fluorophenyl) -1- (4-pyridinyl) -3-propene-l-one (9.29 mmol) was added and the mixture was refluxed overnight. It was evaporated followed by column chromatography (5% methanol /dichloromethane to 100% methanol) . Crystals (presumably urea) obtained on treating the resultant product with dichloromethane/methanol were filtered. The filtrate was evaporated and the remainder rechromatographed on a column of silica gel (chloroform/methanol/water = 70:20:1) to yield the title compound as a yellowish foam. MS (m/z): 268.2 (M+H) + ; C15H10FN3O requir . 267.3. Ti-NMR
IDMSO-d, d 55, 7.24 (2m, each 2H, Pyrid.) 22 (bs,
IH, H-6, Pyrim.), 7.20-7.10 (m, 4H, PhF). b. 2-Chloro-5- (4-fluorophenyl) -4- (4-pyridyl) pyrimidine :
Figure imgf000112_0001
A mixture of 5- (4-fluorophenyl) -4- (4-pyridyl) -2- (IH) - pyrimidinone (2.41 mmol) and phosphorus oxychloride (3 ml) was heated at reflux for 45 min . It was evaporated to dryness at a bath temperature of >50° C. The flask was cooled in an ice-bath and ice-water was added. If the pH value was found still acidic, then the mixture was neutralized with aqueous 5% ammonium hydroxide. It was extracted with dichloromethane, followed by washing of the organic solution with aqueous sodium chloride, drying and evaporation to yield the title compound as a yellowish foam which was used without further purification.
MS (m/z): 286.1 (M+H) + ; C15H19C1FN3 requir . 285.7. 'H-NMR (CDClj) : d 8.68 (s, IH, H-6, Pyrim.), 8.62, 7.42 (2m, each 2H, Pyrid.), 7.23-7.10 (m, 4H, PhF). Alternatively, 2-chloro-5- (3 -methylphenyl) -4- (4- pyridyl) -pyrimidine (MS (m/z): 282 (M+H)+; CI6H12CIN3 requir. 281.7) and 2-chloro-4- (4-pyridyl) -5- (3-trifluoro methylphenyl) -pyrimidine (MS (m/z): 336.0 (M) + ; C16H9CIF3N3 requir. 335.7) have been synthesized by the same reaction sequence, but starting from 2-(3-methyl phenyl) -1- (4-pyridinyl) ethanone (prepared according to: I. antos et al . , J. Org. Chem. 53, 4223-4227, 1988) and 1- (4-pyridinyl) -2- (3-trifluoromethylphenyl) ethanone (prepared according to: P.W. Sheldrake, Synth. Commun. 23 (24), 1967-1971, 1993); and WO 97/12876) . Also, thionyl chloride /N, N-dimethylformamide (excess/3 equivalents, reflux) can be used instead of phosphorus oxychloride . c. General procedure:
Figure imgf000113_0001
Typically, a mixture of 2-chloro-5- (4-fluoro phenyl) -4- (4-pyridyl) -pyrimidine (50-120 mg, 0.18-0.42 mmol) and the amine, HΝR5R21, (0.5-5.5 mmol) was heated at 50-100°C for 5-60 in (thin layer chromatography check) . The mixture was applied directly to a column of silica gel which was developed with dichloromethane/ methanol or dichloromethane/methanol/cone . ammonium hydroxide . An alternate procedure using ethanol as a solvent was used in case of Examples 2-6, 2-11, 2-12, 2-20 and 2-26 as described.
The following pyrimidines were prepared according to this procedure using the appropriate amine and substituted 2-chloropyrimidine: 2-1 2- (2-Aminoethylamino) -5- (4-f luorophenyl) -4- (4- pyridyl) -pyrimidine hydrochloride: MS (m/z) : 310.2 (M+H)*; C17H16FN5-HC1 requir. 309.4 + 36.5. 'H-NMR (CD3OD) : d
8.84, 8.10 (2m, each 2H, Pyrid.) , 8.58 (s, IH, H-6, Pyrim.) , 7.28, 7.15 (2m, each 2H, PhF) , 3.83 (t, 2H, CH2) , 3.27 (t, 2H, CH2) . Rl = NH2CH2CH2NH-
2-2 2- (3-Aminopropylamino) -5- (4-f luorophenyl) -4- (4- pyridyl ) -pyrimidine hydrochloride: MS (m/z) : 324.0 (M+H)*; C18H18FN5-HC1 requir. 323.4 + 36.5. 'H-NMR (CD3OD) : d
8.85, 8.10 (m, 2H, Pyrid.) , 8.54 (s, IH, H-6, Pyrim.), 7.27, 7.14 (2m, each 2H, PhF) , 3.84, 3.68 (2t, each 2H, 2CH2N) , 2.18 (m, 2H, CH2) .
Rl = NH2CH2CH2CH2NH- 2-3 2- (4-Aminobutylamino) -5- (4-f luorophenyl) -4- (4- pyridyl) -pyrimidine hydrochloride: MS (m/z) : 338.0 (M+H)*; C19H20FNS-HC1 requir. 337.4+36.5. 'H-NMR (CD3OD) : d 8.80, 8.05 (2m, each 2H, Pyrid.) , 8.50 (s, IH, H-6, Pyrim.) , 7.25, 7.14 (2m, each 2H, PhF) , 3.58 (bt, 2H, CH2) , 3.02 (bt, IH, CH2) , 1.80 (m, 4H, 2CH2) . Rl = NH2CH2CH2CH2CH2NH-
2-4 2- (2-Dimethylaminoethylamino) -5- (4-f luorophenyl) -4- ( 4-pyridyl ) -pyrimidine : MS (m/z) : 338.2 (M+H)*; C19H20FN5 requir. 337.4. "H-NMR (CDC13) : d 8.57, 7.30 (2m, each 2H, Pyrid.) , 8.37 (s, IH, H-6, Pyrim.) , 7.10, 7.03 (2m, each 2H, PhF), 6.00 (t, IH, NH) , 3.66 (q, 2H, CH.) , 2.71 (t, 2H, CH2) , 2.41 (s, 6H, 2CH3) . Rl = (CH3)2NCH2CH2NH-
2-5 5- (4 -Fluorophenyl) -2- (2-phenylaminoethylamino) -4- ( 4-pyridyl ) -pyrimidine : MS (m/z) : 386 (M+H)*; C23H20FN5 requir. 385.5. "H-NMR (CDCl,) : d 8.57, 7.28 (m, 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.18 (t, 2H, Ph) , 7.08, 7.02 (2m, each 2H, PhF) , 6.73 (t, IH, Ph) , 6.64 (d, 2H, Ph) , 5.62 (bt, IH, NH) , 3.80 (q, 2H, CH2) , 3.47 (t, 2H, CH2) .
Figure imgf000115_0001
2-6 5- (4-Fluorophenyl) -2- (2- (4-fluorophenylamino) - ethylamino) -4- (4-pyridyl) -pyrimidine: A solution of 2- chloro-5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine (103 mg, 0.36 mmol) and N- (4-fluorophenyl) ethylendiamine (1 ml) in ethanol (1 ml) was heated to reflux for 3 h. Evaporation was followed by column chromatography (3% methanol/dichloromethane) to provide the title compound as a yellowish solid. MS (m/z): 404.2 (M+H)*; C23H19F2N5 requir. 403.4. 'H-NMR (CDC13) : 8.60 7.31 (2m, each 2H, Pyrid.), 8.40 (s, IH, H-6, Pyrim.), 7.11-7.02 (2m, each 2H, PhF), 6.90, 6.60 (t, dd, each 2H, PhF), 5.62 (t, IH, NH) , 3.82 (q, 2H, CH2) , 3.44 (t, 2H, CH2) .
Figure imgf000115_0002
2-7 5- (4 -Fluorophenyl) -2- (4-methylbenzylamino) -4- (4- pyr idyl ) -pyrimidine : MS (m/z) : 371.2 (M+H)*; C23H19FN4 requir. 370.4. 'H-NMR (CDC13) : d 8.55, 7.34 (2m, each 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.30, 7.18 (2d, each 2H, PhMe) , 7.08, 7.02 (2m, each 2H, PhF) , 5.69 (bs, IH, NH) , 4.69 (d, 2H, CH2) , 2.36 (s, 3H, CH3)
Figure imgf000115_0003
2-8 5- (4 -Fluorophenyl) -2- (2- (4-f luorophenyl) - ethylamino) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 389.2 (M+H)*; C23H18F2N4 requir . 388.4. 'H-NMR (CDC13) : d 8.57 (m, 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.32-7.20, 7.12- 6.98 (2m, 10H, 2PhF, Pyrid.), 5.37 (bt, IH, NH) , 3.79 (q, 2H, CH2N) , 2.97 (t, 2H, CH2) . H NL
Figure imgf000116_0001
2-9 2- (2- (4-Chlorophenyl) -ethylamino) -5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 405.0 (M+H)*; C23H18C1FN4 requir . 404.9. "H-NMR (CDCl3) : d 8.56 (bs, 2H, Pyrid.), 8.34 (s, IH, H-6, Pyrim.), 7.29 (m, d, 4H, Pyrid., PhCl) , 7.20 (d, 2H, PhCl) , 7.08, 7.02 (2m, each 2H, PhF) , 5.35 ;t, IH, NH) , 3.78 (q, CH.N) , 2.96 (t, 2H, CH2) .
Figure imgf000116_0002
2-10 2- (2- (4-Bromophenyl) -ethylamino) -5- (4- f luorophenyl) -4- (4-pyridyl) -pyrimidine: MS (m/z) :449.0 (M)*; C23H18BrFN4 requir . 449.3. "H-NMR (CDC13) : d 8.58, 7.47 (m, 2H, Pyrid.), 8.37 (s, IH, H-6, Pyrim.) , 7.29, 7.17 (2d, each 2H, PhCl) , 7.10, 7.02 (2d, each 2H, PhF), 5.34 (t, IH, NH) , 3.80 (q, 2H, CH2N) , 2.97 (t, 2H, CH .
Figure imgf000116_0003
2-11 5- (4-Fluorophenyl) -2- (2- (4-hydroxyphenyl) - ethylamino) -4- (4-pyridyl) -pyrimidine: A mixture of 2- chloro-5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine (61 mg, 0.21 mmol), tyramine hydrochloride (186 mg, 1.01 mmol) and sodium hydrogencarbonate (90 mg, 1.07 mmol) in aqueous ethanol (1 ml) was heated to reflux for 1 h. Solvent evaporation and subsequent column chromatography (5% methanol/dichloromethane) provided the title compound as a yellow solid. MS (m/z): 387.2 (M+H)*;
C23H19FN40 requir . 386.4. 'H-NMR (DMSO-d6) : d 9.12 (bs, IH, OH), 8.54, 7.26 (2m, each 2H, Pyrid.), 8.38 (s, IH, H-6, Pyrim.), 7.52 (t, IH, NH) , 7.20-7.10 ( , 4H, PhF), 7.05, 6.69 (2d, each 2H, PhOH) , 3.52 (q, 2H, CH2N) , 2.78 (t, 2H, CH,)-.
Figure imgf000117_0001
2-12 2- (2- (4-Aminophenyl) -ethylamino) -5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine: A solution of 2-chloro-5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine (71 mg, 0.25 mmol) and 2- (4-aminophenyl) ethylamine (0.5 ml, 3.80 mmol) in ethanol (1.5 ml) was heated to reflux for 20 min. Evaporation and subsequent chromatography on a column of silica gel (2% methanol/dichloromethane) provided the title compound as a yellow syrup. MS (m/z): 386.4 (M+H)*; C23H20FN5 requir . 385.5. 'H-NMR (CDC13) : d 8.56, 7.32 (2m, each 2H, Pyrid.), 8.35 (s, IH, H-6, Pyrim.), 7.12-6.99 (m, 6H, PhF, PhNH2) , 6.68 (d, 2H, PhNH2) , 5.37 (t, IH, NH) , 3.75 (q, 2H, CH2N) , 2.88 (t, 2H, CH2) .
Figure imgf000117_0002
2-13 5- (4-Fluorophenyl) -2- (2- (2 -fluorophenyl) - ethylamino) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 389.2 (M+H)*; C23H18F2N4 requir . 388.4. "H-NMR (CDC13) : 8.57 (m,
2H, Pyrid.), 8.35 (s, IH, H-6, Pyrim.), 7.34-7.20, 7.14- 7.00 (2m, 10H, 2PhF, Pyrid.), 5.42 (bt, IH, NH) , 3.82 (q, 2H, CH2N) , 3.05 (t, 2H, CH2) .
Figure imgf000117_0003
2-14 2- (2- (2 -Chlorophenyl) -ethylamino) ) -5- (4- f luorophenyl) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 405.0 (M+H)*; C23H18C1FN4 requir. 404.9. 'H-NMR (CDC13) : d 8.57 (m, 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.40-7.00 (m, 10H, PhF, PhCl2, Pyrid.) , 5.44 (bt, IH, NH) , 3.84 (q, 2H, CH2N) , 3.15 (t, 2H, CH2) .
Figure imgf000118_0001
2-15 5- (4-Fluorophenyl) -2- (2- (2-methoxyphenyl) - ethylamino) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 401.2
(M+H)*; C24H21FN40 requir . 400.5 'H-NMR (CDC13) : d 8.56, 7.30 (2m, each 2H, Pyrid.) , 8.34 (s, IH, H-6, Pyrim.) , 7.24, 7.08, 7.02, 6.92 (4m, each 2H, PhF, PhOMe) , 5.50
(bt, IH, NH) , 3.87 (s, 3H, CH3) , 3.78 (q, 2H, CH2N) , 3.02
(t, 2H, CH2) .
Figure imgf000118_0002
2-16 2- (2- (2,4-Dichlorophenyl) -ethylamino) -5- (4- f luorophenyl) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 439.0
(M)*; C23H17C12FN4 requir. 439.3. XH-NMR (CDC13) : 8.56 (bs, 2H, Pyrid.) , 8.34 (s, IH, H-6, Pyrim.), 7.37 (s, IH, PhCl) , 7.30 (bd, 2H, Pyrid.) , 7.22-7.15 (m, 2H, PhCl) , 7.08, 7.05 (2m, each 2H, PhF) , 5.40 (t, IH, NH) , 3.80
(q, 2H, CH2N) , 3.10 (t, 2H, CH2) .
Figure imgf000118_0003
2-17 2- (2- (2 , 6 -Dichlorophenyl) -ethylamino) -5- (4- f luorophenyl) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 439.0
(M)*; C23H17C12FN4 requir. 439.3. "H-NMR (CDC13) : 8.57 (m, 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.35 (d, 2H, PhCl) , 7.11 (m, 3H, PhF, PhCl) , 7.03 (m, 2H, PhF) , 5.45
(t, IH, NH) , 3.86 (q, 2H, CH2N) , 3.38 (t, 2H, CH2) .
Figure imgf000119_0001
2-18 5- (4 -Fluorophenyl) -2- (2- (3-methoxyphenyl) - ethylamino) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 401.2 (M+H)*; C24H21FN40 requir. 400.5.1H-NMR (CDC13) : d 8.56 (m, 2H, Pyrid.) , 8.34 (s, IH, H-6, Pyrim.) , 7.32-7.22, 7.11- 6.98, 6.89-6.77 (3m, 10H, PhF, PhOMe, Pyrid.) , 5.38 (t, IH, NH) , 3.82 (m, 5H, CH2N, CH3) , 2.96 (t, 2H, CH2) .
Figure imgf000119_0002
OMe
2-19 2- (2- (3 -Chlorophenyl) -ethylamino) ) -5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 405.4 (M+H)*; C23H18C1FN4 requir. 404.9. 'H-NMR (CDC13) : d 8.60 (d, 2H, Pyrid.) , 8.38 (s, IH, H-6, Pyrim.) , 7.32-7.24 (m, 5H, Pyrid., PhCl) , 7.18 (m, IH, PhCl) , 7.11, 7.04 (2m, each 2H, PhF) , 5.35 (t, IH, NH) , 3.83 (q, 2H, CH2N) , 3.00 (t, 2H, CH2) .
Figure imgf000119_0003
2-20 5- (4-Fluorophenyl) -2- ( (2-hvdroxy-2-phenyl) - ethylamino) -4- (4-pyridyl) -pyrimidine: A mixture of 2- chloro-5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine (87 mg, 0.31 mmol) and 2-amino-1-phenylethanol (300 mg, 2.19 mmol) in ethanol (2 ml) was heated to reflux for 2 h. Evaporation and subsequent chromatography on a column of silica gel (4% methanol/dichloromethane) provided the title compound as as yellow foam. MS (m/z): 387.0 (M+H)*; C23H19FN40 requir . 386.4. i-NMR (CDC13) : d 8.58 (d, 2H, Pyrid.), 8.38 (s, IH, H-6, Pyrim.), 7.47 (d, 2H, Ph) , 7.41 (t, 2H, Ph) , 7.34 (t, IH, Ph) , 7.28 (d, 2H, Pyrid.) ," 7.10, 7.02 (2m, 2H, PhF) , 5.72 (t, IH, NH) , 5.06 (m CHOH) ) , 4.02-3.92 (m, 2H, OH, 1CH2) , 3.72 (ddd, IH, 1CH.) .
Figure imgf000120_0001
2-21 5- (4 -Fluorophenyl) -2- (methyl- (2 -phenyl ethyl) - amino) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 385.0 (M+H)*; C24H21FN4 requir . 384.5. 'H-NMR (CDC13) : d 8.57, 7.35 (2m, each 2H, Pyrid.) , 8.40 (s, IH, H-6, Pyrim.) , 7.34-7.21 (m, 5H, Ph) , 7.10, 7.03 (2m, each 2H, PhF) , 3.96 (t, 2H, CH2N) , 3.23 (s, 3H, CH3) , 3.00 (t, 2H, CH2) .
2-22 5- (4 -Fluorophenyl) -2- ( ( 3 -phenylpropyl ) -amino) -4- (4- pyridyl) -pyrimidine: MS (m/z) : 385.2 (M+H)*; C24H21FN4 requir. 384.5. lH-NMR (CDC13) : d 8.56 (m, 2H, Pyrid.) , 8.34 (s, IH, H-6, Pyrim.) , 7.34-7.20 (m, 7H, Ph, Pyrid.) , 7.08, 7.01 (2m, each 2H, PhF) , 5.38 (t, IH, NH) , 3.58 (q, 2H, CH2N) , 2.78 (t, 2H, CH2) , 2.03 (m, 2H, CH .
Figure imgf000120_0003
2-23 5- (4 -Fluorophenyl) -2- ( (1 -methyl -3 -phenylpropyl) - amino) -4- (4-pyridyl) -pyrimidine: MS (m/z) : 399.0 (M+H)*; C25H23FN4 requir . 398.5. 'H-NMR (CDC13) : d 8.56 (m, 2H, Pyrid.) , 8.32 (s, IH, H-6, Pyrim.) , 7.32-7.17 (m, 7H, Pyrid., Ph) , 7.09-7.02 (2m, each 2H, PhF) , 5.16 (d, IH, NH) , 4.28 (m, IH, CH) , 2.77 (m, 2H, CH2) , 1.94 (m, 2H, CH2) , 1.34 (d, 3H, CH3) .
Figure imgf000121_0001
2-24 5- (4 -Fluorophenyl) -2- ( (3-imidazolylpropyl) -amino) - 4- (4 -pyridyl) -pyrimidine: MS (m/z) : 375.0 (M+H)*; C2 ^JFNJ requir . 374.4. 'H-NMR (CDC13) : d 8.57, 7.26 (2m, each 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.56 (s, IH, Imid.) , 7.16-6.96 (m, 6H, PhF, Imid. ) , 5.38 (bt, IH, NH) , 4.12 (t, 2H, CH2N) , 3.56 (q, 2H, CH2NH) , 2.20 (m, 2H, CH2) .
Figure imgf000121_0002
2-25 5- (4 -Fluorophenyl) -2- ( (4 -phenyl -n-butyl) -amino) -4- ( 4 -pyridyl ) -pyrimidine : MS (m/z) : 399.0 (M+H)*; C25H23FN4 requir. 398.5. 'H-NMR (CDC13) : d 8.56 (m, 2H, Pyrid.) , 8.34 (s, IH, H-6, Pyrim.) , 7.33-7.17 (m, 7H, Ph, Pyrid.) , 7.08, 7.02 (2m, each 2H, PhF) , 5.33 (bt, IH, NH) , 3.56 (q, 2H, CH2N) , 2.71 (t, 2H, CH2) , 1.76 (m, 4H, 2CH2) .
Figure imgf000121_0003
2-26 5- (4-Fluorophenyl) -2- (1-piperazinyl) -4- (4-pyridyl) - pyrimidine : A mixture of 2-chloro-5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine (71 mg, 0.25 mmol) and piperazine (214 mg, 2.48 mmol) in ethanol (1 ml) was heated to reflux for 5 min. Evaporation and subsequent chromatography on a column of silica gel (5% methanol/dichloromethane) provided the title compound as as yellow solid. MS (m/z): 336.2 (M+H)*; C19H18FN5 requir . 335.4. 'H-NMR (CDC13) : d 8.54, 7.29 (2m, each 2H, Pyrid.), 8.37 (s, IH, H-6, Pyrim.), 7.08, 7.00 (2m, each 2H, PhF), 3.95 (t, 4H, 2CH2) , 3.01 (t, 4H, 2CH2) .
Figure imgf000122_0001
2-27 5- (4 -Fluorophenyl) -2- ( 1-piperidinyl) -4- (4-pyridyl) pyrimidine: MS (m/z) : 335.2 (M+H)*; C20H19FN4 requir . 334.4. 'H-NMR (CDC13) : d 8.55, 7.30 (2m, each 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.08, 7.01 (2m, 2H, PhF) , 3.91 (t, 4H, 2CH2N) , 1.74, 1.68 (2m, 6H, 3CH2) .
Figure imgf000122_0002
2-28 5- (4 -Fluorophenyl) -2- (4 -me thyl -1-piperazinyl) -4- (4- pyr idyl ) -pyrimidine : MS (m/z) : 350.0 (M+H)*; C20H20FN5 requir. 349.4. 'H-NMR (CDC13) : d 8.58, 7.32 (2m, each 2H, Pyrid.) , 8.40 (s, IH, H-6, Pyrim.) , 7.10, 7.04 (2m, each 2H, PhF) , 4.00 (t, 4H, 2CH2) , 2.57 (t, 4H, 2CH2) , 2.42 (s, 3H, CH3) .
/ \
Rl - H3C— N N—
\ /
2-29 5- (4 -Fluorophenyl) -2- (4 -phenyl -1 -piperazinyl) -4- (4- pyridyl ) -pyrimidine : MS (m/z) : 412.2 (M+H)*; C25H22FN5 requir. 411.5. "H-NMR (CDC13) : d 8.58 (bd, 2H, Pyrid.) , 8.42 (s, IH, H-6, Pyrim.) , 7.38-7.30 (m, 4H, Pyrid., Ph) , 7.15-7.00 (m, 6H, PhF, Ph) , 6.94 (t, IH, Ph) , 4.13 (t, 4H, 2CH2) , 3.33 (t, 4H, 2CH2) .
Figure imgf000122_0003
2-30 5- (4 -Fluorophenyl) -2- (2-morpholinoethylamino) -4- (4- pyridyl ) -pyrimidine : MS (m/z) : 380.4 (M+H)*; C21H22FN50 requir. 379.4. 'H-NMR (CDC13) : d 8.58, 7.30 (2m, each 2H, Pyrid.) , 8.38 (s, IH, H-6, Pyrim.) , 7.10, 7.03 (2m, each 2H, PhF) , 5.91 (bs, IH, NH) , 3.79 (bs, 4H, 2CH2) , 3.66 (bs, 2H, CH2) , 2.71 (bs, 2H, CH2) , 2.59 (bs, 4H, 2CH2) .
Figure imgf000123_0001
2-31 5- (4 -Fluorophenyl) -2- (2-piperidinoethylamino) -4- (4- pyridyl) -pyrimidine: MS (m/z) : 378.2 (M+H)*; C22H24FN5 requir. 377.5 "H-NMR (CDC13) : d 8.54, 7.27 (2d, each 2H, Pyrid.) , 8.34 (s, IH, H-6, Pyrim.) , 7.06, 7.00 (2m, each 2H, PhF) , 6.04 (bt, IH, NH) , 3.66 (q, 2H, CH2NH) , 2.74 (t, 2H, CH2) , 2.61 (bs, 4H, 2CH2) , 1.68 (m, 4H, 2CH2) , 1.50 (m, 2H, CH2) .
Figure imgf000123_0002
2-32 5- (4 -Fluorophenyl) -4- (4-pyridyl) -2- (2- pyrrolidinoethylamino) -pyrimidine : MS (m/z) : 364.0 (M+H)*; C21H22FN5 requir . 363.4 'H-NMR (CDCl,) : d 8.55, 7.2c (2m, each 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.08, 7.02 (2m, each 2H, PhF) , 6.28 (t, IH, NH) , 3.86 (q, 2H, CH2NH) , 3.18 (t, 2H, CH2N) , 3.10 (bs, 4H, 2CH2N) , 2.02 (bs, 4H, 2CH2) .
Figure imgf000123_0003
2-33 5- (4 -Fluorophenyl) -2- (3-morpholinopropylamino) -4- ( 4 -pyridyl ) -pyrimidine : MS (m/z) : 394.2 (M+H)*; C22H24FN50 requir. 393.5. 'H-NMR (CDC13) : d 8.54, 7.27 (2m, each 2H, Pyrid.), 8.33 (s, IH, H-6, Pyrim.), 7.06, 7.00 (2m, each 2H, PhF), 6.00 (t, IH, NH) , 3.76 (t, 4H, 2CH20) , 3.60 (q, 2H, CH2NH) , 2.52 (t, 2H, CH2N) , 2.50 (m, 4H, CH2N) , 1.86 (m, 2H, CH2) .
Figure imgf000123_0004
2-34 5- (4 -Fluorophenyl) -2- (3- (2-pyrrolidinon-l-yl) - propylamino) -4- (4-pyridyl) -pyrimidine: S (m/z) : 392.2 (M+H)*; C22H22FN50 requir . 391.5. 'H-NMR
(CDC13) : d 8.58, 7.30 (m, 2H, Pyrid.) , 8.36 (s, IH, H-6, Pyrim.) , 7.10, 7.04 (m, 2H, PhF) , 5.88 (t, IH, NH) , 3.56
(q, 2H, CH2NH) , 3.48, 3.45 (2t, each 2H, 2CH2) , 2.46 (t, 2H, CH2) , 2.08 (m, 2H, CH , 1.90 (m, 2H, CH,) .
Figure imgf000124_0001
2-35 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine hydrochloride:
MS (m/z): 400.1 (M+H)+; C24H22FN5 requir. 399.5 (free base) .
Figure imgf000124_0002
2-36 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine hydrochloride : 2-Chloro-4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine and (S) -1 , 2- benzylethylendiamine were reacted according to the General Procedure, Step C (70°C for 75 min) to give the title compound. MS (m/z): 450.4 (M+H)+; C25H22F3N5 requir. 4449.5 (free base).
Figure imgf000124_0003
2-37 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) - 5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine hydrochloride: 2-Chloro-5- (3-methylphenyl) -4- (4-pyridyl) -pyrimidine and (S) -1, 2-benzylethylendiamine were reacted according to the General Procedure, Step C (100°C for 20 min) to give the title compound. MS (m/z): 396.2 (M+H)+; C25H25N5 requir. 395.5 (free base).
Figure imgf000124_0004
2-38 2- ( ( (S) -2-N, N-Dimethylamino-3-phenylpropyl) -amino) - 5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine: 2-Chloro-5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine and ( S) -2-N, N- dimethylamino-3-phenylpropylamine were reacted according to the General Procedure, Step C (100°C for 45 min) to give the title compound. MS (m/z): 427.8 (M+H) + ; C26H26FΝ5 requir. 427.5.
Figure imgf000125_0001
2-39 2- ( ( (S) -2 -N, N-Dimethylamino-3-phenylpropyl) -amino) - 5- (3-methylphenyl) -4- (4-pyridyl) -pyrimidine: 2-Chloro-5- (3-methylphenyl) -4- (4-pyridyl) -pyrimidine and (S) -2-N, N- dimethylamino-3-phenylpropylamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 424.2 (M+H)+; C27H29FΝ5 requir . 423.6.
Figure imgf000125_0002
2-40 2-( ( 3-Amino-3-phenylpropyl) -amino) - 5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine hydrochloride: 2- Chloro-5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine and 1-phenyl-l, 3-propanediamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 4001. (M+H) + ; C24H22FN5 requir. 399.5 (free base).
2-41 2- ( (3-Amino-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine hydrochloride: 2- Chloro-4- (4-pyridyl) -5- (3-trifluoromethylphenyl) - pyrimidine and 1-phenyl-l, 3-propanediamine were reacted according to the General Procedure, Step C (100°C for 1 h) to give the title compound . MS (m/ z ) : 450 . 3 (M+H) + ; C25H22F3N5 requir . 449 . 5 ( free base ) .
Figure imgf000126_0001
2-42 2- ( (3 -Amino-3- (2-fluorophenyl) propyl) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine hydrochloride : 2-Chloro-4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine and l-(2- fluorophenyl) -1, 3-propanediamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 468.4 (M+H)+; C25H21F4N5 requir. 467.5 (free base).
Figure imgf000126_0002
2-43 2- ( (3-Amino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine hydrochloride: 2 -Chloro-5- (3 -methylphenyl) -4- (4-pyridyl) -pyrimidine and 1-phenyl-l, 3-propanediamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 396.1 (M+H) + ; C25H25N5 requir. 395.5 (free base).
Figure imgf000126_0003
2-44 2- ( (2-Amino-2-methyl-3-phenylpropyl) -amino) - 5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine hydrochloride: 2- Chloro-5- (3 -methylphenyl) -4- (4-pyridyl) -pyrimidine and 2-amino-2-methyl-3-phenylpropylamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 410.2 (M+H) + ; C,fiH27N5 requir. 409.5 (free base).
Figure imgf000127_0001
2-45 2- ( (3 -Hydroxy-3 -phenylpropyl) -amino) 5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine: 2-Chloro-5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine and 3-hydroxy-3- phenylpropylamine were reacted according to the General
Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 397.2 (M+H) + ; C25H24N40 requir. 396.5.
Figure imgf000127_0002
2-46 2- ( ( (2R, 3R) -3-Amino-2-methyl-3-phenylpropyl) - amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) - pyrimidine hydrochloride: 2-Chloro-4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine and (1R, 2R) -2-methyl- l-phenyl-l, 3-propanediamine were reacted according to the General Procedure, Step C (50°C for 1 h) to give the title compound. MS (m/z): 464.4 (M+H)+; C26H24F3N5 requir. 463.5 (free base). H2
Figure imgf000127_0003
2-47 2- ( ( (2S.3S) -3-Amino-2-methyl-3-phenylpropyl) - amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) - pyrimidine hydrochloride: 2-Chloro-4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine and (IS, 2S) -2-methyl- l-phenyl-l, 3-propanediamine were reacted according to the General Procedure, Step C (90°C for 45 min) to give the title compound. MS (m/z): 464.1 (M+H)+; C26H24F3N5 requir. 463.5 (free base).
Figure imgf000128_0001
2-48 2- ( (S) -3-Benzylpjperazinyl) - 4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine hydrochloride: 2- Chloro-4- (4-pyridyl) -5- (3-trifluoromethylphenyl) - pyrimidine and (S) -2-benzylpiperazine were reacted according to the General Procedure, Step C (70°C for 30 min) to give the title compound. MS (m/z): 475.5 (M+H)+; C27H24F3N5 requir. 476.1 (free base).
Rl =
2-49 C4- (4-CPyriCdyl) -2- ( ( (S) -tetrahydroisoquinol-3- ylmethylen) amino) -5- (3-trifluoromethylphenyl) -pyrimidine hydrochloride: 2-Chloro-4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine and (S)- tetrahydroisoquinol-3-ylmethylenamine were reacted according to the General Procedure, Step C (50°C for 1.5 h) to give the title compound. MS (m/z): 462.4 (M+H)+; C26H22F3 5 requir. 461.5 (free base).
Figure imgf000128_0002
2-50 5- (3-Methylphenyl) -4- (4-pyridyl) -2- ( ( (S) - tetrahydroisoσuinol-3-ylmethylen) amino) -pyrimidine hydrochloride : 2-Chloro-5- (3-methylphenyl) -4- (4- pyridyl) -pyrimidine and (S) -tetrahydroisoquinol-3- ylmethylenamine were reacted according to the General Procedure, Step C (100°C for 45 min) to give the title compound. MS (m/z): 408.2 (M+H)+; C26H25N5 requir. 407.5 (free base) .
Figure imgf000128_0003
Example 3
General procedure for the preparation of 2-acylamino-S- (4- luorophenyl ) -4- (4-pyridyl ) -pyrimidines
Figure imgf000129_0001
R = R21, OR20 or NR5R21 The chlorocarbonyl R-C(0)C1 (0.57 mmol) was added dropwise to a solution of 2-amino-5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine (0.38 mmol) in pyridine (3 ml) at ice-bath temperature. It was stirred for 3 h at room temperature, monitored by thin layer chromatography, poured into ice-water, extracted with dichloromethane, dried and evaporated. The crude product can be purified by silica gel column chromatography (hexane-acetone) and recrystallized from a suitable solvent such as ethyl acetate.
The following compounds were prepared using the appropriate acid chloride according to this procedure: 3-1 2-Acetamido-5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine: MS (m/z): 309.0 (M+H)*; C17H13FN40 requir .
308.3. XH-NMR (CDC1,) : d 8.63 (s, IH, H-6, Pyrim.), 8.60, 7.29 (2m, each 2H, Pyrid.), 8.26 (bs, IH, NH) , 7.14, 7.08 (2m, each 2H, PhF), 2.58 (s, 3H, CH3C0) . R = CH3-
3-2 2-Butyramido-5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine: MS (m/z): 337.2 (M+H)*; C19Hl7FN40 requir .
336.4. "H-NMR (CDCl,) : d 8.64, (s, IH, H-6, Pyrim.), 8.60, 7.31 (2m, each 2H, Pyrid.), 8.17 (bs, IH, NH) , 7.14, 7.08 (2m, each 2H, PhF), 2.80 (t, 2H, CH2C0) , 1.82 (m, 2H, CH.) , 1.06 (t, 3H, CH.) . R = CH.CE CH,
3-3 5- (4 -Fluorophenyl) -2-pivalamido-4- (4-pyridyl) - pyrimidine: MS (m/z) : 351.0 (M+H)*; C20H19FN4O requir . 350.4. 'H-NMR (CDClj) : d 8.69 (s, IH, H-6, Pyrim.) ,
8.60, 7.35 (2m, each 2H, Pyrid.) , 8.25 (bs, IH, NH) , 7.15, 7.08 (2m, each 2H, PhF) , 1.4 (s, 9H, 3CH3) .
R = (CH3)3C-
3-4 2-Benzamido-5- (4-f luorophenyl) -4- (4-pyridyl) - pyrimidine: MS (m/z) : 371.0 (M+H)*; C22H15FN40 requir . 370.4. "H-NMR (CDCI3) : d 8.75 (s, 2H, NH, H-6, Pyrim.)
8.61, 7.36 (2m, each 2H, Pyrid.) , 8.00, 7.63, 7.55 (d, t, t, 2H, IH, 2H, Ph) , 7.18, 7.10 (2m, each 2H, PhF) .
Figure imgf000130_0001
3-5 5- (4 -Fluorophenyl) -2-phenylacetamido-4- (4-pyridyl pyrimidine: MS (m/z) : 385.0 (M+H)*; C23H17FN40 requir . 384.4. 'H-NMR (CDCI3) : d 8.66 (s, IH, H-6, Pyrim.) , 8.59, 7.28 (2m, each 2H, Pyrid.) , 8.21 (bs, IH, NH) , 7.43-7.30 (m, 5H, Ph) , 7.14, 7.08 (2m, each 2H, PhF) , 4.13 (s, 2H, CH2) .
Figure imgf000130_0002
3-6 5- (4 -Fluorophenyl) -2-hvdrocinnamamido-4- (4- pyridyl ) -pyrimidine : MS (m/z) : 399.2 (M+H)*; C24H19FN40 requir. 398.4. "H-NMR (CDC13) : d 8.60 (s, IH, H-6, Pyrim.) , 8.54 (m, 2H, Pyrid.), 8.20 (bs, IH, NH) , 7.31- 7.16 (m, 7H, Ph, Pyrid.) , 7.11, 7.05 (2m, each 2H, PhF) , 3.20, 3.09 (2t, each 2H, 2CH2) .
Figure imgf000130_0003
Example 4
General procedure for the preparation of -substituted 5- (4 -f luorophenyl ) -6- (4 -pyridyl ) -4 (3H) -pyrimidones
Figure imgf000131_0001
a. 2- (4-Fluorophenyl) -3- (4-pyridyl) -acrylic acid: A mixture of 4-fluorophenylacetic acid (9 g, 58.4 mmol), 4-pyridinecarboxaldehyde (5.6 ml, 58.6 mmol), pyridine (6 ml) and acetic anhydride (6 ml) was heated at 150°C for 1 h followed by evaporation and co-distillation with water. The resulting material crystallized on addition of ethanol. The solids were filtered and washed with ethanol and ethyl acetate to provide the title compound. MS (m/z): 244.0 (M+H)*; C14H10FNO2 requir . 243.2 "H-NMR (DMSO-d6) : d 8.43, 6.98 (2d, each 2H, Pyrid.), 7.73 (s, IH, CH=) , 7.21 (d, 4H, PhF). b. Ethyl 2- (4-fluorophenyl) -3- (4-pyridyl) -acrylate: Cone, sulfuric acid (2.2 ml) was added carefully to a suspension of 2- (4-fluorophenyl) -3- (4-pyridyl) -acrylic acid (6.7 g, 27.5 mmol) in ethanol (120 ml) and the mixture was heated at reflux for 24 h. The solvent was evaporated, the remainder was taken up in dichloromethane and the organic solution was washed with aqueous sodium hydrogencarbonate and water, followed by drying and evaporation. Flash column chromatography on silica gel (hexane-acetone = 2:1) provided the pure title compound. MS (m/z) : 271.8 (M+H)*; Cl6H14FN02 requir . 271.3 'H-NMR (CDClj) : 8.44, 6.88 (2m, each 2H, Pyrid.) , 7.72 (s, IH, CH=) , 7.16, 7.06 (2m, each 2H, PhF) , 4.28 (q, 2H, CH2) , 1.28 (t, 3H, CH3) . c. General procedure: A stirred mixture of ethyl 2- (4- fluorophenyl) -3- (4-pyridyl) -acrylate (357 mg, 1.38 mmol), the amidine hydrochloride (2.61 mmol) and sodium methoxide (250 mg, 4.62 mmol) in ethanol (5 ml) was heated in a sealed tube at 120°C for 3 h. It was neutralized with 2N hydrochloric acid prior to evaporation. The residue was taken up in acetic acid (25 ml) and treated with sodium nitrite (670 mg, 9.71 mmol) at 44° C for 20 min. After evaporation, the resultant product was taken up in dichloromethane and the solution was washed with aqueous sodium hydrogencarbonate and water before drying and evaporation. The product was purified by recrystallization from methanol . If the crude product of nitrite oxidation was water soluble, as was found for 5- (4-fluorophenyl) -2-methyl-6- (4-pyridyl) -4 (3H) - pyrimidinone, then no aqueous work up was done, but the material obtained on evaporation was applied to a column of silica gel (5% methanol/dichloromethane) prior to recrystallization.
The following compounds were prepared accordingly using the appropriate amidine hydrochloride:
4-1 5- (4-Fluorophenyl) -2-methyl-6- (4-pyridyl) -4 (3H) - pyrimidinone: MS (m/z): 282.2 (M+H)*; C16H12FN30 requir . 281.3 "H-NMR (DMSO-d6) : d 8.46 (m 2H, Pyrid.), 7.2-7.03 (m, 6H, PhF, Pyrid.). 2.38 (s, 3H, CH3) . Rl = CH3-
4-2 5- (4-Fluorophenyl) -2-isopropyl-6- (4-pyridyl) -4 (3H) - pyrimidinone: MS (m/z): 310.0 (M+H)*; C18H16FN30 requir . 309.4 'H-NMR (DMSO-d : 8.45 (m, 2H, Pyrid.), 7.21-7.03 (m, 6H, PhF, Pyrid.) , 2.90 (m, IH, CH(CH3)2,) 1.26, 1.24 (2s, each 3H, 2CH3) . Rl = (CH3)2CH-
4-3 2- (2 , 6-Dichlorobenzyl) -5- (4-f luorophenyl) -6- (4- pyridyl) -4 (3H) -pyrimidinone: MS (m/z) : 426.0 (M)*;
C22H14C12FN30 requir. 426.3 XH-NMR (DMSO-d6) : d 8.37 (m, 2H, Pyrid.) , 7.50 (d, 2H, PhCl.) , 7.35 (t, IH, PhCl.) , 7.18- 7.08 ( , 4H, PhF) , 6.96 (m, 2H, Pyrid.) , 4.36 (s, 2H, CH2) .
Figure imgf000133_0001
4-4 5- (4 -Fluorophenyl) -2-phenyl-6- (4-pyridyl) -4 (3H) - pyrimidinone : MS (m/z) : 344.2 (M+H)*; C21H14FN30 requir . 343.4 'H-NMR (DMSO-d6) : d 8.49 (d, 2H, Pyrid.) , 8,20 (d, 2H, Ph) , 7.66-7.50 (m, 3H, Pyrid., Ph) , 7.32-7.11 (m, 6H, PhF, Ph) .
Figure imgf000133_0002
4-5 5- (4-Fluorophenyl) -2- (4-phenylbutyl) -6- (4-pyridyl) - 4 (3H) -pyrimidinone: Ethyl 2- (4-fluorophenyl) -3-oxo-3- (4-pyridyl ) -propionate (293 mg, 1.02 mmol), 4- phenylbutanecarboxamidine (315 mg, 1.79 mmol) and pyridinium p-toluenesulfonate (10 mg) were suspended in p-xylene (10 ml) . With efficient stirring, the mixture was heated to reflux using a Dean-Stark apparatus with continuous removal of water. After 16 h, the solvent was evaporated and the product purified by column chromatography on silica gel (3% methanol/ dichloromethane) followed by recrystallization from acetone. MS (m/z): 400.3 (M+H) +; C25H22FN3O requir. 399.5 Rl = Ph(CH2)4- Example 5
General procedure for the preparation of 5- (4 - fluorophenyl ) -6- (4 -pyridyl ) -2- thioalkyl -4 (3H) pyrimidinones Step A. Ethyl 2- (4-fluorophenyl) -3-oxo-3- (4-pyridyl) propionate :
Figure imgf000134_0001
(According to: Legrand and ozac'h, Bull . Soc . Chim . Fr. , 79-81 (1955) ) . A mixture of ethyl 4-fluorophenylacetate (13 g, 71.35 mmol), ethyl isonicotinate (10.7 ml, 71.4 mmol) and sodium spheres (1.64 g, 71.34 mmol) was heated at 90-95_ C under argon. The mixture started to reflux and gradually turned into a solid. After 2.5 h, the mixture was neutralized with dil. acetic acid with cooling followed by extraction with dichloromethane. The organic solution was washed with water, dried and evaporated. Flash chromatography on a column of silica gel (hexane-acetone = 4:1, 3:1, 2:1) provided the title compound as an oil. MS (m/z) : 287.8 (M+H)*; C16H14FN03 requir. 287.3 XH-NMR (CDC13) , (ketone : enole = 1 : 0.33): d 13.50 (s, 0.3H, OH-E), 8.81 (m, 2H, Pyrid. -K), 8.48 (m, 0.66 H, Pyrid. -E), 7.72 (m, 2H, Pyrid. -K), 7.38 (m, 2H, PhF-K) , 7.14-7.04 (m, 2H, PhF-K; -0.65H, Pyrid. - E; -0.65H, PhF-E) , 6.96 (t, 0.64H, PhF-E) , 5.51 (s, IH, CH-K) , 4.23-4.2- (m, CH2-K,E), 1.26 (t, CH3-K,E). Step B. 5- (4-fluorophenyl) -6- (4-pyridyl) -2-thiouracil:
Figure imgf000134_0002
A stirred mixture of ethyl 2- (4-fluorophenyl) -3- oxo-3- (4-pyridyl) -propionate (22.3 g, 77.6 mmol) and thiourea (5.9 g, 77.6 mmol) was reacted at 190_ C under argon for 40 min. The reaction mixture was allowed to reach room temperature, taken up in acetone and the precipitate was filtered to provide the title compound. MS (m/z) : 300.2 (M+H)*; C15H10FN3OS requir . 299.3 'H-NMR (DMSO-d6) : d 12.74, 12.65 (2s, 2H) , 8.51 (m, 2H, Pyrid.), 7.26 (m, 2H, Pyrid.), 7.09 and 7.03 (2m, each 2H, PhF) .
Alternatively, ethyl 2- (4-fluorophenyl) -3-oxo-3- (4- pyridyl) -propionate (2.87 g, 10 mmol) and thiourea (2.28 g, 30 mmol) were suspended in anhydrous p-xylene (50 ml) with very efficient stirring. To the mixture pyridinium p-toluenesulfonate (100 mg) was added and refluxed for 12-16 h using a Dean-Stark apparatus with continuous removal of water (0.2 ml). Reaction mixture was cooled and a dark brown solid was filtered using a Buchner funnel. The collected solid was suspended in acetone (25 ml) and filtered. The acetone washed product contained a trace of thiourea, which was removed by trituration with hot water (20-30 ml) . The product was filtered and airdried.
Step C. General procedure: The arylalkyl bromide (0.36 mmol) was added dropwise to a stirring mixture of 5- (4-fluorophenyl) -6- (4-pyridyl) -2-thiouracil (100 mg, 0.33 mmol) and potassium carbonate (46 mg, 0.33 mmol) in N, N- dimethylformamide (4.6 ml). Stirring was continued for 3h followed by evaporation. Flash chromatography on a column of silica gel (hexane-acetone = 3:1, 2:1, 1:1) and recrystallization from hot methanol provided the target compound.
The following compounds were obtained using the appropriate arylalkyl bromide according to the above procedure : 5-1 5- (4 -Fluorophenyl) -2- (2-phenylethyl) thio-6- (4- pyridyl) -A (3H) -pyrimidinone: MS (m/z) : 404.2 (M+H)*; C23H18FN3OS requir . 403.4. Tl-NMR (DMSO-d6) : d 13.08 (bs, 0.7H) , 8.49 (m, 2H, Pyrid.) , 7.30-7.06 (m, 11H, Pyrid., Ph, PhF) , 3.41 (dd, 2H, CH2S) , 3.00 (t, 2H, CH2) .
Figure imgf000136_0001
5-2 5- (4 -Fluorophenyl) -2- ( 3 -phenylpropyl ) thio-6- (4- pyridyl) -4 (3H) -pyrimidinone: MS (m/z) : 418.0 (M+H)*; C24H20FN3OS requir . 417.5. 'H-NMR (DMSO-d6) : d 13.10 (bs, 0.7H) , 8.47 (m, 2H, Pyrid.) , 7.29-7.06 (m, 11H, Pyrid., Ph, PhF) , 3.18 (t, 2H, CH2S) , 2.71 (t, 2H, CH2Ph) , 2.03 (m, 2H, CH2) .
Figure imgf000136_0002
5-3 5- (4 -Fluorophenyl) -2- (2-phenoxyethyl) thio-6- (4- pyridyl) -4 (3H) -pyrimidinone: MS (m/z) : 420.0 (M+H)*; C23Hl8FN302S requir . 419.5. *H-NMR (DMSO-d6) : d 13.20 (bs, 0.7H) , 8.46 ( , 2H, Pyrid.) , 7.24-7.07 (m, 8H, Pyrid., PhF, Ph) , 6.95 (d, 2H, Ph) , 6.92 (t, overlapped, IH,
Ph) , 4.30 (t, 2H, CH20) , 3.5! (t, 2H, CH,S)
Figure imgf000136_0003
5-4 5- (4 -Fluorophenyl) -2- (2-phenylaminoethyl) thio-6- (4- pyridyl ) -4 ( 3H) -pyrimidinone : MS (m/z) : 419.0 (M+H)*; C23H19FN40S requir . 418.5. *H-NMR (DMSO-d6) : d 13.20 (bs, 0.8H) , 8.48, 7.22 (2m, each 2H, Pyrid.) , 7.16, 7.10 (2m, each 2H, PhF) , 6.89 (t, 2H, Ph) , 6.54 (d, 2H, Ph) , 6.48 (t, IH, Ph) , 5.90 (bs, 0.6H, NH) , 3.43-3.25 (m, 2CH2) .
Figure imgf000136_0004
Example 6
General -procedure for the preparation of 2-N substi tuted 2-amino-5- (4 - fluorophenyl ) -6- (4 -pyridyl ) -4 (3H) - pyr imidinones :
Step A. 5- (4-Fluorophenyl) -2-methylthio-6- (4-pyridyl) - 4 ( 3H) -pyrimidinone:
Figure imgf000137_0001
Methyl iodide (90 ml, 1.44 mmol) was added dropwise to a stirred mixture of 5- (4-fluorophenyl) -6- (4- pyridyl) -2-thiouracil (430 mg, 1.44 mmol) and potassium carbonate (198 mg, 1.43 mmol) in N, N-dimethylformamide (13 ml) at ice-bath temperature. After 40 min, it was evaporated and the crude product purified by flash chromatography on a column of silica gel (hexane-acetone = 2:1, 1:1, 1:2) to provide the title compound as a solid. MS (m/z) : 314.2 (M+H)*; C16H12FΝ3OS requir . 313.3. 'H-NMR (DMSO-d6) : d 13.10 (bs) , 8.47, 7.22 (2m, each 2H, Pyrid.), 7.16, 7.10 (2m, each 2H, PhF), 2.56 (s, 3H, CH3) . Step B. General procedure:
Figure imgf000137_0002
A mixture of 5- (4-fluorophenyl) -2-methylthio-6- (4- pyridyl) -4 (3tf) -pyrimidinone (100 mg, 0.32 mmol) and an amine HNR5R21 (1 mmol) was heated at 180°C for 2 h. The resulting product was purified by flash chromatography on a column of silica gel (hexane-acetone or methanol- dichloromethane or dichloromethane-methanol-conc . ammonium" hydroxide) to provide the target compound.
The following compounds were prepared using the general procedure outlined above and an appropriate amine :
6-1 2 - ( 2 - ( 2 -Chlorophenyl ) ethyl -amino ) - 5 - ( 4 - f luorophenyl ) - 6 - ( 4 -pyridyl ) - 4 ( 3 H) -pyrimidinone : MS (m/z) : 421.2 (M+H)*; C23H18ClFN40 requir . 420.9. "H-NMR (DMSO-d6) : d 11.24 (bs) , 8.44, 7.16 (2m, each 2H, Pyrid.) , 7.43, 7.38 (2dd, each IH, PhCl) , 7.30, 7.26 (2dt, each IH, PhCl) , 7.10-7.00 (m, 2H, PhF) , 6.74 (bs, IH, NH) , 3.60 (q, 2H, CH2N) , 3.03 (t, 2H, CH2) .
Figure imgf000138_0001
6-2 5- (4 -Fluorophenyl) -2- ( ( 3 -phenylpropyl ) -amino) -6- (4- pyridyl ) -4 (3H) -pyrimidinone : MS (m/z) : 401.2 (M+H)*; C24H21FN40 requir . 400.5. XH-NMR (DMSO-d6) : d 11.16 (bs) , 8.44, 7.14 (2m, each 2H, Pyrid.) , 7.32-7.01 (m, 9H, Ph, PhF) , 6.78 (bs, NH) , 3.36 (q, 2H, CH2N) , 2.67 (t, 2H, Cff2Ph) , 1.89 (m, 2H, CH2) .
Figure imgf000138_0002
6-3 5- (4 -Fluorophenyl) -2- ( (1 -methyl -3 -phenylpropyl) - amino) -6- (4 -pyridyl) -4 (3H) -pyrimidinone: A reaction time of 15 h at 180_ C was required. MS ( /z) : 415.0 (M+H)*; C25H23FN40 requir . 414.5. XH-NMR (CDC13) : d 8.48 (m, 2H, Pyrid.), 7.28-7.08 (m, 9H, Pyrid., Ph, PhF) , 6.94 (m, 2H, PhF) , 5.67 (bs, IH, NH) , 4.08 (m, IH, CHCH3) , 2.61 (t, 2H, Cff2Ph) , 1.67 (m, 2H, CH2) , 1.08 (d, 3H, CH3) .
Figure imgf000139_0001
6-4 5- (4 -Fluorophenyl) -2- ( (3-imidazolylpropyl) -amino) - 6- (4-pyridyl) -4 (3ff) -pyrimidinone: MS (m/z) : 391.0 (M+H)*; C21H19FN60 requir . 390.4. 'H-NMR (DMSO-d6) : d 11.24 (bs) , 8.42, 7.12 (2m, each 2H, Pyrid.) , 7.62, 7.18 (2s, each IH, Imid.) , 7.08-6.99 (m, 4H, PhF) , 6.88 (s, IH, Imid.) , 4.02 (t, 2H, CH2N) , 3.28 (overlapped by water signal, CH2NH) , 2.00 (m, 2H, CH2) .
Figure imgf000139_0002
6-5 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (4- fluorophenyl) -6- (4-pyridyl) -4 (3H) -pyrimidinone hydrochloride : The reaction was done at 170°C for 7 h. MS (m/z): 416.1 (M+H) +; C26H22FN5O requir. 415.5.
Figure imgf000139_0003
Example 7
5- (4 -Fluorophenyl) -2-hydrazino-6- (4-pyridyl) -4 (3H) - pyrimidinone A mixture of 5- (4-fluorophenyl) -6- (4-pyridyl) -2- thiouracil (500 mg, 1.66 mmol) and hydrazine hydrate (800 ml, -14 mmol) was heated at 120°C for 60 min. It was evaporated and the reaction product was recrystallized from hot methanol to provide the title compound. MS (m/z): 298.0 (M+H)*; C15H12FN50 requir . 297.3. XH-NMR (DMS0-d6) : d 8.41, 7.12 (2m, each 2H, Pyrid.), 7.05, 7.00 (2m, each 2H, PhF).
R1 = NH-NH2 Example 8
General procedure for the preparation of 5-aryl -2, 6- dipyridyl - (3H) -pyrimidinones
Figure imgf000140_0001
These compounds were prepared according to the literature (Kabbe, supra; German Patent 1271116 (1968)) as follows:
A stirred mixture of the ethyl phenylacetate (3.13 mmol), cyanopyridine (6.24 mmol) and sodium methoxide (3.5 mmol) in n-butanol (1.2 ml) was heated at 110°C for 2h. The reaction mixture was concentrated and dissolved in water (4 ml) , followed by the addition of aqueous sat. ammonium chloride (2 ml) . The precipitate was filtered and recrystallized from hot methanol. The following compounds were prepared according to this procedure using the appropriate starting materials:
8-1 5-Phenyl-2, 6-bis- (4-pyridyl) -4- (3H) pyrimidinone : MS (m/z) : 327.2 (M+H)*; C20H14N4O requir . 326.4. 'H-NMR (DMSO- d6) : d 8.78, 8.47, 8.13 (3m, each 2H, Pyrid.), 7.40-7.14 (m, 7H, Ph, Pyrid. ) .
8-2 5- (4 -Fluorophenyl) -2, 6-bis- (4-pyridyl) -4 (3H) - pyrimidinone: MS (m/z) : 345.2 (M+H)*; C20H13FN4O requir . 344.4 'H-NMR (DMSO-d6) : d 8.80, 8.49, 8.13 (3m, each 2H, Pyrid.) , 7.40-7.08 (m, 6H, PhF, Pyrid.) .
8-3 2,5, 6 -Tris- (4-pyridyl) -4 (3H) -pyrimidinone was prepared according to the general procedure by reacting ethyl 4-pyridylacetate and 4-cyanopyridine in the presence of sodium methoxide. MS (m/z) : 328.2 (M+H)*; C19H13N50 requir . 327.4 'H-NMR (DMSO-d6) : 8.65, 8.45, 8.35, 8.18, 7.25, 7.13 (6m, each 2H, Pyrid.) .
8-4 5- (4 -Fluorophenyl) -2 , 6-bis- (3-pyridyl) -4 (3H) - pyrimidinone: MS (m/z) : 345.2 (M+H)*; C20H13FN4O requir . 344.4 'H-NMR (DMSO-d6) : d 9.34, 8.77, 8.54, 8.48, 7.78, 7.60, 7.34 (7m, 3xlH, 2H, 3xlH, Pyrid.), 7.26, 7.15 (2m, each 2H, PhF) .
Example 9
4-Amino-5- (4- fluorophenyl) -2, 6-bis- (4-pyridyl) - pyrimidine
Figure imgf000141_0001
4-Amino-5- (4-fluorophenyl) -2 , 6-bis- (4-pyridyl) - pyrimidine was prepared according to the literature (Kabbe, supra) :
Sodium methoxide (180 mg, 3.33 mmol) was added to a stirred solution of 4-cyanopyridine (650 mg, 6.24 mmol) and 4-fluorophenylacetonitrile (375 mml, 3.12 mmol) in n-butanol (1.5 ml). The mixture was stirred for 20 min at room temperature before heating it at 110°C for 1.5 h. It was allowed to reach room temperature and ethanol (2.5 ml) was added. The precipitate was filtered and recrystallized from acetic acid/water (3.5/10 ml) to provide the title compound. MS (m/z) : 344.2 (M+H)*; C20H14FN5 requir . 343.4 I-NMR (DMSO-d6) : 8.76, 8.47, 8.22 (3m, each 2H, Pyrid.), 7.4-7.16 (m, 6H, PhF, Pyrid.).
Example 10
4 -Me thoxy- 5 -phenyl -2 , 6-bis- (4 -pyridyl ) -pyrimidine
Figure imgf000142_0001
A mixture of 5-phenyl-2 , 6-bis- (4-pyridyl) -4 (3ff) - pyrimidinone (360 mg, 1.10 mmol) and phosphorus oxychloride (2 ml) was heated at reflux for 1.5 h.
Work-up was done as described for the preparation of 2- chloro-5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine. To a solution of the crude 4-chloro-5-phenyl-2 , 6-bis- (4- pyridyl) -pyrimidine (250 mg, 0.73 mmol) in methanol (5 ml) was added methanolic 0.5 N sodium methoxide (1.45 ml, 0.73 mmol) and it was heated at reflux for 1 h. After evaporation, the resultant material was partitioned between ethyl acetate and water. The organic solution was washed with water, dried and evaporated. Chromatography of the crude product on a column of silica gel (ethyl acetate) provided the title compound. MS (m/z) : 341.2 (M+H)*; C21H16N40 requir . 340.4 'H-NMR (CDC13) : 8.82, 8.54, 8.40 (3m, each 2H, Pyrid.), 7.40-7.18 (m, 7H, Ph, Pyrid.), 4.15 (s, 3H, CH30) . Example 11
Procedure for the preparation of 5- (4 -Fluorophenyl ) -2 , 4 - bis- (4 -pyridyl ) -pyrimidine Step A. 4-Chloro-5- (4-fluorophenyl) -2 , 6-bis- (4- pyridyl) -pyrimidine :
Figure imgf000143_0001
A mixture of 5- (4-fluorophenyl) -2 , 6-bis- (4- pyridyl) -4 ( 3H) -pyrimidinone (760 mg, 2.21 mmol) in phosphorus oxychloride (3 ml) was heated at reflux for 1 h. Work-up was done as described for the preparation of 2-chloro-5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine . A portion (290 mg) of the resulting product (495 mg) was purified by flash chromatography (ethyl acetate, trace triethylamine) on silica gel. MS (m/z) : 363.2 (M+H)*; C20H12C1FN4 requir. 362.8 'H-NMR (CDC13) : d 8.84, 8.60, 8.38, 7.30 (4m, each 2H, Pyrid.), 7.22, 7.13 (2m, each 2H, PhF) .
Step B. 5- (4-Fluorophenyl) -2 , 4-bis- (4-pyridyl) - pyrimidine:
Figure imgf000143_0002
A stirred mixture of 4-chloro-5- (4-fluorophenyl) - 2, 6-bis- (4-pyridyl) -pyrimidine (99 mg, 0.27 mmol) and 10% palladium-on-carbon (70 mg) in ethanol (10 ml) was hydrogenated under an atmosphere of hydrogen for 28 h. Filtration and evaporation of the solvent was followed by flash chromatography (ethyl acetate) on a column of silica gel to provide the title compound. MS (m/z) : 329.2 (M+H)*; C20H13FN4 requir . 328.4. Ti-NMR (CDC13) : d 8.91 (s, IH, H-6, Pyrim.) , 8.83, 8.65, 8.40, 7.45 (4m, each 2H, Pyrid.) , 7.30-7.06 (m, 4H, PhF) . Example 12
Procedure for the preparation of 2- ( ( (S) -2-N-
Glycylamino-3 -phenylpropyl ) -amino) -4- (4-pyridyl) -5- (3- trif luoromethylphenyl ) -pyrimidine hydrochloride
Figure imgf000144_0001
12-1 2- ( ( (S) -2-N-Glvcylamino-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine hydrochloride : Ethyl chloroformate (86 μl, 0.901 mmol) was added at ice-bath temperature to a stirring mixture of N- ( er . -butoxycarbonyl) glycine (160 mg, 0.911 mmol) and 4-methylmorpholine (110 μl, 1.00 mmol) in tetrahydrofuran (10 ml) . After 40 min, a solution 2- ( ( (S) -2-amino-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine (409 mg, 0.911 mmol) in tetrahydrofuran (15 ml) was added at ice-bath temperature. Within 1 h, the mixture was allowed to reach room temperature. It was diluted with dichloromethane, washed with aqueous sodium hydrogencarbonate, followed by drying of the organic solution and evaporation. The resulting material was purified on a column of silica gel (5% methanol/dichloromethane) , then dissolved in methanol (2 ml) and 4N hydrogen chloride/dioxane (2 ml) was added. After 1 h at room temperature, it was evaporated and the remainder taken up in dichloromethane followed by washing with aqueous sodium hydrogencarbonate, drying of the organic solution and evaporation. Column chromatography on silica gel (dichloromethane - methanol - cone, ammonium hydroxide = 95 : 5 : 0; 90 : 10 : 0.6) provided the title compound as the free base which was converted into the hydrochloride by the addition of 4N hydrogen chloride/dioxane (85 μl) to its methanolic solution (3 ml) followed by evaporation. MS (m/z) : 507.4 (M+H)*; C27H25F3N60 requir . 506.5 (free base).
The following compound was prepared using the above procedure and the appropriate starting materials :
12 -2 2 - ( ( ( S) -2 -N-Glvcylamino-3 -phenylpropyl ) -amino) -5- ( 3 -methylphenyl ) -4- ( 4-pyridyl ) -pyrimidine hydrochloride : MS ( /z) : 453 . 2 (M+H) * ; C27H28Ν60 requir . 452 . 6 ( free base) .
Example 13 Procedure for the preparation of (S) -l , 2-
Benzyl e thyl endi amine
Figure imgf000145_0001
(S) -1, 2-Benzylethylendiamine: The diamine was prepared according to the literature (H. Brunner, P. Hankofer, U. Holzinger, B. Treittinger and H. Schoenenberger, Eur. J. Med. Chem. 25, 35-44, (1990)) by reduction of L- phenylalanine amide with lithium aluminium hydride. The
(R) -enantiomer was prepared in the same manner from D- phenylalanine amide .
Example 14
Procedure for the preparation of 2- ( ( (S) -2-Acetamido-3- phenylpropyl ) -amino) -5- (4-f luorophenyl) -3 -methyl -6- (4- pyridyl ) -4 (3H) -pyrimidinone
Figure imgf000146_0001
2- ( ( (S) -2-Acetamido-3-phenylpropyl) -amino) -5- (4- fluorophenyl) -3-methyl-6- (4-pyridyl) -4 (3H) -pyrimidinone: A solution of 2- ( ( (S) -2-amino-3 -phenylpropyl) -amino) -5- (4-fluorophenyl) -3-methyl-6- (4-pyridyl) -4 ( 3H) - pyrimidinone (25 mg, 0.058 mmol) and acetic anhydride (200 ml) in methanol (2 ml) was kept at room temperature for 1 h. Evaporation followed by chromatography of the resultant product on a column of silica gel (10% methanol/dichloromethane) provided the title compound.
MS (m/z) : 472.3 (M+H)+; C27H26FN5O2 requir. 471.5.
Example 15
Procedure for the preparation of 2- ( ( (S) -2-N- Isopropylamino-3 -phenylpropyl ) -amino) -4 - (4 -pyridyl ) -5- (3 - tri f luoromethylphenyl ) -pyrimidine hydrochloride
Figure imgf000146_0002
15-1 2- ( ( (S) -2-N-Isopropylamino-3-phenylpropyl) -amino) - 4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine hydrochloride : Sodium triacetoxyborohydride (184 mg, 0.868 mmol) was added to a strirring mixture of 2-(((S)- 2-amino-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine (300 mg, 0.668 mmol) and acetone (50 μl, 0.675 mmol) in 1, 2-dichloroethane (4 ml) . After 16 h, the reaction was quenched by the addition of sat. aqu. sodium hydrogencarbonate, followed by extraction with dichloromethane, drying of the organic solution and evaporation. Chromatography on a column of silica gel (5% methanol/chloroform) provided the title compound as a free base which was converted into the monohydrochloride by the addition of 6N hydrochloric acid (73 μl) to its methanolic solution (3 ml) and subsequent evaporation. MS (m/z): 491.7 (M)+; C28H28F3N5 requir. 491.6 (free base).
The following compounds were prepared using the above procedure and the appropriate starting materials :
15-2 2- ( ( (S) -2 -N-Cvclohexylamino-3-phenylpropyl) -amino) - 4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine hydrochloride: MS (m/z) : 532.0 (M+H)+; C31H32F3Ν5 requir . 531.6 (free base) .
Figure imgf000147_0001
15-3 2- ( ( (S) -2 -N-Isopropylamino-3 -phenylpropyl) -amino) - 5- (3 -methylphenyl) -4- (4-pyridyl) -pyrimidine hydrochloride : MS (m/z) : 439.1 (M+H) + ; C28H31Ν5 requir . 437.6 (free base) .
Figure imgf000147_0002
15-4 2- ( ( (S) -2-N- Butylamino-3 -phenylpropyl) -amino) -5- (3- methylphenyl ) -4- (4 -pyridyl) -pyrimidine hydrochloride: MS (m/z) : 452.1 (M+H)+; C29H33Ν5 requir . 451.6 (free base) .
Figure imgf000147_0003
15-5 2- ( ( (S) -2 -N-Cvclohexylamino-3 -phenylpropyl) -amino) - 5- (3 -methylphenyl) -4- (4 -pyridyl) -pyrimidine hydrochloride: MS (m/z) : 478.3 (M+H)+; C31H35Ν5 requir . 477.7 (free base) .
Figure imgf000148_0001
15-6 5- (4 -Fluorophenyl) -2- ( ( (S) -2-N-isopropylamino-3- phenylpropyl ) -amino) -4- (4-pyridyl) -pyrimidine hydrochloride: MS (m/z) : 442.1 (M+H)+; C27H28FΝ5 requir , 441.6 (free base) .
Figure imgf000148_0002
15-7 5- (4-Fluorophenyl) -2- ( (3-N-isopropylamino-3- phenylpropyl) -amino) -4- (4-pyridyl) -pyrimidine hydrochloride: MS (m/z): 442.2 (M+H) + ; C27H28FΝ5 requir . 441.6 (free base) .
I
Figure imgf000148_0003
Example 16
Procedure for the preparation of 2 - ( ( (S) -2-Amino-3 - phenylpropyl ) -amino) -5- ( 3 -chloro-4 - fluorophenyl ) -4 - (4 - pyridyl ) - pyrimidine hydrochloride
Figure imgf000149_0001
Step A: 4- (4-Pyridyl) -2 (IH) -pyrimidinone: A mixture of 4-acetylpyridine (25 ml, 226.0 mmol) and bis (dimethylamino)methoxymethane (44 ml, 293.8 mmol) was heated at 85°C for 30 min followed by evaporation to dryness to recover a solid of 3- (dimethylamino) -1- (4- pyridyl) -3-propen-l-one. Its ethanolic solution (200 ml) was transferred into ethanolic 1.13 N sodium ethoxide (200 ml) containing urea (16.3 g, 271 mmol). The mixture was heated to reflux overnight, then cooled down to ice-bath temperature. The precipitate was filtered, dissolved in a minimal amount of water and the aqueous solution was washed with dichloromethane . The title compound was precipitated from the aqueous solution by neutralization with 6N hydrochloric acid and filtered. More material was obtained from the original reaction filtrate which was concentrated, diluted with a minimal amount of water and washed with dichloromethane. The aqueous solution was neutralized with 6N hydrochloric acid and the precipitate filtered. MS (m/z) : 174.1 (M+H) + ; C9H7N30 requir . 173.2. Step B: 2-Chloro-4- (4-pyridyl) -pyrimidine: With ice- bath cooling under argon, 4- (4-pyridyl) -2 (IH) - pyrimidinone (13.45 g, 77.7 mmol) and thionyl chloride (92 ml) were combined. N, N-Dimethylformamide (13.2 ml, 170.5 mmol) was added slowly and the mixture was heated to reflux for 1 h. It was evaporated and co-distilled with toluene. At 0°C, water was added to the remainder, then 10% ammonium hydroxide until neutral followed by extraction with dichloromethane. Drying of the organic solution was followed by evaporation and the resultant solid was recrystallized from acetone. MS (m/z) : 192.1,194.0 (M+H) + ; C9H6C1Ν3 requir. 191.6. Step C: 2- ( ( (S) -2-Amino-3 -phenylpropyl) -amino) -4- (4- pyridyl) -pyrimidine: A mixture of 2-chloro-4- (4- pyridyl) -pyrimidine (4.5 g, 23.7 mmol) and (S)-l,2- benzylethylendiamine (8.0 g, 53.3 mmol) was heated at 100°C for 25 min. Column chromatography on silica gel (dichloromethane - methanol - cone, ammonium hydroxide = 95 : 5 : 0.4) provided the title compound. MS (m/z) : 306.5 (M+H)+; C18H19N5 requir. 305.4.
Step D: 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5-bromo-
4- (4-pyridyl) -pyrimidine : Bromine (787 μl, 15.28 mmol) was added to a stirring solution of 2- ( ( (S) -2-amino-3- phenylpropyl) -amino) -4- (4-pyridyl) -pyrimidine (2.33 g, 7.64 mmol) in chloroform (25 ml). Stirring was continued for 2 d. The mixture was partitioned between dichloromethane and aqueous sodium hydrogencarbonate. The organic solution was washed with brine, dried and evaporated. The resultant product was purified on a column of silica gel (dichloromethane - methanol - cone, ammonium hydroxide = 92 : 8 : 0.6). MS (m/z) : 384.0, 386.0 (M+H) + ; C18H18BrN5 requir . 384.3. Step E: 2- ( ( (S) -2-Amino-3-phenylpropyl) amino) -5- (3- chloro-4-fluorophenyl) -4- (4-pyridyl) -pyrimidine hydrochloride : A mixture of 2- ( (2 (S) -amino-3-phenyl propyl) amino) -5-bromo-4- (4-pyridyl) -pyrimidine (204 mg, 0.53 mmol), aqueous 2M sodium carbonate (1.66 ml, 3.32 mmol) and 3-chloro-4-fluorobenzene boronic acid (103 mg, 0.637 mmol) in toluene (5 ml) was stirred for 10 min under argon. The mixture was thoroughly degassed (10 times) , before the addition of tetrakis
(triphenylphosphine) palladium(O) (18 mg, 0.016 mmol). After heating at reflux for 16 h, the reaction mixture was diluted with toluene and washed with brine. The organic solution was dried and evaporated. Subsequent column chromatography on silica gel (dichloromethane - methanol - cone, ammonium hydroxide = 95 : 5 : 04) provided the title compound which was converted into the hydrochloride by the addition of 6N hydrochloric acid (64 μl) to its methanolic solution (2 ml) followed by evaporation. MS (m/z) : 434.1 (M)+; C24H21ClFN5 requir . 433.9 (free base) .
The following compounds were prepared according to Step E of this procedure by using the appropriate boronic acid and 5-bromopyrimidine:
16-2 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3- fluorophenyl) -4- (4-pyridyl) -pyrimidine hydrochloride: MS
(m/z) : 400.1 (M+H) + ; C24H22FN5 requir. 399.5 (free base).
16-3 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3- isopropylphenyl) -4- (4-pyridyl) -pyrimidine hydrochloride: MS (m/z) : 424.2 (M+H)+; C27H29N5 requir . 423.6 (free base).
16-4 5- (3-Acetamidophenyl) -2- ( ( (S) -2-amino-3- phenylpropyl) -amino) -4- (4-pyridyl) -pyrimidine hydrochloride: MS (m/z) : 439.1 (M+H) + ; C26H26N60 requir . 438.5 (free base) .
16-5 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (4- chlorophenyl) -4- (4-pyridyl) -pyrimidine hydrochloride: MS (m/z) 416.3 (M+H)+; C2.H22C1N5 requir . 415.9 (free base). 16-6 2- ( ( (S) -2 -Amino-3 -phenylpropyl) -amino) -5- (benzothienyl) -4- (4-pyridyl) -pyrimidine hydrochloride : MS (m/z): 438.3 (M+H)+; C26H23N5S requir . 437.6 (free base) .
16-7 2- ( ( (S) -2 -Amino-3 -phenylpropyl) -amino) -5- (2- naphthyl) -4- (4-pyridyl) -pyrimidine hydrochloride: MS (m/z): 432.5 (M+H)+; C28H25N5 requir . 431.5 (free base).
Example 17
Procedure for the preparation of (S) -2 -Benzylpiperazine
Figure imgf000152_0001
(S) -2-Benzylpiperazine: At ice-bath temperature, lithium aluminium hydride (1.6 g, 42.16 mmol) was added in portions to a stirring mixture of (S)-2-benzyl piperazine-3 , 6-dione (3.0 g, 14.70 mmol) and tetrahydrofuran (80 ml) . After 30 min at ice-bath temperature, the mixture was refluxed for 4 h with stirring. The reaction was quenched by the portionwise addition of sodium sulfate decahydrate and some methanol until hydrogen evolution ceased. It was filtered and the solids were washed several times with dichloromethane. The combined filtrates were evaporated to leave a white solid. MS (m/z): 177.1 (M+H)*; CnH16N2 requir. 176.3.
Example 18
Procedure for the preparation of (S) -2-N,N-
Dimethylamino-3 -phenylpropylamine
Figure imgf000152_0002
( S) -2-N, -Dimethylamino-3-phenylpropylamine : Sodium triacetoxyhydride (13.0 g, 61.3 mmol) was added to a stirring mixture of phenylalanine amide (3.6 g, 21.9 mmol) and 37% formaldehyde solution (4.4 ml, 58.7 mmol) in 1,2-dichloroethane (77 ml). After stirring for 2 h, the reaction was quenched by the addition of sat. aqu. sodium hydrogencarbonate. Then potassium hydroxide pellets were added followed by extraction with dichloromethane, drying of the organic solution and evaporation. The resulting (S) -2 -N, N-dimethylamino-3- phenylpropylamide was reduced with lithium aluminium hydride according to the literature (H. Brunner, P. Hankofer, U. Holzinger, B. Treittinger and H. Schoenenberger, Eur. J. Med. Chem. 25, 35-44, (1990)) to provide the title compound.
Example 19 Procedure for the preparation of 2- ( ( (S) -2-N, N-
Dimethylamino-3 -phenylpropyl ) -amino) -5- (4 -f luor opheny 1 - 3 -methyl -6- (4-pyridyl ) -4 (3H) -pyrimidinone hydrochloride
Figure imgf000153_0001
Step A. 5- (4-Fluorophenyl) -3-methyl-2-methylsulfonyl-6- (4-pyridyl) -4 (3H) -pyrimidinone: A mixture of 5- (4- fluorophenyl) -3-methyl-2-methylthio-6- (4-pyridyl) -4 (3H) - pyrimidinone (400 mg, 1.22 mmol) and OxoneR (potassium peroxymonosulfate, 2.3 g, 3.74 mmol) in methanol (100 ml) and water (45 ml) was stirred for 13 h. The solvent was concentrated to about 50 ml, followed by extraction with dichloromethane, drying of the organic solution and evaporation. The resulting white solid was used without purification in the next step. Step B. 2- ( ( (S) -2-N, -Dimethylamino-3 -phenylpropyl) - amino) -5- (4-fluorophenyl-3-methyl-6- (4-pyridyl) -4 (3H) - pyrimidinone hydrochloride: A mixture of crude 5- (4- fluorophenyl) -3-methyl-2-methylsulfonyl-6- (4-pyridyl) - 4 ( 3H) -pyrimidinone (430 mg g, 1.19 mmol) and ( S ) -2-N, N- dimethylamino-3-phenylpropylamine (600 mml, -3.4 mmol) was stirred at room temperature for lh and then briefly o warmed at 50 C. Column chromatography on silica gel (3- 5% methanol/chloroform) provided the title compound as a free base which was converted into the monohydrochloride by the addition of 4Ν hydrochloric acid/dioxane (160 mml, 0.64 mmol) to its methanolic solution (4 ml) and subsequent evaporation. MS (m/z) : 458.0 (M+H)+; C27H28FN5O requir. 457.5 (free base).
Example 20
5- (4-f luorophenyl) -6- (4- (2-acetamido) -pyridyl) -2- thioalkyl-4 (3H) -pyrimidinones
Step A. Ethyl 2- (4-fluorophenyl) -3-oxo-3- (4- (2- acetamido) -pyridyl) ) -propionate:
A solution of 2-chloroisonicotinic acid (25. Og, 0.16 mol) in 65 mL of concentrated ammonium hydroxide was warmed to 205 Celsius in a steel bomb for 72 h. After cooling to 23 C, the solution was acidified to a pH of 1 using 6N HCl and subsequently filtered to remove unreacted starting material. The solution was concentrated to one fourth the original volume (approx 200 mL) in vacuo, and carefully adjusted to a pH of 6 using 1 N NaOH. After storing the cloudy solution at 0 C for 20 h, the desired 2-aminoisonicotinic acid was filtered off. To a suspension of 2-aminoisonicotinic acid in ethanol (600 mL) was added 47.1 mL of 4 N anhdrous HCl in dioxane. After warming to achieve reflux for 20 h, an additional 47.1 mL of 4 N anhdrous HCl in dioxane was added and the reaction was warmed to reflux for an additional 20 h. Concentration with a stream of nitrogen in the hood was followed by further concentration in vacuo, the remaining solid was diluted with saturated bicarbonate (200 mL) , extracted with ethyl acetate (2 x 200mL) , dried (Na2S04) . After concentration in vacuo, the desired ethyl 2- a inoisonicotinate was obtained. To a solution of ethyl 2-aminoisonicotinic acid in pyridine (45 mL) at 0 C undr an argon atmosphere was added acetyl chloride dropwise over 5 min. After 2 h at 0 C, the reaction was pored into over ice 300 g, extracted with ethyl acetate (2 x300 mL) , washed with water (2 xlOO ml) followed by brine ( 2 x 100 mL) , and dried (Na2S04) . After concentration in vacuo, the residue was purified by application of flash chromatography ( step gradient ethyl acetate: hexane 1:4 then ethyl acetate: hexane 1:1) to afford ethyl 2-acetamidoisonicotinate .
To a solution of diisopropylamine (14.15 mL, 101 mmol) and THF (40 mL) at -78 C was added n-butyl lithium (38.1 mL, 95 mmol) dropwise over 5 min. After 10 min, ethyl 4-fluorophenylacetate (17.3 g, 95 mmol) was added in 40 mL of dry THF. After 10 min, ethyl 2- acetamidoisonicotinate (6.0 g, 29 mmol) was added in 20 ml of dry THF. The reaction was allowed to warm to 23 C overnight, and then acetic acid (95 mmol) was added in one portion. The reaction was concentrated in vacuo, then partitioned repeatedly between saturated bicarbonate (200 ml) and ether (300 mL) , the combined bicarbonate layers were neutralized with 10% citric acid, and extracted with ethyl acetate (2 x 300 mL) . The organic layers were dried (Na2S04) , concentrated in vacuo to afford the Ethyl 2- (4-fluorophenyl) -3-oxo-3- (4- (2-acetamido) -pyridyl) -propionate.
Step B. 5- (4-fluorophenyl) -6- (4- (2-acetamido)pyridyl) ) - 2-thiouracil:
Ethyl 2- (4-fluorophenyl) -3-OXO-3- (4- (2- acetamido) pyridyl) -propionate (1.3 g, 3.78 mmol) and thiourea (863 mg, 11.3 mmol) were suspended in anhydrous p-xylene (15 ml) with very efficient stirring. To the mixture pyridinium p-toluenesulfonate (38 mg) was added and refluxed for 12-16 h using a Dean-Stark apparatus with continuous removal of water (0.1 ml). Reaction mixture was cooled and a dark brown solid was filtered using a Buchner funnel. The collected solid was suspended in acetone (25 ml) and filtered. The acetone washed product contained a trace of thiourea, which was removed by trituration with hot water (20-30 ml) . The product was filtered and air dried followed by azeotroping with toluene.
Example 21
Procedure for the preparation of (S) -2-N-Ethylamino-3 - ph enylpropyl amine
Figure imgf000157_0001
(S) -2-N-Ethylamino-3-phenylpropylamine : Acetic anhydride (1.2 ml, 12.7 mmol) was added to a stirring solution of L-phenylalanine amide (1.0 g, 6.10 mmol) in methanol (25 ml) . After 1.5 h at room temperature, it was evaporated followed by drying in an oil pump vacuum. The resultant L-N-ethylphenylalanine amide (6.1 mmol) was reduced with lithium aluminium hydride (570 mg, 15.0 mmol) in tetrahydrofuran (65 mml) at 55°C for 4 h. The reaction mixture was poured into sat. aqu. sodium hydrogencarbonate followed by extraction with dichloromethane, drying and evaporation. Column chromatography on silica gel (chloroform : methanol : triethylamine = 90:7:3) provided the amine as a yellowish oil. MS (m/z) : 179.1 (M+H)+; C11H18 2 requir. 178.3.
Example 22
Procedure for the preparation of 2 -Amino-2 -methyl - 3 - phenylpropylamine
Figure imgf000157_0002
2-Amino-2-methyl-3-phenylpropylamine: A solution of commercially available D, L-α-methyl phenylalanine methyl ester (5.0 g, 25.7 mmol) in aqu. 28% ammonium hydroxide (50 ml) was kept at room temperature for 3 d. The resulting white precipitate of D, L-α-methyl phenylalanine amide was filtered and dried (2.5 g) . This material (2.0 g, 11.22 mmol) was reduced with lithium aluminium hydride (1.3 g, 34.26 mmol) in boiling tetrahydrofuran for 24 h. The reaction was quenched by the addition of sodium sulfate decahydrate at ice-bath temperature. The salts were filtered off, followed by evaporation to leave the title compound as an oil. MS
(m/z) : 165.1 (M+H)+; C10H16N2 requir. 164.2. An alternative preparation was reported by M. Freiberger and R. B. Hasbrouck, J. Am. Chem. Soc. 82, 696-698 (1960) .
Example 23
Procedure for the preparation of 2 -Methyl -3- ph enylpropyl amine
NH2
CH3
2-Methyl-3-phenylpropylamine : A mixture of commercially available 2-methyl-3-phenylpropylamide (4.32 g, 26.5 mmol) and lithium aluminium hydride (1.3 g, 34.3 mmol) in tetrahydrofuran (184 ml) was stirred at room temperature for 5 h. It was poured into aqu. sat. sodium sulfate and extracted with dichloromethane followed by drying of the organic solution and evaporation to provide the amine as an oil . Other syntheses have been reported, e.g. Dornow and Fust, Chem. Ber. 87, 984 (1954). Example 24
Procedure for the preparation of 5- (4 -Fluorophenyl) -3- methyl -2- ( ( 2 -methy- 3 -phenylpropyl ) amino) -6- (4 -pyridyl ) ■ 4 (3H) -pyrimidinone hydrochloride
Figure imgf000159_0001
5- (4-Fluorophenyl) -3-methyl-2- ( (2-methv-3-phenylpropyl) amino) -6- (4-pyridyl) -4 (3H) -pyrimidinone hydrochloride: A mixture of crude 5- (4-fluorophenyl) -3-methyl-2- methylsulfonyl-6- (4-pyridyl) -4 ( 3H) -pyrimidinone (520 mg g, 1.45 mmol) and 2-methyl-3-phenylpropylamine (1.5 g, 10.1 mmol) was heated at 50°C for 30 min. Column chromatography on silica gel (2-5% methanol/ dichloromethane; hexane-acetone= 2 : 1) provided the title compound. MS (m/z) : 429.4 (M+H)+; C26H25FN4O requir. 428.5 (free base).
Example 25
Procedure for the preparation of 1 -Phenyl -l , 3- propanediamine
Figure imgf000159_0002
1-Phenyl-l, 3-propanediamine: 3-Phenyl-3-aminopropionic acid (S. G. Cohen and S. Y. Weinstein, J. Am. Chem. Soc. 86, 725-728, 1964) was converted into 1-phenyl-l, 3- propanediamine as reported in the literature (M. Kojima and J. Fujita, Bull. Chem. Soc. Jpn. 55, 1454-1459 (1982) ) . Analogously, 1- (2-fluorophenyl) -1, 3-propanediamine, 1- (2-methylphenyl) -1 , 3-propanediamine and 1- (2- chlorophenyl) -1 , 3-propanediamine have been prepared by using the above procedure and the appropriate starting material .
Example 26
Procedure for the preparation of 3 -Ethyl -5- (4- f luorophenyl ) -2 -methyl thio- 6- (4 -pyridyl) -4 (3H) pyrimidinone
Figure imgf000160_0001
3-Ethyl-5- (4-fluorophenyl) -2-methylthio-6- (4-pyridyl) - 4 (3H) -pyrimidinone: Ethyl bromide (600 ml, 8.03 mmol) was added to a stirred mixture of 5- (4-fluorophenyl) -2- methylthio-6- (4-pyridyl) -4 (3H) -pyrimidinone (1.8 g, 5.97 mmol) and sodium hydride (60% oily suspension, 320 mg, 8 mmol) in N, N-dimethylformamide (60 ml) at room temperature. More ethyl bromide (2x 600 ml, 2x8.03 mmol) was added after 2 and 3.5 h. After 8 h, the reaction mixture was neutralized with acetic acid and evaporated. The remainder was taken up in dichloromethane, the organic solution was washed with water, dried and evaporated. Flash chromatography on a column of silica gel (hexane-acetone = 3:1, 2:1). provided in the second main fraction the title compound as a solid. Example 27
Procedure for the preparation of 3 -Ethyl - 5- (4- f luorophenyl ) -2-methylsulfonyl -6- (4 -pyridyl ) -4 (3H) pyrimidinone
Figure imgf000161_0001
3-Ethyl-5- (4-fluorophenyl) -2-methylsulfonyl-6- (4- pyridyl) -4 (3H) -pyrimidinone: A mixture of 3-ethyl-5- (4- fluorophenyl) -2-methylthio-6- (4-pyridyl) -4 (3H) - pyrimidinone (300 mg, 0.88 mmol) and OxoneR (potassium peroxymonosulfate, 2.54 g, 4.14 mmol) in methanol (71 ml) and water (33 ml) was stirred for 14 h. The solvent was concentrated to about 35 ml, followed by extraction with dichloromethane, drying and evaporation. The resulting white solid was used without purification in the next step.
Example 28
Procedure for the preparation of 2- ( ( (S) -2-Amino-3- phenylpropyl ) -amino) -3 -ethyl -5- (4 -f luorophenyl ) -6- (4 - pyridyl) -4 (3H) -pyrimidinone hydrochloride
Figure imgf000161_0002
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -3-ethyl-5- (4- fluorophenyl) -6- (4-pyridyl) -4 (3H) -pyrimidinone hydrochloride : A mixture of 3-ethyl-5- (4-fluorophenyl) 2-methylthio-6- (4-pyridyl) -4 (3H) -pyrimidinone (150 mg, 0.44 mmol) and (S) -1, 2-benzylethylendiamine (200 ml,
-1.3 mmol) was heated at 190°C for 4.5 h. Column chromatography on IatrobeadsR (chloroform : methanol : triethylamine = 90 : 7 : 3) provided the title compound as a free base which was converted into the crystallizing monohydrochloride by the addition of 2N hydrochloric acid (165 ml, 0.33 mmol) and methanol (1.5 ml) . Filtration provided the title compound. MS (m/z) :
444.0 (M+H)+; C265H27FN5O requir. 443.5 (free base).
Example 29
Procedure for the preparation of 3 -Ethyl -5- (4 - f luorophenyl ) -2- ( ( 2 -me thy- 3 -phenylpropyl ) amino) -6- (4 - pyridyl) -4 (3H) -pyrimidinone hydrochloride
Figure imgf000162_0001
3-Ethyl-5- (4-fluorophenyl) -2- ( (2-methy-3-phenylpropyl) amino) -6- (4-pyridyl) -4 (3H) -pyrimidinone hydrochloride: A mixture of crude 3-ethyl-5- (4-fluorophenyl) -2- methylsulfonyl-6- (4-pyridyl) -4 ( 3H) -pyrimidinone (320 mg g, 0.89 mmol) and 2-methyl-3-phenylpropylamine (600 ml, ~4 mmol) was heated at 60°C for 2 h. Column chromatography on silica gel (hexane-acetone= 2 : 1; 2- 5% methanol/dichloromethane) provided the title compound. MS (m/z) : 443.2 (M+H)+; C27H27FN4O requir. 442.5.
Example 30
Procedure for the preparation of 3 - (2- Me thylphenyl ) propyl amine
Figure imgf000162_0002
3- (2-Methylphenyl) propylamine : Diethyl cyanomethylphosphonate (5.0 ml, 30.9 mmol) was added to a stirring suspension of sodium hydride (60% oily suspension, 1.24 g, 31 mmol) in tetrahydrofuran (50 ml) under argon. After 3o min, 2-methylbenzaldehyde (3.6 ml, 31.1 mmol) was added and stirring continued for 1 h. The reaction was quenched by the addition of water and extracted with dichloromethane followed by drying and evaporation of the organic solution. Column chromatography (hexane; hexane : ethylacetate = 3 : 1) provided 2- (2 -methylphenyl) acrylonitrile as an oil. This material (3.8 g) , 10% palladium on carbon (3.8 g) and 12 N hydrochloric acid (11.8 ml, 142 mmol) in methanol (125 ml) were hydrogenated with hydrogen at atmospheric pressure for 2 d. The catalyst was removed by filtration and the solvent was evaporated. The resultant material was partitioned between dichloromethane and water . The aqueous layer was made basic with 10 N sodium hydroxide and extracted with dichloromethane, followed by drying and evaporation. The resultant material was purified on a silica gel column (chloroform : methaol : triethylamine = 85 : 10 : 5) to provide the title compound as an oil.
Example 31
Procedure for the preparation of 2-amino-3- (2- f luorophenyl ) -propylamine
Figure imgf000163_0001
Step A. Methyl 2-amino-3- (2-fluorophenyl) propionate: 5g (27.3 mmol) of (D,L) - (2-fluoro-phenyl) alanine was suspended in 50 ml methanolic HCl and stirred at room temperature for 3 days . The reaction mixture was concentrated in vacuo and dried to give a yellow oil . MS (m/z): 198 (M+H)* ; C10H12FNO2 requir . 197.2.
Step B. 2-Amino-3- (2-fluorophenyl)propionamide: Methyl 2-amino-3- (2-fluorophenyl) propionate was suspended in 50 ml 30% ammonium hydroxide and stirred at room temperature for 18 hrs. The mixture was filtered, washed with cold water and 2-amino-3- (2-fluorophenyl) propionamide was collected as a white solid. MS (m/z) : 183.1 (M+H)* ; C9HuFN20 requir. 182.2.
Step C. 2-Amino-3- (2-fluorophenyl) -propylamine : 2- Amino-3- (2-fluorophenyDpropionamide was added carefully to a chilled (5°) mixture of LAH (l.Og, 26.3 mmol) and 20 ml THF under argon. The reaction was then heated at reflux for 10 hrs. The reaction was cooled to 5°C and carefully treated with Na2SO4»10 H20. The resulting mixture was stirred for 18 hrs, then filtered to remove the solids. The filtrate was concentrated in vacuo to give an amber oil. MS (m/z) : 169 (M+H)* ; C9HnFN2 requir. 168.19
Example 32 Procedure for the preparation of (1R, 2R) -2 -Methyl - 1 - phenyl -1 , 3 -propanedi amine
Figure imgf000164_0001
Step A: Methyl (2S.3R, αS) -3- (N-benzyl -N-α- methylbenzylamino) -2-methyl-3-phenylpropionate was prepared as reported for the 2R, 3S,αR-enantiomer (S) .G. Davies and I.A.S. Walters, J. Chem. Soc. Perkin Trans. I, 1129-1139 (1994).
Step B: Methyl (2S , 3R) -3-amino-2-methyl-3- phenylpropionate : A mixture of methyl (2S, 3R, αS) -3- (N- benzyl -N-α-methylbenzylamino) -2-methyl-3- phenylpropionate (13.0 g, 33.55 mmol) and 10% palladium- on-carbon (13.0 g) in glacial acetic acid (260 ml) was hydrogenated under a balloon of hydrogen for 24 h. The catalyst. was removed by filtration followed by evaporation and co-distillation with toluene to provide the title compound as a white solid. MS (m/z) : 194.2 (M+H)*; C^H^NO. requir. 193.3.
Step C: (2S, 3R) -3-Amino-2-methyl-3-phenylpropionamide : A solution of methyl (2S, 3R) -3-amino-2-methyl-3- phenylpropionate (6.3 g, 33 mmol) in 2N methanolic ammonia (20 ml) and ammonium hydroxide (28-30%, 40 ml) was stirred at room temperature. After 4d, it was evaporated followed by chromatography on a short column of silica gel (dichloromethane - methanol - cone, ammonium hydroxide = 93 : 7 : 0.7; 90 : 10 : 0.8) to provide the amide as a white solid. MS (m/z) : 179.2 (M+H)+; C10H14N2O requir. 178.2.
Step D: (1R, 2R) -2-methyl-1-phenyl-l, 3-propanediamine: Lithium aluminium hydride (2.3 g, 60.60 mmol) was added in portions to a stirring solution of (2S, 3R) -3-amino-2- methyl-3-phenylpropionamide (2.6 g, 14.59 mmol) in tetrahydrofuran (54 ml) at ice-bath temperature. After 45 min, the mixture was heated at reflux for 16 h. With ice-bath cooling, the reaction was quenched by the portionwise addition of sodium sulfate decahydrate and some methanol until hydrogen evolution ceased. The solids were removed by filtration and washed with dichloromethane. The combined filtrates were evaporated to provide the title compound. MS (m/z) : 165.2 (M+H)*; C10H16N2 requir. 164.3.
Analogously, the enantiomer (IS, 2S) -2-methyl-l- phenyl-1 , 3-propanediamine was prepared from methyl
( 2R , 3 S , OCR) -3 - (N-benzyl -N-α-methylbenzylamino ) -2 -methyl - 3 -phenylpropionate . MS (m/z) : 165 . 3 (M+H) *; C10H16Ν2 requir . 164 . 3 . Analogously, the enantiomers ( IS , 2R) -2-methyl-l- phenyl-1 , 3-propanediamine and (IR, 2S) -2-methyl-1-phenyl- 1 , 3-propanediamine may be prepared from tert.butyl
(2S,3S,αR)- and - (2R, 3R, αS) -3- (N-benzyl -N-α- methylbenzylamino) -2-methyl-3-phenylpropionate (Davies et al., J. Chem. Soc. Chem. Commun. 1153-1155, 1993).
Example 33
Procedure for the preparation of 5- (4 -f luorophenyl ) -2 - ( 4 -pheny lbutyl ) -6- (4-pyridyl ) -4 (3H) -pyrimidinone
Figure imgf000166_0001
5- (4-Fluorophenyl) -2- (4-phenylbutyl) -6- (4-pyridyl) - 4 ( 3H) -pyrimidinone : Ethyl 2- (4-fluorophenyl) -3-oxo-3- (4-pyridyl) -propionate (293 mg, 1.02 mmol), 4- phenylbutanecarboxamidine (315 mg, 1.79 mmol) and pyridinium p-toluenesulfonate (10 mg) were suspended in p-xylene (10 ml) . With efficient stirring, the mixture was heated to reflux using a Dean-Stark apparatus with continuous removal of water. After 16 h, the solvent was evaporated and the product purified by column chromatography on silica gel (3% methanol/dichloromethane) followed by recrystallization from acetone. MS (m/z) : 400.3 (M+H) + ; C25H22FΝ3O requir. 399.5. Example 34
Procedure for the preparation of 5- (4 -f luorophenyl ) -2- (N-methyl -N- ( 2 -pheny le thyl ) amino) -6- (4 -pyridyl ) -4 (3H) ■ pyrimidinone
Figure imgf000167_0001
5- (4-Fluorophenyl) -2- (N-methyl-N- (2-phenylethyl) amino) - 6- (4-pyridyl) -4 (3H) -pyrimidinone was prepared using the methods described above. MS (m/z) : 401.2 (M+H)+; C24H21FN4O requir. 400.5.
Example 35
The compounds shown in Tables I-II can be prepared using the procedures of Examples 1-33.
TABLE I
Figure imgf000167_0002
166
Figure imgf000168_0001
Figure imgf000169_0001
TABLE II
Figure imgf000170_0001
R*
Figure imgf000170_0002
Figure imgf000171_0001
Example 36
Biological Assays The following assays were used to characterize the ability of compounds of the invention to inhibit the production of TNF-α and IL-l-β. The second assay measured the inhibition of TNF-α and/or IL-l-β in mice after oral administration of the test compounds . The third assay, a glucagon binding inhibition in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit glucagon binding. The fourth assay, a Cyclooxygenase enzyme (COX-1 and COX-2) inhibition activity in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit COX-1 and/or COX-2.
Lipopolysaccharide-activatθd monocyte TNF production assay Isolation of monocytes
Test compounds were evaluated in vi tro for the ability to inhibit the production of TNF by monocytes activated with bacterial lipopolysaccharide (LPS) . Fresh residual source leukocytes (a byproduct of plateletpheresis) were obtained from a local blood bank, and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation on Ficol- Paque Plus (Pharmacia) . PBMCs were suspended at 2 x 10s/ml in DMEM supplemented to contain 2% FCS, 10 mM, 0.3 mg/ml glutamate, 100 U/ml penicillin G and 100 mg/ml streptomycin sulfate (complete media) . Cells were plated into Falcon flat bottom, 96 well culture plates (200 μl/well) and cultured overnight at 37°C and 6% C02. Non-adherent cells were removed by washing with 200 μl/well of fresh medium. Wells containing adherent cells (-70% monocytes) were replenished with 100 μl of fresh medium.
Preparation of test compound stock solutions
Test compounds were dissolved in DMZ. Compound stock solutions were prepared to an initial concentration of 10 - 50 uM. Stocks were diluted initially to 20 - 200 μM in complete media. Nine twofold serial dilutions of each compound were then prepared in complete medium. Treatment of cells wi th test compounds and activation of
TNF production with lipopolysaccharide
One hundred microliters of each test compound dilution were added to icrotiter wells containing adherent monocytes and 100 μl complete medium. Monocytes were cultured with test compounds for 60 min at which time 25 μl of complete medium containing 30 ng/ml lipopolysaccharide from E. coli K532 were added to each well. Cells were cultured an additional 4 hrs. Culture supernatants were then removed and TNF presence in the supernatants was quantified using an ELISA. TNF ELISA
Flat bottom, 96 well Corning High Binding ELISA plates were coated overnight (4°C) with 150 μL/well of 3 μg/ml murine anti-human TNF-α MAb (R&D Systems #MAB210) . Wells were then blocked for 1 hr at room temperature with 200 μL/well of CaCl2-free ELISA buffer supplemented to contain 20 mg/ml BSA (standard ELISA buffer: 20 mM, 150 mM NaCI, 2 mM CaCl2, 0.15 mM thimerosal, pH 7.4). Plates were washed and replenished with 100 μl of test supernatants (diluted 1:3) or standards. Standards consisted of eleven 1.5-fold serial dilutions from a stock of 1 ng/ml recombinant human TNF (R&D Systems) . Plates were incubated at room temperature for 1 hr on orbital shaker (300 rpm) , washed and replenished with 100 μl/well of 0.5 μg/ml goat anti-human TNF-α (R&D systems #AB-210-NA) biotinylated at a 4:1 ratio. Plates were incubated for 40 min, washed and replenished with 100 μl/well of alkaline phosphatase-conjugated streptavidin (Jackson ImmunoResearch #016-050-084) at 0.02 μg/ml. Plates were incubated 30 min, washed and replenished with 200 μl/well of 1 mg/ml of p-nitrophenyl phosphate. After 30 min, plates were read at 405 nm on a Vmax p*-late reader.
Data analysis
Standard curve data were fit to a second order polynomial and unknown TNF-α concentrations determined from their OD by solving this equation for concentration. TNF concentrations were then plotted vs. test compound concentration using a second order polynomial. This equation was then used to calculate the concentration of test compounds causing a 50% reduction in TNF production. Compounds of the invention can also be shown to inhibit LPS-induced release of IL-lβ, IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-lβ, IL- 6 and/or IL-8 by methods well known to those skilled in the art. In a similar manner to the above described assay involving the LPS induced release of TNF-α from monocytes, compounds of this invention can also be shown to inhibit LPS induced release of IL-lβ, IL-6 and/or IL- 8 from monocytes by measuring concentrations of IL-lβ, IL-6 and/or IL-8 by methods well known to those skilled in the art. Thus, the compounds of the invention may lower elevated levels of TNF-α, IL-1, IL-6, and IL-8 levels. Reducing elevated levels of these inflammatory cytokines to basal levels or below is favorable in controlling, slowing progression, and alleviating many disease states. All of the compounds are useful in the methods of treating disease states in which TNF-α, IL- lβ, IL-6, and IL-8 play a role to the full extent of the definition of TNF-α-mediated diseases described herein.
Inhibition of LPS-induced TNF-α production in mice
Male DBA/1LACJ mice were dosed with vehicle or test compounds in a vehicle (the vehicle consisting of 0.5% tragacanth in 0.03 N HCl) 30 minutes prior to lipopolysaccharide (2 mg/kg, I.V.) injection. Ninety minutes after LPS injection, blood was collected and the serum was analyzed by ELISA for TNF levels .
The following compounds exhibit activities in the monocyte assay (LPS induced TNF release) with IC50 values of 20 μM or less: 5- (4-Fluorophenyl) -2- (4-pyridyl) -4- (4-pyridyl) - pyrimidine
5- (4-Fluorophenyl) -2- (2-methylthiazol-4-yl) -4- (4- pyridyl) -pyrimidine
5- (4-Fluorophenyl) -4- (4-pyridyl) -2- (2-thienyl) - pyrimidine 2- (2-Diethylaminoethylamino) -5- (4-fluorophenyl) -4- (4- pyridyl) -pyrimidine
2- (2-Aminoethylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine 2- ( 3-Aminopropylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine
2- (4-Aminobutylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine
2- (2 , 6-Dichlorobenzyl) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine
2- (2 , 6-Dichlorophenylamino) -5- (4-fluorophenyl) -4- (4- pyridyl ) -pyrimidine
2- (2 , 6-Dimethylphenylamino) -5- (4-fluorophenyl) -4- (4- pyridyl) -pyrimidine 5- (4-Fluorophenyl) -2- (2-methoxyphenylamino) -4- (4- pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- (4-fluorophenylamino) -4- (4- pyridyl ) -pyrimidine
5- (4-Fluorophenyl) -2-phenylthiomethyl-4- (4-pyridinyl) - pyrimidine
2- (Benzylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine
5- (4-Fluorophenyl) -2- (2-phenylethylamino) -4- (4-pyridyl) - pyrimidine 5- (4-Fluorophenyl) -2- (methyl- (2-phenylethyl) -amino) -4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- ( (2-hydroxy-2-phenyl-ethyl) amino) - 4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- (2- (4-hydroxyphenyl) ethyl-amino) -4- (4-pyridyl ) -pyrimidine
2- (2- (4-Aminopheny1) ethyl-amino) -5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- (2- (4-fluorophenyl) ethyl-amino) -4- (4-pyridyl) -pyrimidine 5- (4-Fluorophenyl) -2- (2- (2-fluorophenyl) ethyl-amino) -4- (4-pyridyl) -pyrimidine
2- (2- (2-Chlorophenyl) ethyl-amino) ) -5- (4-fluorophenyl) -4- ( 4-pyridyl ) -pyrimidine
2- (2- (4-Chlorophenyl) ethyl-amino) -5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine
2- (2- (3-Chlorophenyl) ethyl-amino) ) -5- (4-fluorophenyl) -4- ( 4-pyridyl) -pyrimidine
2- (2- (2, 4-Dichlorophenyl) ethyl-amino) -5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine 2- (2- (4-Bromophenyl) ethyl-amino) -5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- (2- (2-methoxyphenyl) ethyl-amino) -4- (4-pyridyl) -pyrimidine 5- (4-Fluorophenyl) -2- (2- (3-methoxyphenyl) ethyl-amino) -4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- ( (3-phenylpropyl) amino) -4- (4- pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- ( (1-methyl-3 -phenylpropyl) -amino) - 4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-Amino-3 -phenylpropyl) -amino) -5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- (2-phenylaminoethylamino) -4- (4- pyridyl) -pyrimidine 5- (4-Fluorophenyl) -2- ( (3-imidazolylpropyl) -amino) -4- (4- pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- ( (4-phenylbutyl) -amino) -4- (4- pyridyl) -pyrimidine
5- (4-Fluorophenyl) -4- (4-pyridyl) -2-pyrrolidino- pyrimidine
5- (4-Fluorophenyl) -2-morpholino-4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- ( 1-piperazinyl) -4- (4-pyridyl) - pyrimidine
5- (4-Fluorophenyl) -4- (4-pyridyl) -2- (2- pyrrolidinoethylamino) -pyrimidine
5- (4-Fluorophenyl) -2- (2-morpholinoethylamino) -4- (4- pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- (2-piperidinoethylamino) -4- (4- pyridyl) -pyrimidine 5- (4-Fluorophenyl) -2- (3- (2-pyrrolidinon-l-yl) propylamino) -4- (4-pyridyl) -pyrimidine
2- (2, 6-Dichlorobenzyl) -5- (4-fluorophenyl) -6- (4-pyridyl) - 4 (3H) -pyrimidinone
5- (4-Fluorophenyl) -2- (2-phenylethyl) thio-6- (4-pyridyl) - 4 ( 3H) -pyrimidinone
5- (4-Fluorophenyl) -2- (3-phenylpropyl) thio-6- (4-pyridyl) - 4 ( 3H) -pyrimidinone
5- (4-Fluorophenyl) -2- (2-phenoxyethyl) thio-6- (4-pyridyl) - 4 ( 3H) -pyrimidinone 5- (4-Fluorophenyl) -2- (2-phenylaminoethyl) thio-6- (4- pyridyl) -4 ( 3H) -pyrimidinone
2- (2- (2-Chlorophenyl) ethyl-amino) -5- (4-fluorophenyl) -6- (4-pyridyl) -4 ( 3H) -pyrimidinone
5- (4-Fluorophenyl) -2- ( (3 -phenylpropyl) amino) -6- (4- pyridyl) -4 (3H) -pyrimidinone 5- (4-Fluorophenyl) -2- ( (1-methyl-3-phenylpropyl) -amino) - 6- (4-pyridyl) -4 ( H) -pyrimidinone
5- (4-Fluorophenyl) -2- ( (3-imidazolylpropyl) amino) -6- (4- pyridyl) -4 ( 3H) -pyrimidinone 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine
2- ( ( (S) -2-Amino-3 -phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-N, N-Dimethylamino-3-phenylpropyl) -amino) -5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-N, N-Dimethylamino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine
2- ( (3-Amino-3-phenylpropyl) -amino) -5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine 2- ( (3-Amino-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine
2- ( (3-Amino-3- (2-fluorophenyl) propyl) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine
2- ( (3-Amino-3-phenylpropyl) -amino) -5- (3-methylphenyl) -4- (4-pyridyl) -pyrimidine
2- ( (2-Amino-2-methyl-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine
2- ( (3-Hydroxy-3-phenylpropyl) -amino) -5- (3-methylphenyl) - 4- (4-pyridyl) -pyrimidine 2-(((2S,3S) -3-Amino-2-methyl-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine
2- ( ( (2R, 3R) -3-Amino-2-methyl-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine
2- ( (S) -3-Benzylpiperazinyl) -4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine
4- (4-Pyridyl) -2- ( ( (S) -tetrahydroisoquinol-3- ylmethylen) amino) -5- (3-trifluoromethylphenyl) -pyrimidine
5- (3-Methylphenyl) -4- (4-pyridyl) -2- ( ( (S) - tetrahydroisoquinol-3-ylmethyl) amino) -pyrimidine 2- ( ( (S) -2 -N-Isopropylamino-3-phenylpropyl) -amino) -4- (4- pyridyl) - 5- (3-trifluoromethylphenyl) -pyrimidine
2- ( ( (S) -2 -N-Cyclohexylamino-3-phenylpropyl) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine
2- ( ( (S) -2-N-Isopropylamino-3 -phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2 -N-Butylamino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2 -N-Cyclohexylamino-3-phenylpropyl) -amino) -5- (3- me hylpheny1) -4- (4-pyridyl) -pyrimidine 5- (4-Fluorophenyl) -2- ( ( (S) -2 -N-isopropylamino-3 - phenylpropyl ) -amino) -4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- ( ( 3 -N-isopropylamino-3 - phenylpropyl) -amino) -4- (4-pyridyl) -pyrimidine 2- ( ( (S) -2 -N-Glycylamino-3-phenylpropyl) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine
2- ( ( (S) -2 -N-Glycylamino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3-chloro-4- fluorophenyl) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3- fluorophenyl) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3- isopropylphenyl) -4- (4-pyridyl) -pyrimidine 5- (3-Acetamidophenyl) -2- ( ( (S) -2-amino-3-phenylpropyl) - amino) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (4- chlorophenyl) -4- (4-pyridyl) -
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (benzothienyl) - 4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (2-naphthyl) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (4- fluorophenyl) -6- (4-pyridyl) -4 ( 3H) -pyrimidinone. The following compounds exhibit activities in the monocyte assay (LPS induced TΝF release) with IC50 values of 5 μM or less:
2- (2-Aminoethylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine 2- (3-Aminopropylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine
2- (Benzylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine
5- (4-Fluorophenyl) -2- (2-phenylethylamino) -4- (4-pyridyl) - pyrimidine
5- (4-Fluorophenyl) -2- (Ν-methyl-Ν- (2-phenylethyl) amino) - 4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- (2-hydroxy-2-phenyl-ethyl) amino-4- (4-pyridyl) -pyrimidine 5- (4-Fluorophenyl) -2- (2- (4-hydroxyphenyl) ethylamino) -4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- (2- (4-fluorophenyl) ethylamino) -4- (4-pyridyl) -pyrimidine 5- (4-Fluorophenyl) -2- (2- (2-fluorophenyl) ethylamino) -4- (4-pyridyl) -pyrimidine
2- (2- (2-Chlorophenyl) ethylamino) ) -5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine 2- (2- (4-Chlorophenyl) ethylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine
2- (2- (2, 4-Dichlorophenyl) ethylamino) -5- (4-fluorophenyl) - 4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- (3-phenylpropyl ) amino-4- (4- pyridyl) -pyrimidine
2- ( (S) -2-Amino-3-phenylpropyl) amino-5- (4-fluorophenyl) - 4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- (2-phenylaminoethylamino) -4- (4- pyridyl) -pyrimidine 5- (4-Fluorophenyl) -2- (3-imidazolylpropyl) amino-4- (4- pyridyl) -pyrimidine
5- (4-Fluorophenyl) -4- (4-pyridyl) -2-pyrrolidino- pyrimidine
5- (4-Fluorophenyl) -2- ( 1-piperazinyl) -4- (4-pyridyl) - pyrimidine
5- (4-Fluorophenyl) -2- (2-phenylethyl) thio-6- (4-pyridyl) - 4 (3H) -pyrimidinone
5- (4-Fluorophenyl) -2- (3-phenylpropyl) thio-6- (4-pyridyl) - 4 ( 3H) -pyrimidinone 2- (2- (2-Chlorophenyl) ethyl-amino) -5- (4-fluorophenyl) -6-
( 4-pyridyl) -4 ( 3H) -pyrimidinone
5- (4-Fluorophenyl) -2- (3-phenylpropyl ) amino-6- (4- pyridyl) -4 ( 3H) -pyrimidinone
5- (4-Fluorophenyl) -2- (1-methyl-3-phenylpropyl) amino-6- (4-pyridyl) -4 ( 3H) -pyrimidinone
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine 2- ( ( (S) -2 -N, N-Dimethylamino-3-phenylpropyl) -amino) -5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine
2-( ( (S) -2 -N, N-Dimethylamino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine
2- ( (3-Amino-3-phenylpropyl) -amino) -5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine
2- ( (3-Amino-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine
2- ( (3-Amino-3- (2-fluorophenyl) propyl) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine 2- ( (3-Amino-3 -phenylpropyl) -amino) -5- (3-methylphenyl ) -4- (4-pyridyl) -pyrimidine
2- ( (2-Amino-2-methyl-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine 2- ( (3-Hydroxy-3-phenylpropyl) -amino) -5- (3-methylphenyl) - 4- (4-pyridyl) -pyrimidine
2- ( ( (2S, 3S) -3 -Amino-2-methyl-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine
2- ( ( (2R, 3R) -3 -Amino-2-methyl-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine
2- ( (S) -3-Benzylpiperazinyl) -4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine
4- (4-Pyridyl) -2- ( ( (S) -tetrahydroisoquinol-3- ylmethyl) amino) -5- (3-trifluoromethylphenyl) -pyrimidine 5- (3 -Methylphenyl) -4- (4-pyridyl) -2- ( ( (S) - tetrahydroisoquinol-3-ylmethylen) amino) -pyrimidine
2- ( ( (S) -2 -N-Isopropylamino-3-phenylpropyl) -amino) -4- (4- pyridyl) - 5- (3-trifluoromethylphenyl) -pyrimidine
2- ( ( (S) -2 -N-Cyclohexylamino-3-phenylpropyl) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine
2- ( ( (S) -2 -N-Isopropylamino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2 -N-Butylamino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine 2- ( ( (S) -2 -N-Cyclohexylamino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- ( ( (S) -2-N-isopropylamino-3 - phenylpropyl) -amino) -4- (4-pyridyl) -pyrimidine
5- (4-Fluorophenyl) -2- ( ( 3 -N-isopropylamino-3 - phenylpropyl) -amino) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2 -N-Glycylamino-3-phenylpropyl) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine
2- ( ( (S) -2 -N-Glycylamino-3-phenylpropyl) -amino) -5- (3- methylpheny1) -4- (4-pyridyl) -pyrimidine 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3-chloro-4- fluorophenyl) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3- fluorophenyl) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3- isopropylpheny1) -4- (4-pyridyl) -pyrimidine
5- (3-Acetamidophenyl) -2- ( ( (S) -2-amino-3-phenylpropyl) - amino) -4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (4- chlorophenyl) -4- (4-pyridyl) - 2- ( ( (S) -2-Amino-3 -phenylpropyl) -amino) -5- (benzothienyl) - 4- (4-pyridyl) -pyrimidine
2- ( ( (S) -2 -Amino-3 -phenylpropyl) -amino) -5- (2-naphthyl) -4- (4-pyridyl) -pyrimidine 2- ( ( (S) -2-Amino-3 -phenylpropyl) -amino) -5- (4- fluorophenyl) -6- (4-pyridyl) -4- ( 3H) pyrimidinone .
Compounds of the invention may be shown to have anti-inflammatory properties in animal models of inflammation, including carageenan paw edema, collagen induced arthritis and adjuvant arthritis, such as the carageenan paw edema model (C. A. Winter et al Proc. Soc. Exp. Biol. Med. (1962) vol 111, p 544; K. F. Swingle, in R. A. Scherrer and M. W. Whitehouse, Eds., Antiinflammatory Agents, Chemistry and Pharmacology, Vol. 13-11, Academic, New York, 1974, p. 33) and collagen induced arthritis (D. E. Trentham et al J. Exp. Med. (1977) vol. 146, p 857; J. S. Courtenay, Nature (New Biol.) (1980), Vol 283, p 666).
"5I-Glucagon Binding Screen with CHO/hGLUR Cells
The assay is described in WO 97/16442, which is incorporated herein by reference in its entirety. Reagents The reagents can be prepared as follows: (a) prepare fresh IM o-Phenanthroline (Aldrich) (198.2 mg/ml ethanol); (b) prepare fresh 0.5M DTT (Sigma); (c) Protease Inhibitor Mix (1000X) : 5 mg leupeptin, 10 mg benzamidine, 40 mg bacitracin and 5 mg soybean trypsin inhibitor per ml DMSO and store aliquots at -20°C; (d) 250 μM human glucagon (Peninsula): solubilize 0.5 mg vial in 575 μl 0. IN acetic acid (1 μl yields 1 μM final concentration in assay for non-specific binding) and store in aliquots at -20°C; (e) Assay Buffer: 20mM Tris (pH 7.8), 1 mM DTT and 3 mM o-phenanthroline; (f) Assay Buffer with 0.1% BSA (for dilution of label only; 0.01% final in assay) : 10 μl 10% BSA (heat-inactivated) and 990 μl Assay Buffer; (g) 125I-Glucagon (NEN, receptor- grade, 2200 Ci/mmol) : dilute to 50,000 cpm/25 μl in assay buffer with BSA (about 50pM final concentration in assay) .
Harvesting of CHQ/hGLUR Cells for Assay 1. Remove media from confluent flask then rinse once each with PBS (Ca, Mg-free) and Enzyme-free
Dissociation Fluid (Specialty Media, Inc.).
2. Add 10 ml Enzyme-free Dissoc. Fluid and hold for about 4 min. at 37°C. 3. Gently tap cells free, triturate, take aliquot for counting and centrifuge remainder for 5 min. at 1000 rpm.
4. Resuspend pellet in Assay Buffer at 75000 cells per 100 μl . Membrane preparations of CHO/hGLUR cells can be used in place of whole cells at the same assay volume.
Final protein concentration of a membrane preparation is determined on a per batch basis.
Assay The determination of inhibition of glucagon binding can be carried out by measuring the reduction of I125- glucagon binding in the presence of compounds of Formula
I. The reagents are combined as follows:
Compound/ 125 —
250 μM CHO/hGLUR
Vehicle Glucagon Glucagon Cells
Total —/5 μl -- 25 μl 100 μl
Binding
+ 5 μl/— -- 25 μl 100 μl
Compound
Nonspecif —/5 μl 1 μl 25 μl 100 μl ic
Binding
The mixture is incubated for 60 min. at 22°C on a shaker at 275 rpm. The mixture is filtered over pre-soaked (0.5% polyethylimine (PEI)) GF/C filtermat using an Innotech Harvester or Tomtec Harvester with four washes of ice-cold 20mM Tris buffer (pH 7.8). The radioactivity in the filters is determined by a gamma- scintillation counter. Thus, compounds of the invention may also be shown to inhibit the binding of glucagon to glucagon receptors .
Cyclooxygenase Enzyme Activity Assay The human monocytic leukemia cell line, THP-1, differentiated by exposure to phorbol esters expresses only COX-1; the human osteosarcoma cell line 143B expresses predominantly COX-2. THP-1 cells are routinely cultured in RPMI complete media supplemented with 10% FBS and human osteosarcoma cells (HOSC) are cultured in minimal essential media supplemented with 10% fetal bovine serum (MEM-10%FBS) ; all cell incubations are at 37°C in a humidified environment containing 5% C02.
COX-1 Assay
In preparation for the COX-1 assay, THP-1 cells are grown to confluency, split 1:3 into RPMI containing 2% FBS and 10 mM phorbol 12-myristate 13-acetate (TPA) , and incubated for 48 hours on a shaker to prevent attachment. Cells are pelleted and resuspended in Hank's Buffered Saline (HBS) at a concentration of 2.5 x 106 cells/mL and plated in 96-well culture plates at a density of 5 x 105 cells/mL. Test compounds are diluted in HBS and added to the desired final concentration and the cells are incubated for an additional 4 hours. Arachidonic acid is added to a final concentration of 30 mM, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.
COX-2 Assay For the COX-2 assay, subconfluent HOSC are trypsinized and resuspended at 3 x 106 cells/mL in MEM- FBS containing 1 ng human IL-lb/mL, plated in 96-well tissue culture plates at a density of 3 x 104 cells per well, incubated on a shaker for 1 hour to evenly distribute cells, followed by an additional 2 hour static incubation to allow attachment. The media is then replaced with MEM containing 2% FBS (MEM-2%FBS) and 1 ng human IL-lb/mL, and the cells incubated for 18-22 hours. Following replacement of media with 190 mL MEM, 10 L of test compound diluted in HBS is added to achieve the desired concentration and the cells incubated for 4 hours . The supernatants are removed and replaced with MEM containing 30 mM arachidonic acid, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.
COX Activity Determined
After incubation with arachidonic acid, the reactions are stopped by the addition of 1 N HCl, followed by neutralization with 1 N NaOH and centrifugation to pellet cell debris. Cyclooxygenase enzyme activity in both HOSC and THP-1 cell supernatants is determined by measuring the concentration of PGE2 using a commercially available ELISA (Neogen #404110) . A standard curve of PGE2 is used for calibration, and commercially available COX-1 and COX-2 inhibitors are included as standard controls.
Accordingly, the compounds of the invention or a pharmaceutical composition thereof are useful for prophylaxis and treatment of rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS) ; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis ; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; Alzheimer's disease; stroke; myocardial infarction; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2) , and herpes zoster, all of which are sensitive to TNF-α and/or IL-1 inhibition or glucagon antagonism, will also be positively effected by the compounds and methods of the invention. The compounds of the present invention also may possess analgesic properties and may be useful for the treatment of pain disorders, such as hyperalgesia due to excessive IL-1. The compounds of the present invention may also prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway, including cyclooxygenase (WO 96/03387, incorporated herein by reference in its entirety) .
Because of their ability to lower TNF-α and IL-1 concentrations or inhibit glucagon binding to its receptor, the compounds of the invention are also useful research tools for studying the physiology associated with blocking these effects.
The methods of the invention comprise administering an effective dose of a compound of the invention, a pharmaceutical salt thereof, or a pharmaceutical composition of either, to a subject (i.e., an animal, preferably a mammal, most preferably a human) in need of a reduction in the level of TNF-α, IL-1, IL-6, and/or IL-8 levels and/or reduction in plasma glucose levels and/or which subject may be suffering from rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; osteoarthritis ; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS) ; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; Alzheimer's disease; stroke; myocardial infarction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection, or which subject is infected by HIV-1, HIV-2, HIV-3 , cytomegalovirus (CMV) , influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), or herpes zoster.
In another aspect, this invention comprises the use of a compound of the invention, or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment either acutely or chronically of a TNF-α, IL-lβ, IL-6, and/or IL-8 mediated disease state, including those described previously. Also, the compounds of this invention are useful in the manufacture of a analgesic medicament and a medicament for treating pain disorders, such as hyperalgesia. The compounds of the present invention also are useful in the manufacture of a medicament to prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway. In still another aspect, this invention provides a pharmaceutical composition comprising an effective TNF- α, IL-lβ, IL-6, and/or IL-8 lowering amount and/or effective plasma glucose level lowering amount of a compound of the invention and a pharmaceutically acceptable carrier or diluent, and if desired other active ingredients. The compounds of the invention are administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to arrest the progress or prevent tissue damage associated with the disease are readily ascertained by one of ordinary skill in the art using standard methods.
For the treatment of TNF-α, IL-lβ, IL-6, and IL-8 mediated diseases and/or hyperglycemia, the compounds of the present invention may be administered orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.
The dosage regimen for treating a TNF-α, IL-1, IL- 6, and IL-8 mediated diseases and/or hyperglycemia with the compounds of this invention and/or compositions of this invention is based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. Dosage levels of the order from about 0.01 mg to 30 mg per kilogram of body weight per day, preferably from about 0.1 mg to 10 mg/kg, more preferably from about 0.25 mg to 1 mg/kg are useful for all methods of use disclosed herein.
The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.
For oral administration, the pharmaceutical composition may be in the form of, for example, a capsule, a tablet, a suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg, more preferably from about 5 to 150 mg . A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.
The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water. The daily parenteral dosage regimen will be from about 0.1 to about 30 mg/kg of total body weight, preferably from about 0.1 to about 10 mg/kg, and more preferably from about 0.25 mg to 1 mg/kg.
Injectable preparations, such as sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known are using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1, 3-butanediol . Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides . In addition, fatty acids such as oleic acid find use in the preparation of injectables .
Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable non- irritating excipient such as cocoa butter and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug. A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e . g. , from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.
Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e.g., liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose.
For administration, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinyl- pyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art . The pharmaceutical compositions may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions) . The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings. Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.
Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of the invention can likewise be obtained by using active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.
The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. The salts include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hyroxy-ethanesulfonate, lactate, maleate, methansulfonate, nicotinate, 2- naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 2-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate. Also, the basic nitrogen- containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
Examples of acids that may be employed to from pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents can be given as a single composition. The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims. From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula
Figure imgf000193_0001
or a pharmacutically acceptable salt thereof, wherein
wherein Ri and R2 are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0- 3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Ri and R2 is 0-4;
wherein each Z is independently a (1) bond;
(2) alkyl, alkenyl or alkynyl radical optionally substituted by (a) 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, halo, alkyl or haloalkyl; (3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl; each Y is independently a
( 1 ) hydrogen radical ;
(2) halo or nitro radical; (3) -C(0)-R2o or -C(NR5)-NR5R2ι radical;
(4) -OR21, -0-C(0)-R2ι, -0-C(0)-NR5R2l or -0-C (0) -NR2 - S(O)2-R20 radical;
(5) -SR21, -S(O)-R20r -S(O) 2-R20. ~S (0) 2-NR5R21 , -S(0)2- NR2 -C(0)-R2l, -S(0)2-NR22-C(0)-OR2o or -S (0) 2-NR22-C (0) - NR5R21 radical; or
(6) -NR5R21, -NR22-C(0)-R2ι, -NR22-C(O)-OR20- -NR2 -C(0)- NR5R21, -NR22-C(NR5)-NR5R2i, -NR22-S (0) 2-R20 or -NR22- S(0)2- R5R2i radical;
wherein each R5 is independently
(1) hydrogen radicals;
(2) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, -S03H or halo; or
(3) aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; and
wherein each R20 is independently (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, N-
(alkoxycarbonyl ) -N- (alkyl ) amino , aminocarbonylamino , alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo or aralkoxy, aralkylthio, aralkylsulfonyl, cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkanoyl", hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo, alkyl or haloalkyl;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, halo, azido, alkyl or haloalkyl;
each R21 is independently hydrogen radical or R20;
each R22 is independently
( 1) hydrogen radical ;
(2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; or
(3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino , alkanoylamino , alkoxycarbonylamino , alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; provided when Z is a bond and Y is -NR22- C(0)-NH2, then R22 is other then an optionally substituted aryl radical; and
Rll and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of (1) R30;
(2) halo or cyano radicals; (3) -C(O)-R30, -C(0)-OR29, ~C (0) -NR3ιR32 or -C(NR3i)- NR31R32 radicals;
(4) -OR29, -0-C(0)-R29, -0-C(0)-NR3ιR32 or -0-C (0) -NR33- S(O)2-R30 radicals; (5) -SR29, -S(O)-R30, -S(O)2-R30r -S(0)2-NR3ιR32, -S(0)2- NR33-C(O)-R30, -S(O)2-NR33-C(O)-OR30 or -S (0) 2-NR33-C (0) - NR3ιR32 radicals; or
(6) -NR3ιR32, -NR33-C(0)-R29, -NR33-C (0) -OR30 , -NR33-C(0)- NR31R32 -NR33-C(NR3ι)-NR3ιR32, -NR33-S (0) -R30 or -NR33- S (0) 2-NR31R32 radicals; provided that (1) Rn is other than a 4-pyridyl, 4- pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rn and R12 is 0-1;
wherein each R30 is independently
(1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of -NR31R31, -C02R23/ hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo or aralkoxy, aralkylthio, aralkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;
each R29 is independently hydrogen radical or R30;
each R31 and R32 are each independently
(1) hydrogen radicals;
(2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
(3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; and
wherein each R33 is independently
( 1 ) hydrogen radical ; or
(2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; and
provided that ( 1 ) when R1 and R12 are the same and are a 5- or 6-member ring having from 1-3 heteroatoms independently selected from N, S, and 0, to which ring a benzene ring is optionally fused, R11 is phenyl or naphthyl optionally substituted with halo, C^Cg alkyl, Cx-C4 alkoxy, C1-C4 alkylthiol, hydroxy, amino, C1-C4 alkylamino, or dialkylamino, or R11 is a 5- or 6-membered ring having from 1-3 heteroatoms independently selected from N, S, and 0, to which ring a benzene ring is optionally fused and optionally substituted with C1-C6 alkyl, then R2 is other than OH or NH2; (2) when R2 is H, R11 is phenyl and R12 is phenyl or 4-pyridyl, then R1 is other than H, methyl, or amino; (3) when R2 is H, R11 is 2-methylphenyl and R12 is 2-pyridyl, then R1 is other than n-propyl; and (4) when R11 and R12 are each an optionally substituted phenyl radical, then R1 is other than an optionally substituted 2-pyridyl radical.
2. The compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein
wherein Ri and R2 are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0- 3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Ri and R2 is 0-4;
each Z is independently a
(1) bond;
(2) C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl radical optionally substituted by (a) 1-3 radicals of amino, Ci- C4 alkylamino, di-(Cι~C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; (3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each Y is independently a
(1) hydrogen radical;
(2) halo or nitro radical; (3) -C(O)-R20 or -C (NR5) -NR5R21 radical;
(4) -OR21, -0-C(0)-R2l, -0-C(0)-NRR l or -O-C (0) -NR22- S(O)2-R20 radical;
(5) -SR21, -S(O)-R20, -S(O) 2-R20, -S(0) 2-NR5R21, -S(0)2- NR2 -C(0)-R2l, -S(O)2-NR22-C(O)-OR20 or -S (0) 2-NR22-C (0) - NR5R2ι radical; or
(6) -NR5R21, -NR22-C(0)-R2ι, -NR22-C(O)-OR20, -NR22-C(0)- NR5R21, -NR22-C(NR5 )-NR5R21, -NR22~S (0) 2-R20 or -NR22" S(0)2-NR5R2i radical;
each R5 is independently
(1) hydrogen radicals;
(2) C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (Cι-C4-alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, -S03H or halo; or
(3) aryl, heteroaryl, aryl-Cι-C4-alkyl, heteroaryl-Ci- C4-alkyl, heterocyclyl, heterocyclyl-Cι-C4-alkyl, C3-Cs cycloalkyl or C3-C8-cycloalkyl-Cι-C4-alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (Cι-C4-alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each R20 is independently (1) Ci-Cβ alkyl, C2-C8 alkenyl or C2-Cs alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N- ( (C1-C4 alkoxy) carbonyl) - N- (C1-C4 alkyl) amino, aminocarbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-Cι-C4-alkoxy, aryl-Cι-C4-alkylthio, aryl-Ci- C4-alkylsulfonyl, C3-C8 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C4 haloalkyl of 1- 3 halo radicals;
each R21 is independently hydrogen radical or R20; each R22 is independently
(1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; provided when Z is a bond and Y is -NR22-C (0) -NH2 , then R22 is other then an optionally substituted aryl radical;
Rll and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of (1) R3o; (2) halo or cyano radicals;
(3) -C(O)-R30, -C(0)-OR29, -C(0)-NR3ιR32 or -C(NR3ι)- NR3iR32 radicals;
(4) -OR29, -0-C(0)-R29, -0-C(0)-NR3ιR32 or -O-C (0) -NR33- S(O)2-R30 radicals; (5) -SR29, -S(O)-R30, -S(O)2-R30» -S (0) 2-NR3ιR32 , ~S(0)2- NR33-C(O)-R30, -S(O)2-NR33-C(O)-OR30 or -S (0) 2-NR33-C (0) - NR3ιR32 radicals; or
(6) -NR31R32, -NR33-C(0)-R29, -NR33-C (0) -OR30 , -NR33-C(0)- NR3ιR32, -NR33-C(NR3ι)-NR3ιR32, -NR33-S (0) 2- 30 or -NR33- S(0) 2- R3ιR32 radicals; provided that (1) Rn is other than a 4-pyridyl, 4- pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rn and Rι2 is 0-1;
each R3o is independently
(1) C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl radicals optionally substituted by 1-3 radicals of -NR3ιR3ι, -
C0 R 3, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo or aryl- Cι-C4-alkoxy, aryl-Cι-C4-alkylthio, aryl-Cι-C4~ alkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι~C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or Cι~ C4 haloalkyl of 1-3 halo radicals; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each R29 is independently hydrogen radical or R30; each R3ι and R32 are each independently
(1) hydrogen radicals;
(2) C1-C4 alkyl radical optionally substituted by an C3- Cδ cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(3) aryl, heteroaryl, heterocyclyl or C3-Cs cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; and
each R 3 is independently (1) hydrogen radical; or (2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or Ci- C4 haloalkyl of 1-3 halo radicals; and
wherein heterocyclyl is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic or bicyclic aromatic heterocyclic ring system having 5-6 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C3-C4-carbocyclic-fused.
3. The compound of Claim 2 or a pharmaceutically acceptable salt thereof, wherein
each Z is independently a (1) bond;
(2) Ci-Cδ alkyl, C2-C8 alkenyl or C2-Cs alkynyl radical optionally substituted by (a) 1-3 radicals of amino, Cι~ C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; each R5 is independently
( 1 ) hydrogen radicals ;
(2) C1-C4 alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (Cι-C4-alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, -S03H or halo; or
(3) aryl, heteroaryl, aryl-Cι-C4-alkyl, heteroaryl-Ci- C4-alkyl, heterocyclyl, heterocyclyl-Cι-C4-alkyl, C3-Cβ cycloalkyl or C3-C8-cycloalkyl-Cι-C4-alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (Cι-C4-alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each R20 is independently
(1) Ci-Cβ alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((Cι-C4 alkoxy) carbonyl) - N-(Cι-C4 alkyl)amino, aminocarbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-Cι-C4-alkoxy, aryl-Cι-C4-alkylthio, aryl-Ci- C4-alkylsulfonyl, C3-Cs cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each R21 is independently hydrogen radical or R20;
each R3o is independently
(1) C1-C4 alkyl radical optionally substituted by 1-3 radicals of
(a) -NR31R31;
(b) C1-C4 alkoxy-carbonyl or phenoxycarbonyl or phenylmethoxycarbonyl optionally substituted by 1-3 radicals of amino, alkylamino, di- (Cι-C4~alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl ; or
(c) hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, or phenyl-Ci- C4-alkoxy, phenyl-Cι~C4-alkylthio, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) C1-C4 haloalkyl of 1-3 halo radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R30;
each R31 is independently
(1) hydrogen radicals; or
(2) C1-C4 alkyl radical optionally substituted by an phenyl or heteroaryl radical optionally substituted by
1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or trifluoromethyl radicals; and
each R32 is independently
(1) hydrogen radicals;
(2) C1-C4 alkyl radical optionally substituted by an C3- C6 cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(3) aryl, heteroaryl, heterocyclyl or C3-C6 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; and
each R33 is independently hydrogen or C1-C4 alkyl radical.
4. The compound of Claim 3 or a pharmaceutically acceptable salt thereof, wherein
wherein Ri is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Ri is 0-3;
Z is a
( 1 ) bond;
(2) C1-C8 alkyl or C2-C8 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
(3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(Cι~C4 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl radicals; or
(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
Y is a (1) hydrogen radical; (2) halo radical; (3) -C(0)-R2o or -C(NR5)-NR5R2i radical;
(4) -OR21-, -0-C(0)-R2ι or -O-C(O) -NR5R21 radical;
(5) -SR21, -S(O)-R20, -S(O)2-R20 or -S (0) 2-NR5R2ι radical; or (6) -NR5R21, -NR2 -C(0)-R2ι, -NR22-C(0)-OR2o, -NR22-C(0)- NR5R2I- -NR22-C(NR5 )-NR5R2i, -NR22~S (0) 2-R20 or -NR22" S(0)2~NR5R2l radical;
each R5 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, di-(Cι-C4- alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, - SO3H or halo; or (3) phenyl-Cι-C2-alkyl, heteroaryl-Cι-C2-alkyl, heterocyclyl-Cι-C2-alkyl or C3-C6-cycloalkyl-Cι-C2-alkyl radicals optionally substituted by 1-3 radicals of amino, di- (Cι~C4-alkyl) amino, hydroxy, C1-C4 alkoxy, Ci- C4 alkylthio, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
each R20 i independently
(1) C1-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((Cι-C4 alkoxy) carbonyl) -N- (Ci- C4 alkyl) amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-Cι-C4-alkoxy, aryl-Cι-C4- alkylthio, aryl-Cι-C4~alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or Cι-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C2 haloalkyl of 1- 3 halo radicals;
each R21 is independently hydrogen radical or R2o;
each R22 is independently (1) hydrogen radical; or (2) C1-C4 alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, Ci- C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
R is a radical of hydrogen, C1-C4 alkyl, halo, hydroxy, C1-C4 alkoxy, Cι-C2 haloalkoxy of 1-3 halo radicals, thiol, C1-C4 alkylthio, aminosulfonyl, C1-C4 alkylaminosulfonyl, di- (C1-C4 alkyl) aminosulfonyl, amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino or C1-C2 haloalkyl of 1-3 halo radicals; Rll and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of
(1) R3o;
(2) halo or cyano radicals; (3) -C(O)-R30, -C(0)-OR29, -C (0) -NR31R32 or -C(NR3ι)- NR3ιR32 radicals; or
(4) -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(0)2-NR3ιR32, -NR3ιR32, -NR33-C(0) -R29 or -NR33-C (0) -OR3o radicals; provided that (1) Rn is other than a 4-pyridyl, 4- pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rn and R12 is 0-1;
each R3o is independently
(1) C1-C4 alkyl radical optionally substituted by (a) amino, C1-C4 alkylamino or di- (Cι-C4-alkyl) amino radicals; or (b) hydroxy, C1-C4 alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) C1-C2 haloalkyl of 1-3 halo radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R2g is independently hydrogen radical or R3Q; each R31- is independently hydrogen or C1-C4 alkyl radicals; and
each R32 is independently
(1) hydrogen radicals;
(2) C1-C4 alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or
(3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; and
each R33 is independently hydrogen or methyl radical; and
wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C3-C4-carbocyclic-fused.
5. The compound of Claim 4 or a pharmaceutically acceptable salt thereof, wherein Z is a
( 1 ) bond;
(2) C1-C4 alkyl or C2-C5 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, di- (C1-C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals ; (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(Cι-C2 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or C1-C4 alkyl radicals; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, Ci- C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R5 is independently
(1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by 1-3 radicals of amino, di- (Cι-C2-alkyl) amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo; or (3) phenyI-C1-C2-alkyl, heteroaryl-Cι-C2-alkyl, heterocyclyl-Cι-C2-alkyl or C3-C6-cycloalkyl-Cι-C2-alkyl radicals optionally substituted by 1-3 radicals of amino, di- (Cι-C2-alkyl) amino, hydroxy, C1-C2 alkoxy, Cι~ C2 alkylthio, methoxy, methylthio, C1-C4 alkyl or trifluoromethyl radicals; each R22 is independently hydrogen or C1-C4 alkyl radical ;
Rn is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of
(1) R3o;
(2) halo or cyano radicals; (3) -C(O)-R30, -C(0)-OR29, -C (0) -NR3iR32 or -C(NR3i)-
NR3ιR32 radicals; or
(4) -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(0)2-NR3iR32,
-NR3ιR32 or -NR3 -C(0) -R29 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rn and R12 is 0-1;
each R30 is independently
(1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di-(Cι~C2 alkyl) amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R30; and
each R32 is independently
(1) hydrogen radicals;
(2) C1-C4 alkyl radical or Cι-C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cι-C alkyl) amino, acetamido, hydroxy, C1-C2 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or
(3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di- (C1-C2 alkyl) amino, acetamido, hydroxy, C1-C2 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; and
wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused.
6. The compound of Claim 5 or a pharmaceutically acceptable salt thereof, wherein
wherein Ri is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Ri is 0-2;
Z is a
(1) bond;
(2) C1-C4 alkyl or C2-C5 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, di- (C1-C2 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo, and (b) 1-2 radicals of aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di-(Cι-C2 alkyl) amino, acetamido, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals;, or
(3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di- (C1-C2 alkyl) amino, acetamido, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
Y is a (1) hydrogen radical;
(2) -C(0)-R2o radical;
(3) -OR21, -SR21, -S(O)-R20, -S(O)2-R20 or -S (0) 2-NR5R2l radical; or
(4) -NR5R21, -NR22-C(0)-R2ι, -NR22-C(O)-OR20, -NR22-C(0)- NR5R21, -NR22-S(O)2-R20 or -NR22~S (0) 2-NR5R21 radical;
each R5 is independently
( 1 ) hydrogen radical ;
(2) C1-C4 alkyl radical optionally substituted by 1-3 halo radicals; or
(3) phenyl-Cι-C2-alkyl or heteroaryl-Cι-C2-alkyl, radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals;
each R2o i independently
(1) C1-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((Cι-C4 alkoxy) carbonyl) -N- (Cι~ C4 alkyl) amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-Cι-C4-alkoxy, aryl-Cι-C4- alkylthio, aryl-Cι-C4-alkylsulfonyl, C3-Cδ cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or Cι-C2 haloalkyl of 1-3 halo radicals; (2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di- (C1-C4 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, acetamido, (C1-C4 alkoxy) carbonylamino, Ci- C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;
each R2ι is independently hydrogen radical or R2o;
R is a radical of hydrogen, C1-C4 alkyl, halo, hydroxy, C1-C4 alkoxy, trifluoromethoxy, thiol, C1-C4 alkylthio, amino, C1-C4 alkylamino, di-(Cι~C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino or trifluoromethyl;
Rn is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of
(1) R30;
(2) halo or cyano radicals; or
(3) -C(0)-NR3lR32, -OR29, -SR29, -S(O)-R30, -S(O)2-R30, " S(0) -NR3iR3 , -NR31R32 or -NR33-C (0) -R g radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rn and R12 is 0-1;
each R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
each R2g is independently hydrogen radical or R30;
each R31 is independently hydrogen, methyl or ethyl radicals; and
each R32 is independently
(1) hydrogen radicals;
(2) C1-C4 alkyl radical or Cι~C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; or
(3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
7. The compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein
Rll is an aryl radical optionally substituted by 1-2 radicals of (1) R30; (2) halo or cyano radicals; or
(3) -C(0)-NR3ιR32, -OR29, -SR29, -S(O)-R30, -S(O) 2-R30, - S(0)2-NR3ιR32, -NR31R32 or -NR33-C(0)-R29 radicals; and Rl2 is a heteroaryl radical optionally substituted by 1- 2 radicals of (1) R30; (2) halo or cyano radicals; or
(3) -C(0)-NR3ιR32, -OR29/ -SR29, -NR3iR32 or -NR33-C(0)- R29 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rn and R12 is 0-1;
R30 is independently
(1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals ;
(2) trifluoromethyl radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
R2g is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and
R32 is independently (1) hydrogen or C1-C4 alkyl radical; or
(2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
8. The compound of Claim 7 or a pharmaceutically acceptable salt thereof, wherein wherein Ri is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Ri is 0-1;
Z is a
(1) bond; or
(2) C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, di- (C1-C2 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C1-C2 alkoxy, Cι-C2 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R5 is independently hydrogen or C1-C4 alkyl radical ;
each R2o is independently (1) C1-C8 alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N- ( (C1-C4 alkoxy) carbonyl) -N- (Ci- C4 alkyl) amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di-(Cι~C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or Cι~ C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (C1-C4 alkoxy) carbonyl , amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;
each R21 is independently hydrogen radical or R2o;
R2 is a radical of hydrogen, methyl, ethyl, fluoro, chloro, hydroxy, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino, acetylamino or trifluoromethyl;
Rn is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and
R12 is a heteroaryl radical optionally substituted by 1- 2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals .
9. The compound of Claim 8 or a pharmaceutically acceptable salt thereof, wherein
Z is a (1) bond; or
(2) C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
Y is a
(1) hydrogen radical; (2) -C(0)-R2o radical;
(3) -OR2ι, -SR21, -S(O)-R20, -S(O)2-R20 or -S (0) 2-NR5R21 radical; or
(4) -NR5R21, -NR22-C(0)-R2ι or -NR22-S (0) 2-R2o radical;
R5 is a hydrogen radical;
each R2o is independently
(1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, t- butoxycarbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of hydroxy or C1-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
each R2ι is independently hydrogen radical or R20;
each R22 is independently hydrogen or methyl radical;
Rn is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and Rl2 is a 4-pyridyl, 4-quinolinyl , 4-imidazolyl or 4- pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.
10. The compound of Claim 9 or a pharmaceutically acceptable salt thereof, wherein
Y is a
(1) -C(O)-R20 radical;
(2) -OR2ι, -SR21, -S(0)-R2o, -S(O)2-R20 or -S (0) 2-NR5R2i radical; or
(3) -NR5R21, -NR22-C(0)-R2ι or -NR22-S (0) 2-R20 radical;
each R2o is independently
(1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, t- butoxycarbonylamino , N- ( ( t-butoxy) carbonyl ) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals; and
each R21 is independently hydrogen radical or R2o-
11. The compound of Claim 10 or a pharmaceutically acceptable salt thereof, wherein Y is a -OR21, -SR21 or -NR5R21 radical;
each R20 is independently (1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, hydroxy or phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
each R21 is independently hydrogen radical or R2o;
Rll is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl, methyl or trifluoromethyl radicals; and
R12 is a 4-pyridyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.
12. The compound of Claim 1 which is:
5- (4-Fluorophenyl) -2- (4-pyridyl) -4- (4-pyridyl) - pyrimidine, 5- (4-Fluorophenyl) -2- (2-methylthiazol-4-yl) -4- (4- pyridyl) -pyrimidine, 5- (4-Fluorophenyl) -4- (4-pyridyl) -2- (2-thienyl) - pyrimidine,
2- (2-Diethylaminoethylamino) -5- (4-fluorophenyl) -4- (4- pyridyl) -pyrimidine, 2- (4-Aminobutylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine,
2- (2 , 6-Dichlorobenzyl) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine,
2- (2 , 6-Dichlorophenylamino) -5- (4-fluorophenyl) -4- (4- pyridyl) -pyrimidine,
2- (2 , 6-Dimethylphenylamino) -5- (4-fluorophenyl) -4- (4- pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2- (2-methoxyphenylamino) -4- (4- pyridyl) -pyrimidine, 5- (4-Fluorophenyl) -2- (4-fluorophenylamino) -4- (4- pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2-phenylthiomethyl-4- (4-pyridinyl) - pyrimidine,
2- (2- (4-Aminophenyl) ethyl-amino) -5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine,
2- (2- (2-Chlorophenyl) ethyl-amino) -5- (4-fluorophenyl) -4-
(4-pyridyl) -pyrimidine,
2- (2- (4-Chlorophenyl) ethyl-amino) -5- (4-fluorophenyl) -4-
(4-pyridyl) -pyrimidine, 2- (2- (3 -Chlorophenyl) ethyl-amino) -5- (4-fluorophenyl) -4-
(4-pyridyl) -pyrimidine ,
2- (2- (2, 4-Dichlorophenyl) ethyl-amino) -5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine,
2- (2- (4-Bromophenyl) ethyl-amino) -5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2- (2- (2-methoxyphenyl) ethyl-amino) -4-
(4-pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2- (2- (3-methoxyphenyl) ethyl-amino) -4-
(4-pyridyl) -pyrimidine, 5- (4-Fluorophenyl) -2- ( (1-methyl-3-phenylpropyl) -amino) -
4- (4-pyridyl) -pyrimidine, 5- (4-Fluorophenyl) -2- ( (4-phenyl-butyl) -amino) -4- (4- pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2-morpholino-4- (4-pyridyl) - pyrimidine, 5- (4-Fluorophenyl) -4- (4-pyridyl) -2- (2- pyrrolidinoethylamino) -pyrimidine,
5- (4-Fluorophenyl) -2- (2-morpholinoethylamino) -4- (4- pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2- (2-piperidinoethylamino) -4- (4- pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2- (3- (2-pyrrolidinon-l-yl)propyl- amino) -4- (4-pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2- (2-phenoxyethyl) thio-6- (4-pyridyl) - 4-hydroxy-pyrimidine, 5- (4-Fluorophenyl) -2- (2-phenylaminoethyl) thio-6- (4- pyridyl) -4-hydroxy-pyrimidine,
2- (2-Aminoethylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine,
2- (3-Aminopropylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine,
2- (Benzylamino) -5- (4-fluorophenyl) -4- (4-pyridyl) - pyrimidine,
5- (4-Fluorophenyl) -2- (2-phenylethylamino) -4- (4-pyridyl) - pyrimidine, 5- (4-Fluorophenyl) -2- (N-methyl-N- (2-phenylethyl) -amino) - 4- (4-pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2- (2-hydroxy-2-phenyl-ethyl) amino-4- (4-pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2- (2- (4-hydroxyphenyl) ethyl-amino) -4- (4-pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2- (2- (4-fluorophenyl) ethyl-amino) -4- (4-pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2- (2- (2-fluorophenyl) ethyl-amino) -4- (4-pyridyl) -pyrimidine, 5- (4-Fluorophenyl) -2- ( (3-phenylpropyl ) -amino) -4- (4- pyridyl) -pyrimidine, 2- ( (2 (S) -Amino-3-phenylpropyl) -amino) -5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine,
5- (4-Fluorophenyl) -2- (2-phenylaminoethylamino) -4- (4- pyridyl) -pyrimidine, 5- (4-Fluorophenyl) -2- ( (3-imidazolylpropyl) -amino) -4- (4- pyridyl ) -pyrimidine ,
5- (4-Fluorophenyl) -4- (4-pyridyl) -2-pyrrolidino- pyrimidine,
5- (4-Fluorophenyl) -2- (1-piperazinyl) -4- (4-pyridyl) - pyrimidine,
2- (2, 6-Dichlorobenzyl) -5- (4-fluorophenyl) -6- (4-pyridyl) -
4-hydroxy-pyrimidine,
5- (4-Fluorophenyl) -2- (2-phenylethyl) thio-6- (4-pyridyl) -
4-hydroxy-pyrimidine, 5- (4-Fluorophenyl) -2- ( 3-phenylpropyl ) thio-6- (4-pyridyl) -
4-hydroxy-pyrimidine,
2- (2- (2-Chlorophenyl) ethyl-amino) -5- (4-fluorophenyl) -6- (4-pyridyl) -4-hydroxy-pyrimidine,
5- (4-Fluorophenyl) -2- ( (3-phenylpropyl ) -amino) -6- (4- pyridyl) -4-hydroxy-pyrimidine,
5- (4-Fluorophenyl) -2- ( (l-methyl-3 -phenylpropyl) -amino) - 6- (4-pyridyl) -4-hydroxy-pyrimidine,
2- (2- (2-Chlorophenyl) ethyl-amino) -5- (4-fluorophenyl) -6- (4-pyridyl) -4-hydroxy-pyrimidine, 2- ( (S) -2-Amino-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine, 2- ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine, 2- ( (S) -2 -N, N-Dimethylamino-3-phenylpropyl) -amino) -5- (4- fluorophenyl) -4- (4-pyridyl) -pyrimidine,
2- ( (S) -2 -N, N-Dimethylamino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine,
2- ( (3-Amino-3-phenylpropyl) -amino) -5- (4-fluorophenyl) -4- (4-pyridyl) -pyrimidine, 2- ( (3-Amino-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine, 2- ( (3-Amino-3- (2-fluorophenyl) propyl) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine,
2- ( (3-Amino-3-phenylpropyl) -amino) -5- (3-methylphenyl) -4-
(4-pyridyl) -pyrimidine, 2- ( (2-Amino-2-methyl-3 -phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine,
2- ( (3-Hydroxy-3-phenylpropyl) -amino) -5- (3-methylphenyl) -
4- (4-pyridyl) -pyrimidine,
2- ( ( (2S, 3S) -3-Amino-2-methyl-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine,
2- ( ( (2R, 3R) -3-Amino-2-methyl-3-phenylpropyl) -amino) -4- (4-pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine,
2- ( (S) -3-Benzylpiperazinyl) -4- (4-pyridyl) -5- (3- trifluoromethylphenyl) -pyrimidine, 4- (4-Pyridyl) -2- ( ( (S) -tetrahydroisoquinol-3- ylmethylen) amino) -5- (3-trifluoromethylphenyl) - pyrimidine,
5- (3-Methylphenyl) -4- (4-pyridyl) -2- ( ( (S) - tetrahydroisoquinol-3-ylmethylen) amino) -pyrimidine, 2- ( ( (S) -2 -N-Isopropylamino-3 -phenylpropyl ) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine, 2- ( ( (S) -2 -N-Cyclohexylamino-3-phenylpropyl) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine, 2- ( ( (S) -2 -N-Isopropylamino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine,
2- ( ( (S) -2 -N-Butylamino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine,
2- ( ( (S) -2 -N-Cyclohexylamino-3-phenylpropyl) -amino) -5- (3- methylpheny1) -4- (4-pyridyl) -pyrimidine, 5- (4-Fluorophenyl) -2- ( ( (S) -2-N-isopropylamino-3 - phenylpropyl) -amino) -4- (4-pyridyl) -pyrimidine, 5- (4-Fluorophenyl) -2- ( ( 3 -N-isopropylamino-3 - phenylpropyl) -amino) -4- (4-pyridyl) -pyrimidine, 2- ( ( (S) -2 -N-Glycylamino-3-phenylpropyl) -amino) -4- (4- pyridyl) -5- (3-trifluoromethylphenyl) -pyrimidine,
2- ( ( (S) -2 -N-Glycylamino-3-phenylpropyl) -amino) -5- (3- methylphenyl) -4- (4-pyridyl) -pyrimidine, 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3-chloro-4- fluorophenyl) -4- (4-pyridyl) -pyrimidine,
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3- fluorophenyl) -4- (4-pyridyl) -pyrimidine, 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (3- isopropylpheny1) -4- (4-pyridyl) -pyrimidine,
5- (3-Acetamidophenyl) -2- ( ( (S) -2-amino-3 -phenylpropyl) - amino) -4- (4-pyridyl) -pyrimidine,
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (4- chlorophenyl) -4- (4-pyridyl) -pyrimidine,
2- ( ( (S) -2-Amino-3 -phenylpropyl) -amino) -5- (benzothienyl) -
4- ( 4-pyridyl) -pyrimidine,
2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (2-naphthyl) -4-
( 4-pyridyl) -pyrimidine, or 2- ( ( (S) -2-Amino-3-phenylpropyl) -amino) -5- (4- fluorophenyl) -6- (4-pyridy) -4 (3H) pyrimidinone or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a compound of Claims 1 to 12 and a pharmaceutically acceptable carrier.
14. A method of prophylaxis or treatment of inflammation comprising administering an effective amount of a compound of Claims 1 to 12.
15. A method of prophylaxis or treatment of inflammation comprising administering an effective amount of a composition of Claim 13.
16. A method of prophylaxis or treatment of rheumatoid arthritis, Pagets disease, osteophorosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS) , psoriasis, Crohn's disease, allergic rhinitis,, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount of a compound of Claims 1-12.
17. A method of prophylaxis or treatment of rheumatoid arthritis, Pagets disease, osteophorosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount of a composition of Claim 13.
18. A method of lowering plasma concentrations of either or both TNF-a and IL-1 comprising administering an effective amount of a compound of Claims 1-12.
19. A method of lowering plasma concentrations of either or both TNF-a and IL-1 comprising administering an effective amount of a composition of Claim 13.
20. A method of lowering plasma concentrations of either or both IL-6 and IL-8 comprising administering an effective amount of a compound of Claims 1-12.
21. A method of lowering plasma concentrations of either or both IL-6 and IL-8 comprising administering an effective amount of a composition of Claim 13.
22. A method of prophylaxis or treatment of diabetes disease in a mammal comprising administering an effective amount of a compound according to claims 1 to 12 to produce a glucagon antagonist effect.
23. A method of prophylaxis or treatment of diabetes disease in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 13 to produce a glucagon antagonist effect .
24. A method of prophylaxis or treatment of a pain disorder in a mammal comprising administering an effective amount of a compound according to claims 1 to 12.
25. A method of prophylaxis or treatment of a pain disorder in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 13.
26. A method of decreasing prostaglandins production in a mammal comprising administering an effective amount of a compound according to claims 1 to 12.
27. A method of decreasing prostaglandins production in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 13.
28. A method of decreasing cyclooxygenase enzyme activity in a mammal comprising administering an effective amount of a compound according to claims 1 to 12.
29. The method of claim 28 wherein the cyclooxygenase enzyme is COX-2.
30. A method of decreasing cyclooxygenase enzyme activity in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 13.
31. The method of claim 30 wherein the cyclooxygenase enzyme is COX-2.
PCT/US1997/022390 1996-12-05 1997-12-04 Substituted pyrimidine compounds and their use WO1998024782A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP97954778A EP0948497A2 (en) 1996-12-05 1997-12-04 Substituted pyrimidine compounds and their use
IL13018097A IL130180A0 (en) 1996-12-05 1997-12-04 Substituted pyrimidine compounds and their use
KR1019997005021A KR20000069328A (en) 1997-06-13 1997-12-04 Substituted pyrimidine compounds and their use
AU60120/98A AU733877C (en) 1996-12-05 1997-12-04 Substituted pyrimidine compounds and their use
HU0001698A HUP0001698A3 (en) 1996-12-05 1997-12-04 Substituted pyrimidine compounds and their use
NZ335997A NZ335997A (en) 1996-12-05 1997-12-04 Substituted pyrimidine compounds for treating TNF and interleukin diseases
CA002274063A CA2274063C (en) 1996-12-05 1997-12-04 Substituted pyrimidine compounds and their use
JP52585098A JP2002514195A (en) 1996-12-05 1997-12-04 Substituted pyrimidine compounds and uses thereof
BR9713850-9A BR9713850A (en) 1996-12-05 1997-12-04 Compound, pharmaceutical composition, processes for prophylaxis or treatment of infection and diseases, to decrease plasma concentrations of either or both tnf-. and o; -1 of either or both il-6 and il-8, for the prophylaxis or treatment of diabetes disease and a pain disorder in a mammal, to decrease prostaglandin production in a mammal, and to decrease the activity of the enzyme cyclooxygenase in a mammal.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3212896P 1996-12-05 1996-12-05
US5095097P 1997-06-13 1997-06-13
US60/050,950 1997-11-21
US60/032,128 1997-11-21

Publications (2)

Publication Number Publication Date
WO1998024782A2 true WO1998024782A2 (en) 1998-06-11
WO1998024782A3 WO1998024782A3 (en) 1998-08-27

Family

ID=26708010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/022390 WO1998024782A2 (en) 1996-12-05 1997-12-04 Substituted pyrimidine compounds and their use

Country Status (4)

Country Link
JP (1) JP2002514195A (en)
AR (1) AR038955A1 (en)
TW (1) TW520362B (en)
WO (1) WO1998024782A2 (en)

Cited By (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065897A1 (en) * 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000018758A1 (en) * 1998-09-25 2000-04-06 Mitsubishi Chemical Corporation Pyrimidone derivatives
WO2000031065A1 (en) * 1998-11-20 2000-06-02 Merck & Co., Inc. Compounds having cytokine inhibitory activity
WO2001038311A2 (en) * 1999-11-26 2001-05-31 Glaxo Group Limited Pyrimidine derivatives as selective inhibitors of cox-2
WO2001047897A1 (en) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
WO2001058881A1 (en) * 2000-02-11 2001-08-16 Glaxo Group Limited Pyrimidine derivatives as selective inhibitors of cox-2
EP1136483A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidone derivatives
EP1136485A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo Aminophenyl pyrimidone derivatives
EP1136489A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperidin-1-yl]pyrimidone derivatives
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EP1136099A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors
EP1136493A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives
EP1136484A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Arylalkylamino)pyrimidone derivatives
EP1136491A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[(Heteroaryl)alkylamino]pyrimidone derivatives
EP1136486A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives
WO2001070728A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[nitrogen-heterocyclic]pyrimidone derivatives
WO2001070727A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
WO2002018374A1 (en) * 2000-09-01 2002-03-07 Glaxo Group Limited Substituted pyrimidines as selective cyclooxygenase-2 inhibitors
WO2002020495A2 (en) * 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6469018B1 (en) 1999-01-08 2002-10-22 Smithkline Beecham Corporation Compounds
WO2002096427A1 (en) * 2001-05-25 2002-12-05 Glaxo Group Limited Pyrimidine derivatives as selective inhibitors of cox-2
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
WO2003014091A1 (en) * 2001-08-09 2003-02-20 Glaxo Group Limited Pyrimidine derivatives as selective inhibitors of cox-2
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
WO2003035640A1 (en) * 2001-10-22 2003-05-01 Eisai Co., Ltd. Pyrimidone compounds and pharmaceutical compositions containing the same
WO2003035639A1 (en) * 2001-10-22 2003-05-01 Eisai Co., Ltd. Pyrimidine compound and medicinal composition thereof
WO2003037888A1 (en) * 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2003084935A2 (en) * 2002-04-10 2003-10-16 Orchid Chemicals & Pharmaceuticals Ltd Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
US6649641B2 (en) 1970-11-01 2003-11-18 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2003099808A1 (en) * 2002-05-21 2003-12-04 Amgen Inc. Substituted heterocyclic compounds and methods of use
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
WO2004069846A1 (en) * 2003-02-06 2004-08-19 Basf Aktiengesellschaft Pyrimidines, methods for the production thereof, and use thereof
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
WO2005007648A2 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
US6855709B2 (en) 2002-02-22 2005-02-15 Pharmacia & Upjohn Company Pyridyl sulfone derivatives
WO2005019202A1 (en) * 2003-08-20 2005-03-03 Amgen Inc. Substituted pyrimdinone derivatives and methods of use
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US7026327B2 (en) 2001-05-25 2006-04-11 Glaxo Group Limited Pyrimidine derivatives useful as selective COX-2 inhibitors
EP1707205A2 (en) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
EP1732541A2 (en) * 2004-04-07 2006-12-20 Takeda Pharmaceutical Company Limited Cyclic compounds
US7189717B2 (en) 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
CN1315832C (en) * 2002-02-28 2007-05-16 沙诺费－阿方蒂 Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropydimido[1,2-a]pyrimidin-4-one derivatives
US7235560B2 (en) 2002-08-19 2007-06-26 Glaxo Group Limited Pyrimidine derivative as selective COX-2 inhibitors
US7446117B2 (en) 2002-09-16 2008-11-04 Glaxo Group Limited Cox-2 inhibiting pyridine derivatives
US7449470B2 (en) 2003-10-03 2008-11-11 Universiteit Leiden Substituted pyrimidines as ligands of adenosine receptors
WO2008142031A1 (en) 2007-05-18 2008-11-27 Institut Curie P38alpha as a therapeutic target in bladder carcinoma
US7504411B2 (en) 2003-03-26 2009-03-17 Mitsubishi Tanabe Pharma Corporation 2,3,6-Trisubstituted-4-pyrimidone derivatives
US7572793B2 (en) 2001-09-21 2009-08-11 Mitsubishi Tanabe Pharma Corporation 3-Substituted-4-pyrimidone derivatives
US7589197B2 (en) 2005-06-14 2009-09-15 Taigen Biotechnology Pyrimidine compounds
WO2009131598A1 (en) * 2008-04-21 2009-10-29 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
EP2116245A2 (en) 2004-08-07 2009-11-11 Boehringer Ingelheim International GmbH EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
US7662830B2 (en) 2004-08-13 2010-02-16 Neurogen Corporation Substituted biaryl piperazinyl-pyridine analogues
US7683069B2 (en) 2002-12-16 2010-03-23 Mitsubishi Tanabe Pharma Corporation 3-substituted-4-pyrimidone derivatives
US7759357B2 (en) 2002-02-01 2010-07-20 Novartis Ag Phenylpyrimidine amines as IgE inhibitors
US7790728B2 (en) 2005-07-29 2010-09-07 Laboratorios Almirall, S.A. Pyrazine derivatives useful as adenosine receptor antagonists
US7855202B2 (en) 2005-10-06 2010-12-21 Laboratorios Almirall, S.A. Imidazopyridine derivatives as A2B adenosine receptor antagonists
CN1810802B (en) * 2001-09-21 2011-04-27 三菱制药株式会社 3-substituted-4-pyrimidone derivatives
US8022061B2 (en) 2006-10-10 2011-09-20 Amgen Inc. N-aryl pyrazole compounds, compositions, and methods for their use
EP2384751A1 (en) 2004-12-24 2011-11-09 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
WO2012055942A1 (en) 2010-10-27 2012-05-03 Proximagen Limited Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US8507533B2 (en) 2011-02-08 2013-08-13 Pfizer Inc. Glucagon receptor modulators
JP2014129406A (en) * 2000-05-12 2014-07-10 Genzyme Corp MODULATORS OF TNF-α SIGNALING
US8809342B2 (en) 2010-12-23 2014-08-19 Pfizer Inc. Glucagon receptor modulators
US8835449B2 (en) 2011-11-11 2014-09-16 Pfizer Inc. 2-thiopyrimidinones
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
US9023834B2 (en) 2008-11-13 2015-05-05 Taigen Biotechnology Co., Ltd. Lyophilization formulation
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
WO2017087445A1 (en) * 2015-11-17 2017-05-26 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
US9771332B2 (en) 2015-05-05 2017-09-26 Pfizer Inc. 2-thiopyrimidinones
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
US10220040B2 (en) 2010-10-18 2019-03-05 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilization
US10450273B2 (en) 2016-08-29 2019-10-22 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
WO2021097054A1 (en) * 2019-11-12 2021-05-20 Genzyme Corporation 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
AU2021211982B2 (en) * 2015-11-04 2023-03-02 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502300A (en) * 2003-08-13 2007-02-08 カイロン　コーポレイション GSK-3 inhibitor and use thereof
ES2394126T3 (en) * 2007-07-26 2013-01-22 Novartis Ag Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
TWI651310B (en) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 Triterpenoids and their medical use
WO2017073709A1 (en) * 2015-10-29 2017-05-04 あすか製薬株式会社 Pyrimidine derivative

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1271116B (en) * 1965-05-04 1968-06-27 Bayer Ag Process for the preparation of 4-hydroxypyrimidines
DE2056407A1 (en) * 1969-11-20 1971-05-27 Sandoz Ag, Basel (Schweiz) Process for the preparation of 1 alkyl 4,5 diphenyl or 4 (2 thienyl) 5 phenyl pynmidin 2 (1H) ones
US4438117A (en) * 1980-09-03 1984-03-20 E. I. Du Pont De Nemours And Company 2-Substituted thio-4,5-diarylpyrimidines
DE3319843A1 (en) * 1983-06-01 1984-12-06 Ali-Akbar Dipl.-Chem. Dr. 4300 Mülheim Pourzal Process for the preparation of pyrimidines from nitrile and alkynes
EP0130046A1 (en) * 1983-06-22 1985-01-02 Eli Lilly And Company Pyrimidine derivatives
US5077142A (en) * 1989-04-20 1991-12-31 Ricoh Company, Ltd. Electroluminescent devices
WO1996003387A1 (en) * 1994-07-28 1996-02-08 G.D. Searle & Co. 4,5-substituted imidazolyl compounds for the treatment of inflammation
WO1997012876A1 (en) * 1995-10-06 1997-04-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
WO1997016442A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
WO1997033883A1 (en) * 1996-03-13 1997-09-18 Smithkline Beecham Corporation Novel pyrimidine compounds useful in treating cytokine mediated diseases

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1271116B (en) * 1965-05-04 1968-06-27 Bayer Ag Process for the preparation of 4-hydroxypyrimidines
DE2056407A1 (en) * 1969-11-20 1971-05-27 Sandoz Ag, Basel (Schweiz) Process for the preparation of 1 alkyl 4,5 diphenyl or 4 (2 thienyl) 5 phenyl pynmidin 2 (1H) ones
US4438117A (en) * 1980-09-03 1984-03-20 E. I. Du Pont De Nemours And Company 2-Substituted thio-4,5-diarylpyrimidines
DE3319843A1 (en) * 1983-06-01 1984-12-06 Ali-Akbar Dipl.-Chem. Dr. 4300 Mülheim Pourzal Process for the preparation of pyrimidines from nitrile and alkynes
EP0130046A1 (en) * 1983-06-22 1985-01-02 Eli Lilly And Company Pyrimidine derivatives
US5077142A (en) * 1989-04-20 1991-12-31 Ricoh Company, Ltd. Electroluminescent devices
WO1996003387A1 (en) * 1994-07-28 1996-02-08 G.D. Searle & Co. 4,5-substituted imidazolyl compounds for the treatment of inflammation
WO1997012876A1 (en) * 1995-10-06 1997-04-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
WO1997016442A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
WO1997033883A1 (en) * 1996-03-13 1997-09-18 Smithkline Beecham Corporation Novel pyrimidine compounds useful in treating cytokine mediated diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
G. B. BENNETT ET AL.: JOURNAL OF MEDICINAL CHEMISTRY, vol. 21, no. 7, 1978, pages 623-8, XP000612140 cited in the application *
H.-J. KABBE: LIEBIGS ANNALEN DER CHEMIE, vol. 704, 1967, pages 144-9, XP002065898 cited in the application *
L. GIAMMANCO ET AL.: ANNALI DI CHIMICA, vol. 60, no. 3, March 1970, pages 188-97, XP002064349 *
L. GIAMMANCO: ATTI DELLA ACCADEMIA DI SCIENZE LETTERE E ARTI DI PALERMO, vol. 27, 1968, pages 469-83, XP002064350 *
M. TAKAHASHI ET AL.: HETEROCYCLES, vol. 22, no. 3, 1984, pages 581-4, XP002064343 *
R. J. IFE ET AL.: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 6, 1995, pages 543-6, XP002065899 cited in the application *

Cited By (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649641B2 (en) 1970-11-01 2003-11-18 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6417185B1 (en) * 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP2003527303A (en) * 1998-06-19 2003-09-16 カイロン コーポレイション Inhibitors of glycogen synthase kinase 3
WO1999065897A1 (en) * 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7256199B1 (en) 1998-09-25 2007-08-14 Mitsubishi Chemical Corporation Pyrimidone derivatives
WO2000018758A1 (en) * 1998-09-25 2000-04-06 Mitsubishi Chemical Corporation Pyrimidone derivatives
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6861417B2 (en) 1998-11-04 2005-03-01 Smithkline Beecham Corporation Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines
AU756862C (en) * 1998-11-20 2004-02-12 Merck & Co., Inc. Compounds having cytokine inhibitory activity
EP1131314A1 (en) * 1998-11-20 2001-09-12 Merck & Co., Inc. Compounds having cytokine inhibitory activity
AU756862B2 (en) * 1998-11-20 2003-01-23 Merck & Co., Inc. Compounds having cytokine inhibitory activity
WO2000031065A1 (en) * 1998-11-20 2000-06-02 Merck & Co., Inc. Compounds having cytokine inhibitory activity
EP1131314A4 (en) * 1998-11-20 2002-05-02 Merck & Co Inc Compounds having cytokine inhibitory activity
US6350744B1 (en) 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
US6469018B1 (en) 1999-01-08 2002-10-22 Smithkline Beecham Corporation Compounds
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6875760B2 (en) 1999-05-17 2005-04-05 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
WO2001038311A3 (en) * 1999-11-26 2001-11-01 Glaxo Group Ltd Pyrimidine derivatives as selective inhibitors of cox-2
WO2001038311A2 (en) * 1999-11-26 2001-05-31 Glaxo Group Limited Pyrimidine derivatives as selective inhibitors of cox-2
US6780869B1 (en) 1999-11-26 2004-08-24 Smithkline Beecham Corporation Pyrimidine derivatives
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US7479495B2 (en) 1999-12-28 2009-01-20 Pharmacopeia, Inc. N-heterocyclic inhibitors of TNF-α expression
WO2001047897A1 (en) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
JP2003519130A (en) * 1999-12-28 2003-06-17 ファーマコペイア， インコーポレイテッド N-heterocyclic TNF-α expression inhibitor
US6780870B2 (en) 2000-02-11 2004-08-24 Smithkline Beecham Corporation Pyrimidine derivatives as selective inhibitors of COX-2
WO2001058881A1 (en) * 2000-02-11 2001-08-16 Glaxo Group Limited Pyrimidine derivatives as selective inhibitors of cox-2
EP1136486A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives
EP1136493A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EP1136489A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperidin-1-yl]pyrimidone derivatives
EP1136485A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo Aminophenyl pyrimidone derivatives
WO2001070727A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
EP1136483A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidone derivatives
EP1136099A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors
EP1136484A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Arylalkylamino)pyrimidone derivatives
EP1136491A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[(Heteroaryl)alkylamino]pyrimidone derivatives
WO2001070725A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives
WO2001070728A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[nitrogen-heterocyclic]pyrimidone derivatives
WO2001070726A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo Aminophenyl pyrimidone derivatives
US7189717B2 (en) 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
JP2014129406A (en) * 2000-05-12 2014-07-10 Genzyme Corp MODULATORS OF TNF-α SIGNALING
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6953812B2 (en) 2000-06-23 2005-10-11 Novo Nordisk, Inc. Glucagon antagonists/inverse agonists
WO2002018374A1 (en) * 2000-09-01 2002-03-07 Glaxo Group Limited Substituted pyrimidines as selective cyclooxygenase-2 inhibitors
US7084148B2 (en) 2000-09-01 2006-08-01 Smithkline Beecham Corporation Substituted pyrimidines as selective cyclooxygenase-2 inhibitors
AU2001295026B2 (en) * 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
WO2002020495A3 (en) * 2000-09-06 2002-06-20 Chiron Corp Inhibitors of glycogen synthase kinase 3
WO2002020495A2 (en) * 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US7074802B2 (en) 2001-05-25 2006-07-11 Glaxo Group Limited Pyrimidine derivatives as selective inhibitors of cox-2
WO2002096427A1 (en) * 2001-05-25 2002-12-05 Glaxo Group Limited Pyrimidine derivatives as selective inhibitors of cox-2
US7026327B2 (en) 2001-05-25 2006-04-11 Glaxo Group Limited Pyrimidine derivatives useful as selective COX-2 inhibitors
WO2003014091A1 (en) * 2001-08-09 2003-02-20 Glaxo Group Limited Pyrimidine derivatives as selective inhibitors of cox-2
US7056928B2 (en) 2001-08-09 2006-06-06 Glaxo Group Limited Pyrimidine derivatives as selective inhibitors of COX-2
EA007576B1 (en) * 2001-09-21 2006-12-29 Мицубиси Фарма Корпорейшн 3-substituted-4-pyrimidone derivatives
US7572793B2 (en) 2001-09-21 2009-08-11 Mitsubishi Tanabe Pharma Corporation 3-Substituted-4-pyrimidone derivatives
CN1810802B (en) * 2001-09-21 2011-04-27 三菱制药株式会社 3-substituted-4-pyrimidone derivatives
WO2003037888A1 (en) * 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
US7427615B2 (en) 2001-09-21 2008-09-23 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
KR100881821B1 (en) * 2001-09-21 2009-02-03 미쓰비시 타나베 파마 코퍼레이션 3-substituted-4-pyrimidone derivatives
US7160892B2 (en) 2001-10-22 2007-01-09 Eisai Co., Ltd. Pyrimidone compounds and pharmaceutical compositions containing the same
AU2002335536B2 (en) * 2001-10-22 2008-11-13 Eisai R&D Management Co., Ltd. Pyrimidine compound and medicinal composition thereof
US7396836B2 (en) 2001-10-22 2008-07-08 Eisai R&D Management Co., Ltd. Pyrimidine compound and medicinal composition thereof
WO2003035640A1 (en) * 2001-10-22 2003-05-01 Eisai Co., Ltd. Pyrimidone compounds and pharmaceutical compositions containing the same
WO2003035639A1 (en) * 2001-10-22 2003-05-01 Eisai Co., Ltd. Pyrimidine compound and medicinal composition thereof
EP2246344A1 (en) 2001-10-22 2010-11-03 Eisai R&D Management Co., Ltd. Pyrimidine compounds and medicinal composition thereof
JPWO2003035640A1 (en) * 2001-10-22 2005-02-10 エーザイ株式会社 Pyrimidone compound and pharmaceutical composition thereof
JPWO2003035639A1 (en) * 2001-10-22 2005-02-10 エーザイ株式会社 Pyrimidine compound and pharmaceutical composition thereof
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US7759357B2 (en) 2002-02-01 2010-07-20 Novartis Ag Phenylpyrimidine amines as IgE inhibitors
US6855709B2 (en) 2002-02-22 2005-02-15 Pharmacia & Upjohn Company Pyridyl sulfone derivatives
CN1315832C (en) * 2002-02-28 2007-05-16 沙诺费－阿方蒂 Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropydimido[1,2-a]pyrimidin-4-one derivatives
WO2003084935A3 (en) * 2002-04-10 2004-05-21 Orchid Chemicals & Pharm Ltd Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
WO2003084935A2 (en) * 2002-04-10 2003-10-16 Orchid Chemicals & Pharmaceuticals Ltd Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
AU2003234628B2 (en) * 2002-05-21 2007-08-23 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2003099808A1 (en) * 2002-05-21 2003-12-04 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7026326B2 (en) 2002-05-21 2006-04-11 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1707205A2 (en) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
US7235560B2 (en) 2002-08-19 2007-06-26 Glaxo Group Limited Pyrimidine derivative as selective COX-2 inhibitors
US7446117B2 (en) 2002-09-16 2008-11-04 Glaxo Group Limited Cox-2 inhibiting pyridine derivatives
US7683069B2 (en) 2002-12-16 2010-03-23 Mitsubishi Tanabe Pharma Corporation 3-substituted-4-pyrimidone derivatives
WO2004069846A1 (en) * 2003-02-06 2004-08-19 Basf Aktiengesellschaft Pyrimidines, methods for the production thereof, and use thereof
CN100357297C (en) * 2003-02-06 2007-12-26 巴斯福股份公司 Pyrimidines, methods for the production thereof, and use thereof
EP2305651A1 (en) 2003-03-26 2011-04-06 Mitsubishi Tanabe Pharma Corporation 2,3,6-trisubstituted-4-pyrimidone derivatives
US7504411B2 (en) 2003-03-26 2009-03-17 Mitsubishi Tanabe Pharma Corporation 2,3,6-Trisubstituted-4-pyrimidone derivatives
WO2005007648A2 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
WO2005007648A3 (en) * 2003-07-16 2005-03-24 Neurogen Corp Biaryl piperazinyl-pyridine analogues
US7566712B2 (en) 2003-07-16 2009-07-28 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
US7429594B2 (en) 2003-08-20 2008-09-30 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005019202A1 (en) * 2003-08-20 2005-03-03 Amgen Inc. Substituted pyrimdinone derivatives and methods of use
AU2004267096B2 (en) * 2003-08-20 2008-10-02 Amgen Inc. Substituted pyrimdinone derivatives and methods of use
US7449470B2 (en) 2003-10-03 2008-11-11 Universiteit Leiden Substituted pyrimidines as ligands of adenosine receptors
EP1732541A2 (en) * 2004-04-07 2006-12-20 Takeda Pharmaceutical Company Limited Cyclic compounds
US7897607B2 (en) 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
EP1732541A4 (en) * 2004-04-07 2008-03-05 Takeda Pharmaceutical Cyclic compounds
EP2116245A2 (en) 2004-08-07 2009-11-11 Boehringer Ingelheim International GmbH EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
US7662830B2 (en) 2004-08-13 2010-02-16 Neurogen Corporation Substituted biaryl piperazinyl-pyridine analogues
US8334382B2 (en) 2004-08-13 2012-12-18 Neurogen Corporation Substituted biaryl piperazinyl-pyridine analogues
EP2878297A1 (en) 2004-12-24 2015-06-03 Boehringer Ingelheim International GmbH Medicaments for the treatment or prevention of fibrotic diseases
EP2384751A1 (en) 2004-12-24 2011-11-09 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
EA015890B1 (en) * 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Pyrimidine compounds
US7589197B2 (en) 2005-06-14 2009-09-15 Taigen Biotechnology Pyrimidine compounds
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
AU2006259525B2 (en) * 2005-06-14 2012-05-24 Gpcr Therapeutics, Inc Pyrimidine compounds
US7790728B2 (en) 2005-07-29 2010-09-07 Laboratorios Almirall, S.A. Pyrazine derivatives useful as adenosine receptor antagonists
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
US7855202B2 (en) 2005-10-06 2010-12-21 Laboratorios Almirall, S.A. Imidazopyridine derivatives as A2B adenosine receptor antagonists
US8022061B2 (en) 2006-10-10 2011-09-20 Amgen Inc. N-aryl pyrazole compounds, compositions, and methods for their use
WO2008142031A1 (en) 2007-05-18 2008-11-27 Institut Curie P38alpha as a therapeutic target in bladder carcinoma
EA019289B1 (en) * 2008-04-21 2014-02-28 Тайджен Байотекнолоджи Ко., Лтд. Aminopiridin, aminopirimidin and amino-1,3,5-triazine derivatives
WO2009131598A1 (en) * 2008-04-21 2009-10-29 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
US8372849B2 (en) 2008-04-21 2013-02-12 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
US9023834B2 (en) 2008-11-13 2015-05-05 Taigen Biotechnology Co., Ltd. Lyophilization formulation
US10220040B2 (en) 2010-10-18 2019-03-05 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilization
WO2012055942A1 (en) 2010-10-27 2012-05-03 Proximagen Limited Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease
US9133178B2 (en) 2010-10-27 2015-09-15 Proximagen Limited Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease
US8809342B2 (en) 2010-12-23 2014-08-19 Pfizer Inc. Glucagon receptor modulators
US9056834B2 (en) 2010-12-23 2015-06-16 Pfizer Inc. Glucagon receptor modulators
US8933104B2 (en) 2010-12-23 2015-01-13 Pfizer Inc. Glucagon receptor modulators
US9452999B2 (en) 2011-02-08 2016-09-27 Pfizer Inc. Glucagon receptor modulators
US9073871B2 (en) 2011-02-08 2015-07-07 Pfizer Inc. Glucagon receptor modulators
US8859591B2 (en) 2011-02-08 2014-10-14 Pfizer Inc. Glucagon receptor modulators
US8507533B2 (en) 2011-02-08 2013-08-13 Pfizer Inc. Glucagon receptor modulators
US9139538B2 (en) 2011-07-22 2015-09-22 Pfizer Inc. Quinolinyl glucagon receptor modulators
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
US9873673B2 (en) 2011-11-11 2018-01-23 Pfizer Inc. 2-thiopyrimidinones
US8841314B2 (en) 2011-11-11 2014-09-23 Pfizer Inc. 2-Thiopyrimidinones
US9399626B2 (en) 2011-11-11 2016-07-26 Pfizer Inc. 2-thiopyrimidinones
US8835449B2 (en) 2011-11-11 2014-09-16 Pfizer Inc. 2-thiopyrimidinones
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
US9771332B2 (en) 2015-05-05 2017-09-26 Pfizer Inc. 2-thiopyrimidinones
AU2021211982B2 (en) * 2015-11-04 2023-03-02 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity
WO2017087445A1 (en) * 2015-11-17 2017-05-26 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
US10716788B2 (en) 2015-11-17 2020-07-21 Merck Patent Gmbh Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity
AU2016357735B2 (en) * 2015-11-17 2021-01-14 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with BTK inhibitory activity
EP4295910A3 (en) * 2015-11-17 2024-03-20 Merck Patent GmbH Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
US10450273B2 (en) 2016-08-29 2019-10-22 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
US11066369B2 (en) 2016-08-29 2021-07-20 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
WO2021097054A1 (en) * 2019-11-12 2021-05-20 Genzyme Corporation 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
CN114981243A (en) * 2019-11-12 2022-08-30 健赞公司 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficiency of CFTR activity

Also Published As

Publication number Publication date
WO1998024782A3 (en) 1998-08-27
TW520362B (en) 2003-02-11
JP2002514195A (en) 2002-05-14
AR038955A1 (en) 2005-02-02

Similar Documents

Publication Publication Date Title
US6610698B2 (en) Substituted pyrimidine compounds and methods of use
WO1998024782A2 (en) Substituted pyrimidine compounds and their use
AU735901C (en) Substituted pyrimidinone and pyridone compounds and methods of use
US6420385B1 (en) Substituted pyrimidinone and pyridone compounds and methods of use
CA2315827C (en) Substituted pyridine and pyridazine compounds and their pharmaceutical use
US6174901B1 (en) Substituted pyridine and pyridazine compounds and methods of use
CA2271767A1 (en) Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
EP1448564A2 (en) Substituted indolizine-like compounds and methods of use
WO1998022457A9 (en) Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
AU733877C (en) Substituted pyrimidine compounds and their use
CA2535644A1 (en) Substituted pyrimdinone derivatives and methods of use
EP1314732A2 (en) Substituted pyrimidine compounds and their use
MXPA99005168A (en) Substituted pyrimidine compounds and their use
KR20000069328A (en) Substituted pyrimidine compounds and their use
AU8142901A (en) Substituted pyrimidinone and pyridone compounds and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97181563.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 335997

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 60120/98

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2274063

Country of ref document: CA

Ref document number: 2274063

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/005168

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV1999-2015

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1019997005021

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1997954778

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997954778

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-2015

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997005021

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 60120/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1997954778

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997005021

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1999-2015

Country of ref document: CZ